<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001833.pub3" GROUP_ID="ARI" ID="057399081614142864" MERGED_FROM="" MODIFIED="2014-06-30 04:32:55 +0100" MODIFIED_BY="Liz Dooley" REVIEW_NO="A062" REVMAN_SUB_VERSION="5.3.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2014-06-30 13:28:11 +1000" MODIFIED_BY="Liz  Dooley">
<TITLE>Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults</TITLE>
<CONTACT>
<PERSON ID="36746A0782E26AA2019829A9C5B1A67B" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Kristine</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Macartney</LAST_NAME>
<SUFFIX/>
<POSITION>Deputy Director - Policy Support</POSITION>
<EMAIL_1>kristine.macartney@health.nsw.gov.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases</DEPARTMENT>
<ORGANISATION>Children's Hospital at Westmead and University of Sydney</ORGANISATION>
<ADDRESS_1>Locked Bag 4001</ADDRESS_1>
<ADDRESS_2>Westmead</ADDRESS_2>
<CITY>Sydney</CITY>
<ZIP>2145</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 2 9845 1419</PHONE_1>
<PHONE_2/>
<FAX_1>+61 2 9845 1418</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2014-06-30 13:26:24 +1000" MODIFIED_BY="Liz Dooley">
<PERSON ID="36746A0782E26AA2019829A9C5B1A67B" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Kristine</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Macartney</LAST_NAME>
<SUFFIX/>
<POSITION>Deputy Director - Policy Support</POSITION>
<EMAIL_1>kristine.macartney@health.nsw.gov.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases</DEPARTMENT>
<ORGANISATION>Children's Hospital at Westmead and University of Sydney</ORGANISATION>
<ADDRESS_1>Locked Bag 4001</ADDRESS_1>
<ADDRESS_2>Westmead</ADDRESS_2>
<CITY>Sydney</CITY>
<ZIP>2145</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 2 9845 1419</PHONE_1>
<PHONE_2/>
<FAX_1>+61 2 9845 1418</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="69258331848371042537100412233309" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Anita</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Heywood</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Lecturer</POSITION>
<EMAIL_1>a.heywood@unsw.edu.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>School of Public Health and Community Medicine</DEPARTMENT>
<ORGANISATION>University of New South Wales</ORGANISATION>
<ADDRESS_1>Level 2, Samuels Building</ADDRESS_1>
<ADDRESS_2>Gate 11, Botany Street</ADDRESS_2>
<CITY>Kensington</CITY>
<ZIP>2052</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 2 9385 3667</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="4832" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Peter</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>McIntyre</LAST_NAME>
<SUFFIX/>
<POSITION>Director</POSITION>
<EMAIL_1>peter.mcintyre@health.nsw.gov.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases</DEPARTMENT>
<ORGANISATION>Children's Hospital at Westmead and University of Sydney</ORGANISATION>
<ADDRESS_1>Locked Bag 4001</ADDRESS_1>
<ADDRESS_2>Westmead</ADDRESS_2>
<CITY>Sydney</CITY>
<ZIP>2145</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 2 9845 1417</PHONE_1>
<PHONE_2/>
<FAX_1>+61 2 9845 1418</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2014-03-27 15:23:57 +1000" MODIFIED_BY="Liz Dooley">
<UP_TO_DATE>
<DATE DAY="18" MONTH="3" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="18" MONTH="3" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="18" MONTH="3" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="6" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-06-30 13:28:11 +1000" MODIFIED_BY="Liz  Dooley">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-06-30 13:28:11 +1000" MODIFIED_BY="Liz  Dooley">
<DATE DAY="30" MONTH="6" YEAR="2014"/>
<DESCRIPTION>
<P>Updated percentage of vaccine recipients developing varicella in Abstract and Results of main text.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-06-30 13:27:57 +1000" MODIFIED_BY="Liz  Dooley">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-06-30 13:27:54 +1000" MODIFIED_BY="Liz  Dooley">
<DATE DAY="18" MONTH="3" YEAR="2014"/>
<DESCRIPTION>
<P>No new studies are included in the updated review. New excluded studies are cited in the conclusions.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-06-30 13:27:57 +1000" MODIFIED_BY="Liz  Dooley">
<DATE DAY="18" MONTH="3" YEAR="2014"/>
<DESCRIPTION>
<P>Updated searches conducted. We excluded 45 new studies (<LINK REF="STD-Andrei-2011" TYPE="STUDY">Andrei 2011</LINK>; <LINK REF="STD-Akazawa-2013" TYPE="STUDY">Akazawa 2013</LINK>; <LINK REF="STD-Bai-2011" TYPE="STUDY">Bai 2011</LINK>; <LINK REF="STD-Barbosa-2012" TYPE="STUDY">Barbosa 2012</LINK>; <LINK REF="STD-Barbosa-2009" TYPE="STUDY">Barbosa 2009</LINK>; <LINK REF="STD-Blatter-2012" TYPE="STUDY">Blatter 2012</LINK>; <LINK REF="STD-Bate-2011" TYPE="STUDY">Bate 2011</LINK>; <LINK REF="STD-Bryant-2012" TYPE="STUDY">Bryant 2012</LINK>; <LINK REF="STD-Bryant-2013" TYPE="STUDY">Bryant 2013</LINK>; <LINK REF="STD-Contopoulos_x002d_Ioannidis-2012" TYPE="STUDY">Contopoulos-Ioannidis 2012</LINK>; <LINK REF="STD-Chlibek-2014" TYPE="STUDY">Chlibek 2014</LINK>; <LINK REF="STD-Chui-2014" TYPE="STUDY">Chui 2014</LINK>; <LINK REF="STD-Chao-2012" TYPE="STUDY">Chao 2012</LINK>; <LINK REF="STD-Dube-2012" TYPE="STUDY">Dube 2012</LINK>; <LINK REF="STD-El_x002d_Darouti-2012" TYPE="STUDY">El-Darouti 2012</LINK>; <LINK REF="STD-Ferrera-2012" TYPE="STUDY">Ferrera 2012</LINK>; <LINK REF="STD-Fridman-2011" TYPE="STUDY">Fridman 2011</LINK>; <LINK REF="STD-Klein-2012a" TYPE="STUDY">Klein 2012a</LINK>; <LINK REF="STD-Klein-2012b" TYPE="STUDY">Klein 2012b</LINK>; <LINK REF="STD-Knuf-2012" TYPE="STUDY">Knuf 2012</LINK>; <LINK REF="STD-Hartung-2013" TYPE="STUDY">Hartung 2013</LINK>; <LINK REF="STD-Huang-2013" TYPE="STUDY">Huang 2013</LINK>; <LINK REF="STD-Leonardi-2011" TYPE="STUDY">Leonardi 2011</LINK>; <LINK REF="STD-Leroux_x002d_Roels-2012" TYPE="STUDY">Leroux-Roels 2012</LINK>; <LINK REF="STD-Li-2012" TYPE="STUDY">Li 2012</LINK>; <LINK REF="STD-Lopez-2011" TYPE="STUDY">Lopez 2011</LINK>; <LINK REF="STD-Loulergue-2013" TYPE="STUDY">Loulergue 2013</LINK>; <LINK REF="STD-McAdam-2013" TYPE="STUDY">McAdam 2013</LINK>; <LINK REF="STD-Macartney-2012" TYPE="STUDY">Macartney 2012</LINK>; <LINK REF="STD-Pileggi-2010" TYPE="STUDY">Pileggi 2010</LINK>; <LINK REF="STD-Pinochet-2012" TYPE="STUDY">Pinochet 2012</LINK>; <LINK REF="STD-Prymula-2014" TYPE="STUDY">Prymula 2014</LINK>; <LINK REF="STD-Riera-2012" TYPE="STUDY">Riera 2012</LINK>; <LINK REF="STD-Rinderknecht-2011" TYPE="STUDY">Rinderknecht 2011</LINK>; <LINK REF="STD-Ruger-2012" TYPE="STUDY">Ruger 2012</LINK>; <LINK REF="STD-Rumke-2011" TYPE="STUDY">Rumke 2011</LINK>; <LINK REF="STD-Shapiro-2011" TYPE="STUDY">Shapiro 2011</LINK>; <LINK REF="STD-Stadtmauer-2013" TYPE="STUDY">Stadtmauer 2013</LINK>; <LINK REF="STD-Streng-2010" TYPE="STUDY">Streng 2010</LINK>; <LINK REF="STD-Tang-2012" TYPE="STUDY">Tang 2012</LINK>; <LINK REF="STD-Vesikari-2012" TYPE="STUDY">Vesikari 2012</LINK>; <LINK REF="STD-Wang-2013" TYPE="STUDY">Wang 2013</LINK>; <LINK REF="STD-Weinberg-2010" TYPE="STUDY">Weinberg 2010</LINK>; <LINK REF="STD-Wu-2010" TYPE="STUDY">Wu 2010</LINK>; <LINK REF="STD-Yetman-2013" TYPE="STUDY">Yetman 2013</LINK>). We did not identify any new trials suitable for inclusion in this update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-03-27 15:24:10 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="18" MONTH="6" YEAR="2010"/>
<DESCRIPTION>
<P>A new review author joined the team to update this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-03-27 15:24:03 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="18" MONTH="6" YEAR="2010"/>
<DESCRIPTION>
<P>Updated searches conducted. We excluded 63 new studies (<LINK REF="STD-Arent-2009" TYPE="STUDY">Arent 2009</LINK>; <LINK REF="STD-Asano-2008" TYPE="STUDY">Asano 2008</LINK>; <LINK REF="STD-Baldacci-2008" TYPE="STUDY">Baldacci 2008</LINK>; <LINK REF="STD-Banz-2009" TYPE="STUDY">Banz 2009</LINK>; <LINK REF="STD-Berghella-2010" TYPE="STUDY">Berghella 2010</LINK>; <LINK REF="STD-Black-2008" TYPE="STUDY">Black 2008</LINK>; <LINK REF="STD-Brotons-2010" TYPE="STUDY">Brotons 2010</LINK>; <LINK REF="STD-Ceyhan-2009" TYPE="STUDY">Ceyhan 2009</LINK>; <LINK REF="STD-Czajka-2009" TYPE="STUDY">Czajka 2009</LINK>; <LINK REF="STD-de-So_x00e1_rez-2009" TYPE="STUDY">de Soárez 2009</LINK>; <LINK REF="STD-Ferrera-2009" TYPE="STUDY">Ferrera 2009</LINK>; <LINK REF="STD-Fu-2010" TYPE="STUDY">Fu 2010</LINK>; <LINK REF="STD-Getaz-2010" TYPE="STUDY">Getaz 2010</LINK>; <LINK REF="STD-Gilderman-2008" TYPE="STUDY">Gilderman 2008</LINK>; <LINK REF="STD-Gillet-2009a" TYPE="STUDY">Gillet 2009a</LINK>; <LINK REF="STD-Gillet-2009b" TYPE="STUDY">Gillet 2009b</LINK>; <LINK REF="STD-Glanz-2010" TYPE="STUDY">Glanz 2010</LINK>; <LINK REF="STD-Gnann-2008" TYPE="STUDY">Gnann 2008</LINK>; <LINK REF="STD-Gonzaga-2008" TYPE="STUDY">Gonzaga 2008</LINK>; <LINK REF="STD-Groves-2010" TYPE="STUDY">Groves 2010</LINK>; <LINK REF="STD-Halperin-2009" TYPE="STUDY">Halperin 2009</LINK>; <LINK REF="STD-Hambleton-2008" TYPE="STUDY">Hambleton 2008</LINK>; <LINK REF="STD-Holcomb-2008" TYPE="STUDY">Holcomb 2008</LINK>; <LINK REF="STD-Jones-2009" TYPE="STUDY">Jones 2009</LINK>; <LINK REF="STD-Knuf-2010" TYPE="STUDY">Knuf 2010</LINK>; <LINK REF="STD-Kreth-2008" TYPE="STUDY">Kreth 2008</LINK>; <LINK REF="STD-Levin-2008a" TYPE="STUDY">Levin 2008a</LINK>; <LINK REF="STD-Levin-2008b" TYPE="STUDY">Levin 2008b</LINK>; <LINK REF="STD-Liu-2009" TYPE="STUDY">Liu 2009</LINK>; <LINK REF="STD-Ma-2009a" TYPE="STUDY">Ma 2009a</LINK>; <LINK REF="STD-Ma-2009b" TYPE="STUDY">Ma 2009b</LINK>; <LINK REF="STD-Marin-2008" TYPE="STUDY">Marin 2008</LINK>; <LINK REF="STD-Marquez_x002d_Pelaez-2009" TYPE="STUDY">Marquez-Pelaez 2009</LINK>; <LINK REF="STD-Marshall-2009" TYPE="STUDY">Marshall 2009</LINK>; <LINK REF="STD-Mick-2010" TYPE="STUDY">Mick 2010</LINK>; <LINK REF="STD-Mills-2010" TYPE="STUDY">Mills 2010</LINK>; <LINK REF="STD-Mustafa-2009" TYPE="STUDY">Mustafa 2009</LINK>; <LINK REF="STD-Nolan-2008" TYPE="STUDY">Nolan 2008</LINK>; <LINK REF="STD-Novadzki-2010" TYPE="STUDY">Novadzki 2010</LINK>; <LINK REF="STD-Oxman-2008" TYPE="STUDY">Oxman 2008</LINK>; <LINK REF="STD-Oxman-2009" TYPE="STUDY">Oxman 2009</LINK>; <LINK REF="STD-Oxman-2010" TYPE="STUDY">Oxman 2010</LINK>; <LINK REF="STD-Prelog-2010" TYPE="STUDY">Prelog 2010</LINK>; <LINK REF="STD-Quian-2010" TYPE="STUDY">Quian 2010</LINK>; <LINK REF="STD-Rios-2009" TYPE="STUDY">Rios 2009</LINK>; <LINK REF="STD-Rozenbaum-2008" TYPE="STUDY">Rozenbaum 2008</LINK>; <LINK REF="STD-Sadaoka-2008" TYPE="STUDY">Sadaoka 2008</LINK>; <LINK REF="STD-Salleras-2009" TYPE="STUDY">Salleras 2009</LINK>; <LINK REF="STD-Salleras-Sanmarti-2008" TYPE="STUDY">Salleras Sanmarti 2008</LINK>; <LINK REF="STD-Sanford-2010" TYPE="STUDY">Sanford 2010</LINK>; <LINK REF="STD-Schmid-2010" TYPE="STUDY">Schmid 2010</LINK>; <LINK REF="STD-Schuster-2008" TYPE="STUDY">Schuster 2008</LINK>; <LINK REF="STD-Seward-2008" TYPE="STUDY">Seward 2008</LINK>; <LINK REF="STD-Shinefield-2008" TYPE="STUDY">Shinefield 2008</LINK>; <LINK REF="STD-Simberkoff-2010" TYPE="STUDY">Simberkoff 2010</LINK>; <LINK REF="STD-Sutradhar-2009" TYPE="STUDY">Sutradhar 2009</LINK>; <LINK REF="STD-Takahashi-2008" TYPE="STUDY">Takahashi 2008</LINK>; <LINK REF="STD-Tillieux-2008" TYPE="STUDY">Tillieux 2008</LINK>; <LINK REF="STD-Vesikari-2010" TYPE="STUDY">Vesikari 2010</LINK>; <LINK REF="STD-Watson-2008" TYPE="STUDY">Watson 2008</LINK>; <LINK REF="STD-Weinberg-2009" TYPE="STUDY">Weinberg 2009</LINK>; <LINK REF="STD-Yamaguti-2008" TYPE="STUDY">Yamaguti 2008</LINK>). We did not identify any new trials suitable for inclusion in this update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-12-22 09:44:18 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="27" MONTH="2" YEAR="2008"/>
<DESCRIPTION>
<P>Searches conducted.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-12-14 17:02:52 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="24" MONTH="1" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-06-30 13:15:58 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2014-06-19 13:46:05 +1000" MODIFIED_BY="Liz Dooley">
<TITLE>Post-exposure prophylaxis vaccine to prevent varicella (chickenpox)</TITLE>
<SUMMARY_BODY MODIFIED="2014-06-19 13:46:05 +1000" MODIFIED_BY="Liz Dooley">
<P>
<B>Review question</B>
</P>
<P>This review assessed how useful the varicella (also known as chickenpox) vaccine is in preventing chickenpox when given to children or adults who have never been immunised or previously had chickenpox, but who receive the vaccine within a short time following exposure to a person infectious with chickenpox. Varicella is a highly contagious viral infection characterised by a widespread pustular rash, fever and generally feeling unwell. We identified three trials involving 110 healthy children who were siblings of household contacts.</P>
<P>
<B>Background</B>
</P>
<P>Although many cases of chickenpox are mild, complications such as secondary bacterial infection, neurological complications and other problems occur in at least 1% of cases, usually resulting in hospitalisation. The virus that causes chickenpox also remains dormant in sensory nerve roots after infection and can reactivate later in life as a painful blistering rash known as herpes zoster or shingles.</P>
<P>Chickenpox can be prevented by vaccination with live attenuated varicella vaccine. However, many countries have not yet funded routine population-based immunisation programmes and exposure to chickenpox remains commonplace. Even in highly vaccinated populations, outbreaks can occur, particularly in childcare and school settings.</P>
<P>
<B>Key results</B>
</P>
<P>The question of how to prevent chickenpox occurring in an adult or child who has been in contact with a person with the disease has led to trials of varicella vaccines in this setting. This review assessed published studies up to March 2014 and found that three separate trials investigated the effectiveness of giving varicella vaccine as post-exposure prophylaxis following household exposure of non-immune children to siblings with varicella compared to a placebo. Overall, 13 of 56 (18%) vaccine recipients developed varicella compared with 42 of 54 (78%) placebo (or no vaccine) recipients. These studies support giving varicella vaccine to a child, particularly if given within three days of contact with a chickenpox case. Although mild chickenpox may still occur in some cases, the vaccine is likely to prevent moderate to severe cases of chickenpox.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>The number of participants in these three trials was small and is a limitation of this review. The quality of the included studies varied, which also limits confidence in the results. There have been no trials of this type undertaken in adults, and none of the trials commented on adverse events following immunisation, such as fever or injection site reactions.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-06-30 13:15:36 +1000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2014-03-18 09:06:44 +1000" MODIFIED_BY="Liz Dooley">
<P>The prevention of varicella (chickenpox) using live attenuated varicella vaccines has been demonstrated both in randomised controlled trials (RCTs) and in population-based immunisation programmes in countries such as the United States and Australia. Many countries do not routinely immunise children against varicella and exposures continue to occur. Although the disease is often mild, complications such as secondary bacterial infection, pneumonitis and encephalitis occur in about 1% of cases, usually leading to hospitalisation. The use of varicella vaccine in persons who have recently been exposed to the varicella zoster virus has been studied as a form of post-exposure prophylaxis (PEP).</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-03-18 09:03:25 +1000" MODIFIED_BY="Liz Dooley">
<P>To assess the efficacy and safety of vaccines for use as PEP for the prevention of varicella in children and adults.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL (2014, Issue 1), MEDLINE (1966 to March week 1, 2014), EMBASE (January 1990 to March 2014) and LILACS (1982 to March 2014). We searched for unpublished trials registered on the clinicaltrials.gov and WHO ICTRP websites.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-03-17 11:54:32 +1000" MODIFIED_BY="[Empty name]">
<P>RCTs and quasi-RCTs of varicella vaccine for PEP compared with placebo or no intervention. The outcome measures were efficacy in prevention of clinical cases and/or laboratory-confirmed clinical cases and adverse events following vaccination.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-12-21 10:47:43 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently extracted and analysed data using Review Manager software. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-06-30 13:15:36 +1000" MODIFIED_BY="[Empty name]">
<P>We identified three trials involving 110 healthy children who were siblings of household contacts. The included trials varied in study quality, vaccine used, length of follow-up and outcomes measured and, as such, were not suitable for meta-analysis. We identified high or unclear risk of bias in two of the three included studies. Overall, 13 out of 56 vaccine recipients (23%) developed varicella compared with 42 out of 54 placebo (or no vaccine) recipients (78%). Of the vaccine recipients who developed varicella, the majority only had mild disease (with fewer than 50 skin lesions). In the three trials, most participants received PEP within three days following exposure; too few participants were vaccinated four to five days post-exposure to ascertain the efficacy of vaccine given more than three days after exposure. No included trial reported on adverse events following immunisation.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>These small trials suggest varicella vaccine administered within three days to children following household contact with a varicella case reduces infection rates and severity of cases. We identified no RCTs for adolescents or adults. Safety was not adequately addressed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-06-30 13:15:58 +1000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2014-06-23 09:19:07 +1000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2014-06-23 09:19:07 +1000" MODIFIED_BY="[Empty name]">
<P>Varicella (chickenpox) is an acute, highly infectious disease, caused by the varicella zoster virus (VZV). In healthy children varicella is usually self limiting and manifests as a vesicular rash, fever and constitutional symptoms. The most common complication in children is secondary bacterial infection. However, other serious complications are well recognised and include pneumonia, dehydration, hepatitis, ataxia and encephalitis (<LINK REF="REF-Gershon-2013" TYPE="REFERENCE">Gershon 2013</LINK>; <LINK REF="REF-Preblud-1984" TYPE="REFERENCE">Preblud 1984</LINK>). The estimated rate of cerebellar ataxia among children is 1 in 4000 cases (<LINK REF="REF-Guess-1986" TYPE="REFERENCE">Guess 1986</LINK>), and for encephalitis 1.7 per 100,000 varicella cases (<LINK REF="REF-Preblud-1984" TYPE="REFERENCE">Preblud 1984</LINK>).</P>
<P>Women who contract varicella in the first 20 weeks of pregnancy have a 2% risk of their fetus developing congenital varicella syndrome and pregnant women who contract varicella in the last trimester are at an increased risk of pneumonia (<LINK REF="REF-Gershon-2013" TYPE="REFERENCE">Gershon 2013</LINK>; <LINK REF="REF-Pastuszac-1994" TYPE="REFERENCE">Pastuszac 1994</LINK>). The onset of varicella in a pregnant woman from five days prior to delivery to two days after delivery can result in severe neonatal varicella in 17% to 30% of cases (<LINK REF="REF-Enders-1994" TYPE="REFERENCE">Enders 1994</LINK>). Following primary infection, VZV remains dormant in the sensory nerve ganglia of individuals and can reactivate to cause herpes zoster. Herpes zoster is especially associated with increasing age and is responsible for significant population morbidity (<LINK REF="REF-Gnann-2002" TYPE="REFERENCE">Gnann 2002</LINK>). Immunocompromised patients are at risk from either primary VZV infection or reactivation, both of which can be associated with substantial morbidity (<LINK REF="REF-Gershon-2013" TYPE="REFERENCE">Gershon 2013</LINK>).</P>
<P>Transmission of VZV is spread from person-to-person either by direct contact with vesicle fluid or through aerosolised respiratory secretions. The incubation period ranges from 7 to 21 days, during which time infected persons are asymptomatic. Secondary attack rates may reach 90% for susceptible household contacts of varicella cases (<LINK REF="REF-Simpson-1952" TYPE="REFERENCE">Simpson 1952</LINK>). In temperate climates, varicella is typically a disease of childhood with more than 90% of adults being immune (<LINK REF="REF-Gershon-2013" TYPE="REFERENCE">Gershon 2013</LINK>). Primary infection usually provides lifetime immunity to varicella but second infections, although unusual, are well recognised (<LINK REF="REF-Hambleton-2005" TYPE="REFERENCE">Hambleton 2005</LINK>). Persistence of immunity (VZV-specific immunoglobulin (Ig) G) following natural infection is reliably measured using commercially available antibody tests. However, commercially available tests are not sufficiently sensitive to detect vaccine-induced antibodies reliably. Numerous laboratory methods, including neutralisation assays (NA), enzyme-linked immunosorbent assay (ELISA), fluorescent antibody membrane antigen (FAMA) techniques, glycoprotein-based ELISA (gpELISA) and measures of cell-mediated immunity, have been employed in clinical trials of varicella vaccines. However, these assays have inherent variability, making comparison of vaccine-induced immunologic responses challenging (<LINK REF="REF-Gershon-2013" TYPE="REFERENCE">Gershon 2013</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>Live attenuated varicella vaccines are available for use in several countries. All varicella-containing vaccines use the attenuated Oka strain of VZV, first developed in Japan from the virus of an infected child (<LINK REF="STD-Takahashi-1974" TYPE="STUDY">Takahashi 1974</LINK>). The Oka vaccine virus has been further modified through passage in cell culture by varicella vaccine manufacturers: Merck and Co. (Varivax), GlaxoSmithKline (GSK) (Varilrix) and the Biken Institute (BIKEN). Two vaccines are also available in China from the Changchun and Shanghai Institutes of Biologic Products (<LINK REF="STD-Fu-2010" TYPE="STUDY">Fu 2010</LINK>). The first trials of live attenuated varicella vaccine were conducted in Japan in the 1970s, predominantly in hospitalised children. Many of the earliest clinical trials of varicella vaccine in the USA and elsewhere were in immunocompromised children, predominantly those with malignancies (<LINK REF="STD-Brunell-1982" TYPE="STUDY">Brunell 1982</LINK>; <LINK REF="STD-Gershon-1982" TYPE="STUDY">Gershon 1982</LINK>; <LINK REF="STD-Iwaza-1977" TYPE="STUDY">Iwaza 1977</LINK>). Large-scale randomised clinical trials of the use of live attenuated varicella vaccine in healthy children were conducted in the following two decades (<LINK REF="STD-Kuter-1991" TYPE="STUDY">Kuter 1991</LINK>; <LINK REF="STD-Varis-1996" TYPE="STUDY">Varis 1996</LINK>; <LINK REF="STD-Weibel-1984" TYPE="STUDY">Weibel 1984</LINK>), and in 1995 the USA was the first country to begin universal varicella vaccination of children from 12 months of age (<LINK REF="REF-MMWR-1996" TYPE="REFERENCE">MMWR 1996</LINK>). Recently, quadrivalent vaccines, which include measles, mumps, rubella and varicella vaccine viruses (MMRV), have been developed by two manufacturers, Merck and Co. (ProQuad) and GSK (Priorix Tetra) and are used in a number of countries.</P>
</INTERVENTION>
<THEORY MODIFIED="2014-06-19 01:04:12 +1000" MODIFIED_BY="[Empty name]">
<P>Many of the early data concerning the efficacy and safety of varicella vaccines were in the form of uncontrolled, prospective cohort studies. In addition, many studies of the post-licensure effectiveness and safety of varicella vaccination, mostly from the United States, add to the body of knowledge regarding the vaccines (<LINK REF="REF-Hambleton-2005" TYPE="REFERENCE">Hambleton 2005</LINK>; <LINK REF="REF-Marin-2007" TYPE="REFERENCE">Marin 2007</LINK>). A number of narrative reviews of the safety and efficacy of varicella vaccines are also available (<LINK REF="REF-Breuer-2001" TYPE="REFERENCE">Breuer 2001</LINK>; <LINK REF="REF-Hambleton-2005" TYPE="REFERENCE">Hambleton 2005</LINK>; <LINK REF="REF-Skull-2001" TYPE="REFERENCE">Skull 2001</LINK>; <LINK REF="REF-Takahashi-1996" TYPE="REFERENCE">Takahashi 1996</LINK>). One review of post-exposure prophylaxis (PEP) studies by Ferson suggested that varicella vaccine may be effective when used as a PEP (<LINK REF="REF-Ferson-2001" TYPE="REFERENCE">Ferson 2001</LINK>). Many of the studies of the efficacy of varicella vaccines include clinically diagnosed disease as an outcome measure. This is often characterised as either mild, moderate or severe, most commonly depending on the number of skin lesions present.</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-06-19 01:02:09 +1000" MODIFIED_BY="[Empty name]">
<P>Although varicella vaccines are licensed and recommended for use in many countries, few countries, including the USA, Canada, Germany, Uruguay and Australia, have adopted publicly funded, national, population-based varicella vaccination programmes (<LINK REF="REF-Macartney-2005" TYPE="REFERENCE">Macartney 2005</LINK>; <LINK REF="REF-MMWR-1996" TYPE="REFERENCE">MMWR 1996</LINK>; <LINK REF="REF-NACI-2004" TYPE="REFERENCE">NACI 2004</LINK>; <LINK REF="REF-Quian-2008" TYPE="REFERENCE">Quian 2008</LINK>; <LINK REF="REF-Sadzot_x002d_Delvaux-2008" TYPE="REFERENCE">Sadzot-Delvaux 2008</LINK>). In populations where universal immunisation does not occur, or in the case of unimmunised susceptible contacts, the use of varicella vaccine as a PEP is a potential strategy for the prevention of morbidity from varicella infection. The objectives of this review were to examine the efficacy and safety of varicella vaccine when used as a PEP. This review has systematically identified RCTs of varicella vaccination and considered the evidence available from these studies. The purpose of this exercise was to add to the evidence base for this intervention and to highlight deficiencies in our knowledge that should be addressed by further research.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-06-19 01:04:32 +1000" MODIFIED_BY="[Empty name]">
<P>To assess the efficacy and safety of vaccines for use as PEP for the prevention of varicella in children and adults.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-06-19 01:06:42 +1000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2008-02-06 07:20:54 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) or quasi-RCTs.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>Healthy children and adults susceptible to VZV infection. We assumed susceptibility if there was no past history of chickenpox or varicella vaccination and serological evidence of no past infection.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Vaccination with live attenuated varicella vaccine within seven days following known exposure to VZV, with comparison to placebo or no intervention. </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>The outcome measure for this study was interruption of transmission of VZV to contacts of a varicella case. This included comparison of secondary attack rates in those given either vaccine or placebo (or no intervention) within seven days of a documented exposure to VZV.</P>
<P>We defined varicella cases using clinical criteria with a case definition of an illness characterised by fever, malaise and a generalised vesicular rash (typically with 250 to 500 lesions) lasting four to five days. We included the severity of cases, as either mild, moderate or severe, depending upon the number of skin lesions present. We also included clinically diagnosed disease, with the additional use of laboratory assays to detect seroconversion to VZV in previously non-immune participants.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-03-18 09:42:38 +1000" MODIFIED_BY="Liz Dooley">
<OL>
<LI>Prevention of varicella in contacts of a varicella case.</LI>
<LI>Vaccine adverse events including local injection site adverse events, fever and systemic adverse events.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-03-18 09:34:03 +1000" MODIFIED_BY="Liz Dooley">
<OL>
<LI>Prevention of moderate to severe varicella in contacts of a varicella case.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>For this update we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (2014, Issue 1) (accessed 18 March 2014), MEDLINE (May 2010 to March week 1, 2014), EMBASE (June 2010 to March 2014) and LILACS (2010 to March 2014). We also reviewed the clinical trials registers <A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A> and <A HREF="http://www.who.int/ictrp">http://www.who.int/ictrp</A> (to March 2014) for unpublished studies. Details of the original search are in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>We used the following search terms to search MEDLINE and CENTRAL. We combined the MEDLINE search with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity- and precision-maximising version (2008 revision); Ovid format (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>). We adapted the search strategy for EMBASE (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</P>
<P>
<B>MEDLINE (OVID) </B>
<BR/>1 Chickenpox/<BR/>2 (chicken pox or chickenpox).tw.<BR/>3 Herpesvirus 3, Human/<BR/>4 Varicellovirus/<BR/>5 varicell*.tw.<BR/>6 vzv.tw.<BR/>7 or/1-6<BR/>8 exp Vaccines/<BR/>9 exp Vaccination/<BR/>10 Immunization/<BR/>11 (vaccin* or immuni* or inocul*).tw.<BR/>12 or/8-11<BR/>13 7 and 12<BR/>14 exp Chickenpox Vaccine/<BR/>15 13 or 14<BR/>
</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>We did not apply any language or publication restrictions. We searched the reference lists of studies and reviews identified during the updating of the review. We identified published articles that cite the previously included studies using Scopus. In addition, we consulted content experts and, where necessary, attempted contact with trial authors of studies considered for inclusion.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-06-19 01:06:42 +1000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2014-03-26 11:17:51 +1000" MODIFIED_BY="[Empty name]">
<P>In the original review, one review author (KM) made initial exclusions of irrelevant studies based on the abstracts obtained from the literature searches. Two review authors (KM, PM) independently assessed the remaining studies to determine whether they fulfilled the inclusion criteria. In this updated review, one review author (AH) made initial exclusions of irrelevant studies based on the abstracts obtained from the updated literature searches. Two review authors (AH, KM) independently assessed potentially relevant studies from the updated search results to determine inclusion eligibility.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-03-24 10:18:17 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors (KM, PM) independently extracted data from the included studies by using a data extraction form. The review authors (KM, PM) attempted to contact trial authors for clarification of study content where necessary. No further trial data or information was subsequently made available.</P>
<P>We extracted and entered the following data into the Review Manager software (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>).</P>
<OL>
<LI>Date and location of trials.</LI>
<LI>Methodological quality of trials.</LI>
<LI>Characteristics of participants.</LI>
<LI>Characteristics of interventions.</LI>
<LI>Characteristics of outcome measures.</LI>
<LI>Data on outcome measures.</LI>
<LI>Publication status.</LI>
</OL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-06-19 01:06:42 +1000" MODIFIED_BY="[Empty name]">
<P>We did not consider blinding of the review authors for assessment of the included studies to be feasible given the limited number of relevant studies. Two review authors (KM, PM) independently graded the methodological quality of the included studies and we resolved any disagreements through discussion.</P>
<P>We used The Cochrane Collaboration's domain-based evaluation tool for assessing the risk of bias (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). The domains included sequence generation, allocation concealment, blinding, completeness of outcome data, non-selective reporting of outcomes and other potential sources of bias. Of particular importance was the assessment of data completeness in the reporting of outcomes. The findings are included in the 'Risk of bias' tables below.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>Vaccine efficacy was measured in a number of ways: efficacy within three days post-exposure; efficacy within five days post-exposure; efficacy in the prevention of varicella of any severity; and the prevention of moderate/severe varicella. Measures of treatment effect extracted included vaccine efficacy (VE) and risk ratio (RR), if reported. VE is calculated as VE = (ARU - ARV)/ARU (x 100), where ARU = attack rate in the unvaccinated and ARV = attack rate in vaccinated participants. We included reporting of any adverse event as a treatment effect. Adverse events that we sought were injection site reactions, fever, other systemic adverse events and serious adverse events.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2014-03-17 11:56:37 +1000" MODIFIED_BY="[Empty name]">
<P>Not applicable.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>In studies estimating vaccine efficacy, missing outcome data can lead to a biased estimate of effect size. We assessed studies for reporting of loss to follow-up.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>There was considerable heterogeneity between the results of the trials and we explored the reasons for this. We assessed methodological heterogeneity by comparing the 'Risk of bias' tables. We assessed statistical heterogeneity by comparing the statistical tests employed by the study authors and the adequacy of the reporting of statistical results.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>We assessed for each study in the review whether all expected outcomes of interest were included and reported, including pre-specified outcomes.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>The two review authors (KM, PM) assessed the homogeneity of participants, intervention and outcomes in each study before deciding whether to combine the data. The synthesis of data was also dependent on the overall quality of trials.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>We planned assessment of efficacy outcomes by disease severity and length of time between exposure and vaccination.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>We did not subject the results of the included studies to meta-analysis and we did not undertake a sensitivity analysis.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-06-30 13:15:58 +1000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2014-06-19 01:10:18 +1000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>The original search identified 780 studies. After eliminating duplicate reports and studies not concerned with varicella vaccine, we examined the abstracts of 144 studies identified from the original searches and an additional 18 publications identified from reference lists.</P>
<P>In the updated searches we identified 222 articles, excluding duplicates, published since the original review. Additionally, we identified 25 potential studies published since the original review from the reference lists or citation reports of previously included studies. After eliminating duplicates and studies not concerned with varicella vaccine, we examined 108 abstracts.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>Three studies from the original review were eligible for inclusion. We identified no further eligible studies in this updated review. All included studies reported on the use of varicella vaccine as a PEP following household exposure of non-immune children to siblings with varicella (<LINK REF="STD-Arbeter-1986a" TYPE="STUDY">Arbeter 1986a</LINK>; <LINK REF="STD-Asano-1977a" TYPE="STUDY">Asano 1977a</LINK>; <LINK REF="STD-Mor-2004" TYPE="STUDY">Mor 2004</LINK>). These studies were conducted over a 27-year time period in Japan, the United States and Israel, respectively. The three studies used three different live attenuated varicella vaccines that varied substantially in viral titre. One of these PEP studies was reported in a publication that reviewed a number of clinical trials on the use of varicella vaccine in different settings (<LINK REF="STD-Arbeter-1986a" TYPE="STUDY">Arbeter 1986a</LINK>). See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-06-19 01:10:18 +1000" MODIFIED_BY="[Empty name]">
<P>We excluded a total of 267 studies: 107 from the updated review and 160 from the original review. See <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<P>Eight uncontrolled studies or observational studies reported on the use of varicella vaccine as a PEP in non-hospital settings (<LINK REF="STD-Asano-1982" TYPE="STUDY">Asano 1982</LINK>; <LINK REF="STD-Brotons-2010" TYPE="STUDY">Brotons 2010</LINK>; <LINK REF="STD-Getaz-2010" TYPE="STUDY">Getaz 2010</LINK>; <LINK REF="STD-Naganuma-1984" TYPE="STUDY">Naganuma 1984</LINK>; <LINK REF="STD-Ma-2009a" TYPE="STUDY">Ma 2009a</LINK>; <LINK REF="STD-Pinochet-2012" TYPE="STUDY">Pinochet 2012</LINK>; <LINK REF="STD-Salzman-1998" TYPE="STUDY">Salzman 1998</LINK>; <LINK REF="STD-Watson-2000" TYPE="STUDY">Watson 2000</LINK>). We also identified a number of placebo-controlled RCTs of varicella vaccines. However, these studies did not examine the use of the vaccine as a PEP. These included placebo-controlled RCTs on the use of varicella vaccine in healthy children for the prevention of varicella (<LINK REF="STD-Ferrera-2009" TYPE="STUDY">Ferrera 2009</LINK>; <LINK REF="STD-Kuter-1991" TYPE="STUDY">Kuter 1991</LINK>; <LINK REF="STD-Meurice-1996" TYPE="STUDY">Meurice 1996</LINK>; <LINK REF="STD-Varis-1996" TYPE="STUDY">Varis 1996</LINK>; <LINK REF="STD-Weibel-1984" TYPE="STUDY">Weibel 1984</LINK>), and placebo-controlled RCTs of the use of varicella vaccine (either live attenuated or heat-inactivated) for the prevention of any VZV disease in oncology patients undergoing chemotherapy or bone marrow transplantation (<LINK REF="STD-Cristofani-1991" TYPE="STUDY">Cristofani 1991</LINK>; <LINK REF="STD-Hardy-1991" TYPE="STUDY">Hardy 1991</LINK>; <LINK REF="STD-Hata-2002" TYPE="STUDY">Hata 2002</LINK>; <LINK REF="STD-Redman-1997" TYPE="STUDY">Redman 1997</LINK>; <LINK REF="STD-Yeung-1992" TYPE="STUDY">Yeung 1992</LINK>). We excluded placebo-controlled RCTs and other studies examining high-titre VZV vaccines for the prevention of herpes zoster in healthy adults (<LINK REF="STD-Gilderman-2008" TYPE="STUDY">Gilderman 2008</LINK>; <LINK REF="STD-Macaladad-2007" TYPE="STUDY">Macaladad 2007</LINK>; <LINK REF="STD-Mills-2010" TYPE="STUDY">Mills 2010</LINK>; <LINK REF="STD-Oxman-2005" TYPE="STUDY">Oxman 2005</LINK>; <LINK REF="STD-Oxman-2008" TYPE="STUDY">Oxman 2008</LINK>; <LINK REF="STD-Simberkoff-2010" TYPE="STUDY">Simberkoff 2010</LINK>; <LINK REF="STD-Trannoy-2000" TYPE="STUDY">Trannoy 2000</LINK>). Many of the other clinical trials on the use of varicella vaccine did not have a prospective RCT design; if controls were reported, they were often non-randomised and historical. A number of studies reported long-term follow-up of vaccinees in terms of immunogenicity, vaccine effectiveness or safety, without control subjects. Other studies not eligible for this review were designed to examine the immunogenicity and safety of varicella vaccine when used concomitantly with other routinely administered vaccines, were dose-ranging studies of varicella vaccine or reported on the immunogenicity and safety of combination measles-mumps-rubella vaccine (MMRV) compared with use of MMR and monovalent varicella vaccine.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors (KM, PM) independently assessed allocation method, allocation concealment, blinding and completeness of follow-up. We did not perform synthesis of results from these three studies as the overall quality was low and bias could not be excluded.</P>
<ALLOCATION MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>The study by <LINK REF="STD-Asano-1977a" TYPE="STUDY">Asano 1977a</LINK> was not blinded and the method of randomisation and completeness of follow-up was unclear. Similarly, the method of randomisation and allocation concealment in the study by <LINK REF="STD-Arbeter-1986a" TYPE="STUDY">Arbeter 1986a</LINK> was unclear. The study by <LINK REF="STD-Mor-2004" TYPE="STUDY">Mor 2004</LINK> stated the method of sequence allocation and concealment and was triple-blinded with no further information included.</P>
</ALLOCATION>
<BLINDING MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>The study by <LINK REF="STD-Arbeter-1986a" TYPE="STUDY">Arbeter 1986a</LINK> was reported to be double-blinded and completeness of follow-up was stated. However, the duration of follow-up was not specified. The most recent study included more complete follow-up and adequate data with regards to methodological quality (<LINK REF="STD-Mor-2004" TYPE="STUDY">Mor 2004</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-03-18 10:06:28 +1000" MODIFIED_BY="Liz Dooley">
<P>For the studies <LINK REF="STD-Arbeter-1986a" TYPE="STUDY">Arbeter 1986a</LINK> and <LINK REF="STD-Mor-2004" TYPE="STUDY">Mor 2004</LINK> there were no missing outcome data. However, for <LINK REF="STD-Asano-1977a" TYPE="STUDY">Asano 1977a</LINK> there was insufficient reporting to permit judgement.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-03-17 13:23:05 +1000" MODIFIED_BY="[Empty name]">
<P>The published reports included all expected outcomes, including those that were pre-specified.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-03-17 13:48:09 +1000" MODIFIED_BY="[Empty name]">
<P>No other potential sources of bias were identified. </P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-06-30 13:15:58 +1000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Prevention of varicella in contacts of a varicella case</HEADING>
<P>The efficacy of varicella vaccine (given within five days post-exposure) as prophylaxis for the prevention of varicella was assessed in a total of 110 healthy children in the three included studies (<LINK REF="STD-Arbeter-1986a" TYPE="STUDY">Arbeter 1986a</LINK>; <LINK REF="STD-Asano-1977a" TYPE="STUDY">Asano 1977a</LINK>; <LINK REF="STD-Mor-2004" TYPE="STUDY">Mor 2004</LINK>). Overall, 13 of 56 vaccine recipients developed varicella (23%) compared with 42 of 54 placebo (or no vaccine) recipients (78%). <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> summarises the results of the studies by 'no disease' and 'mild disease'. The quality of the studies varied, therefore the vaccine used in each study differed (particularly in viral titre) and as there was diversity in the study design and outcome measures chosen we did not deem it appropriate to subject the combined results to a meta-analysis.</P>
<P>The majority of all study participants who received varicella vaccine did so within three days post-exposure: 10/13 participants in <LINK REF="STD-Arbeter-1986a" TYPE="STUDY">Arbeter 1986a</LINK>; 20/21 participants in <LINK REF="STD-Asano-1977a" TYPE="STUDY">Asano 1977a</LINK>; and 41% of vaccine recipients compared with 45% of placebo recipients in <LINK REF="STD-Mor-2004" TYPE="STUDY">Mor 2004</LINK>. However, in the study by <LINK REF="STD-Mor-2004" TYPE="STUDY">Mor 2004</LINK>, outcomes limited to those who received vaccine within three days were not separately described. Thus, the efficacy of varicella vaccine in preventing varicella when given within three days post-exposure could only be assessed in 64 healthy children from two studies (<LINK REF="STD-Arbeter-1986a" TYPE="STUDY">Arbeter 1986a</LINK>; <LINK REF="STD-Asano-1977a" TYPE="STUDY">Asano 1977a</LINK>).</P>
<P>Comparison of the efficacy of post-exposure prophylaxis (PEP) administered on days four and five post-exposure, with vaccination administered within three days of exposure, was not possible due to the low number of participants who were known to have received vaccine on days four or five. However, in the study by <LINK REF="STD-Arbeter-1986a" TYPE="STUDY">Arbeter 1986a</LINK>, the three participants who received vaccine on days four or five all developed clinical disease, although of mild severity. In the study by <LINK REF="STD-Asano-1977a" TYPE="STUDY">Asano 1977a</LINK>, the single participant who received vaccine beyond three days (five days) did not develop the disease. In the study by <LINK REF="STD-Mor-2004" TYPE="STUDY">Mor 2004</LINK>, 59% of vaccine recipients were immunised more than 72 hours after their household exposure, which may have contributed to a decrease in vaccine efficacy seen in comparison to the other studies (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). The study by <LINK REF="STD-Mor-2004" TYPE="STUDY">Mor 2004</LINK> was also notable for a low secondary attack rate in the control participants (9/20 cases of varicella, 45%) in comparison to that seen in the earlier studies, where 100% and 92%, respectively, of control participants developed varicella. Varicella in a household member usually results in infection in almost all susceptible people in that household in the absence of any intervention, with secondary attack rates of more than 90% reported (<LINK REF="REF-Gershon-2013" TYPE="REFERENCE">Gershon 2013</LINK>; <LINK REF="REF-Simpson-1952" TYPE="REFERENCE">Simpson 1952</LINK>). The reason for the low rate of varicella in placebo recipients in the <LINK REF="STD-Mor-2004" TYPE="STUDY">Mor 2004</LINK> study is unclear.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Vaccine adverse events including local injection site adverse events, fever and systemic adverse events</HEADING>
<P>The pre-determined safety outcomes of the review, such as local injection site reactions, fever and other systemic and serious adverse events were not reported in any of the three studies included in this review.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Prevention of moderate to severe varicella in contacts of a varicella case</HEADING>
<P>As shown in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>, all vaccine recipients experienced either no disease or only mild disease, with the exception of one participant in the study of <LINK REF="STD-Mor-2004" TYPE="STUDY">Mor 2004</LINK> who had moderate to severe varicella. All three studies showed an effect individually in the prevention of moderate to severe disease. Of the 34 recipients in the two studies in which efficacy of post-exposure vaccination within three days could be assessed (<LINK REF="STD-Arbeter-1986a" TYPE="STUDY">Arbeter 1986a</LINK>; <LINK REF="STD-Asano-1977a" TYPE="STUDY">Asano 1977a</LINK>), none developed moderate to severe disease compared with 33 of 34 in the control groups.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-06-23 09:56:25 +1000" MODIFIED_BY="Liz Dooley">
<P>This review was limited by the small number of studies eligible for inclusion. In addition, the methodological quality of the studies varied and the number of participants in each study was small. The studies identified only included children who were household contacts of varicella cases.</P>
<P>The varicella vaccines used in the studies examined were produced in three different laboratories over a long period of time and were of different titres. Although the parent vaccine strain of all varicella vaccines was the Oka strain, originally adapted by <LINK REF="STD-Takahashi-1974" TYPE="STUDY">Takahashi 1974</LINK>, subsequent adaptation has occurred by the different vaccine manufacturers. For example, the Oka/Merck vaccine lot used in the <LINK REF="STD-Arbeter-1986a" TYPE="STUDY">Arbeter 1986a</LINK> trial was of the highest dose (4350 plaque-forming units (pfu)), whereas the Oka/GlaxoSmithKline vaccine (Varilrix) contained more than 2000 pfu/dose and the Oka/Biken vaccine contained between 800 to 1000 pfu/dose. The variation in vaccine titre in these studies does not appear to correlate with the results obtained. However, it is worth noting that only the most recent study used a commercially available vaccine (<LINK REF="STD-Mor-2004" TYPE="STUDY">Mor 2004</LINK>).</P>
<P>The results of this review provide limited support for the use of varicella vaccine as a post-exposure prophylaxis (PEP) within three days post-exposure, based on the small number of participants in the studies examined and the variations between the studies described above. Given the incubation period for varicella, it is biologically plausible that varicella vaccine given four to five days after exposure results in some protection against the disease. However, the studies included in this review contain too few participants documented as having received PEP on days four to five to make any conclusions.</P>
<P>The conclusions of this review are supported by a number of observational studies that did not meet the inclusion criteria. In two early Japanese studies (without control participants) vaccine (Oka/Biken, at more than 800 pfu/dose), given as a PEP within three days of exposure, protected all recipients against varicella, whereas children vaccinated more than three days post-exposure were likely to develop the disease (<LINK REF="STD-Asano-1982" TYPE="STUDY">Asano 1982</LINK>; <LINK REF="STD-Naganuma-1984" TYPE="STUDY">Naganuma 1984</LINK>). Five additional uncontrolled or observational studies showed similar findings. The first, conducted during a disease outbreak in a homeless shelter, found that PEP with the licensed Oka/Merck vaccine (more than 1350 pfu/dose) at 36 hours post-exposure had a vaccine effectiveness of 95.2% (95% confidence interval (CI) 81.6% to 91.8%) for children under 13 years of age (<LINK REF="STD-Watson-2000" TYPE="STUDY">Watson 2000</LINK>). Three prospective studies report PEP provided to sibling household contacts. One used the Oka/Merck vaccine, with seven families reporting no disease (50%) or mild disease (50%) in household contact vaccine recipients (<LINK REF="STD-Salzman-1998" TYPE="STUDY">Salzman 1998</LINK>). The other study found PEP with either the Oka/Merck vaccine or the Oka/GSK vaccine was 62.3% effective in preventing any varicella and 79.4% effective in preventing moderate to severe varicella when administered to household contacts within five days after exposure (<LINK REF="STD-Brotons-2010" TYPE="STUDY">Brotons 2010</LINK>). The third, a small cohort study of 33 children, reported a vaccine effectiveness of 40% (95% CI 1% to 64%) against any disease and 77% (95% CI 14% to 94%) against severe disease when the vaccine was received within three days (<LINK REF="STD-Pinochet-2012" TYPE="STUDY">Pinochet 2012</LINK>). A prospective study of PEP in four large primary schools in Beijing, China reported varicella vaccine effectiveness of 85.3% in susceptible children within the same classrooms, floors or school buildings (<LINK REF="STD-Ma-2009a" TYPE="STUDY">Ma 2009a</LINK>). A number of other studies in Japan, conducted without control participants in hospital settings, also suggested that vaccines used as PEP were efficacious (<LINK REF="STD-Asano-1977b" TYPE="STUDY">Asano 1977b</LINK>; <LINK REF="STD-Asano-1983" TYPE="STUDY">Asano 1983</LINK>; <LINK REF="STD-Katsushima-1982" TYPE="STUDY">Katsushima 1982</LINK>; <LINK REF="STD-Katsushima-1984" TYPE="STUDY">Katsushima 1984</LINK>; <LINK REF="STD-Naganuma-1984" TYPE="STUDY">Naganuma 1984</LINK>; <LINK REF="STD-Takahashi-1974" TYPE="STUDY">Takahashi 1974</LINK>).</P>
<P>Unfortunately, the trials in this review do not provide information on the safety of varicella vaccines when used as a PEP. Information regarding adverse events following varicella vaccination is available from other randomised controlled trials (RCTs) identified but not included in this review (<LINK REF="STD-Varis-1996" TYPE="STUDY">Varis 1996</LINK>; <LINK REF="STD-Weibel-1984" TYPE="STUDY">Weibel 1984</LINK>), and from post-licensure studies of the safety of varicella vaccine, particularly from the USA where a population-based varicella vaccination programme has been in place for more than 15 years and has demonstrated that the vaccine has a good safety profile. Safety of varicella vaccines used as a PEP would be expected to be similar to data from these population-based studies (<LINK REF="REF-Black-1999" TYPE="REFERENCE">Black 1999</LINK>; <LINK REF="REF-Sharrar-2000" TYPE="REFERENCE">Sharrar 2000</LINK>; <LINK REF="STD-Wise-2000" TYPE="STUDY">Wise 2000</LINK>).</P>
<P>The use of antiviral medication (acyclovir) in immunocompetent contacts of varicella cases has been suggested to be effective as PEP by a few small, uncontrolled observational studies and isolated case reports. However, this option is not currently recommended, based on the lack of data supporting its use (<LINK REF="REF-Kesson-1996" TYPE="REFERENCE">Kesson 1996</LINK>; <LINK REF="REF-Marin-2007" TYPE="REFERENCE">Marin 2007</LINK>; <LINK REF="REF-Ogilvie-1998" TYPE="REFERENCE">Ogilvie 1998</LINK>). In summary, the conclusions of this review provide some limited support for the use of varicella vaccine as the method of choice for PEP in healthy children, particularly when administered within three days following exposure in the household setting.</P>
<SUMMARY_OF_RESULTS MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>There is limited evidence from RCTs to support the effectiveness of varicella vaccine as a PEP in preventing varicella. Overall, 18% of vaccine recipients developed varicella compared with 78% of placebo (or no vaccine) recipients. Varicella vaccine as a PEP was effective in preventing moderate to severe disease. Overall, only one vaccine recipient developed moderate to severe disease (2%) compared to 41 (29%) placebo recipients.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>The studies included in this review are relevant to the question of the efficacy of varicella vaccine for use as a post-exposure intervention. However, the studies are limited to contacts with household exposure and this restricts the generalisability of PEP to settings where a known contact is present and secondary transmission rates are high. No studies in outbreak settings, such as childcare or primary school settings, were included in this review. We identified no studies of PEP in adolescents and adults.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>The body of evidence identified here provides limited evidence to support the review objectives. Only three RCTs of varying methodological quality were included in this review, with a total of 110 healthy children, randomised to receive the varicella vaccine (56 children) or placebo/no vaccine (54 children).</P>
<P>While study quality varied, these three studies were consistently in support of the use of varicella vaccine as PEP.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-03-17 13:17:47 +1000" MODIFIED_BY="[Empty name]">
<P>It is likely that all relevant RCTs were identified for this review. This study is limited to RCTs of the use of varicella vaccine as PEP.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-06-23 09:56:25 +1000" MODIFIED_BY="Liz Dooley">
<P>The RCTs in this review are supported by observational studies reporting the use of varicella vaccine as PEP (<LINK REF="STD-Asano-1982" TYPE="STUDY">Asano 1982</LINK>; <LINK REF="STD-Asano-1983" TYPE="STUDY">Asano 1983</LINK>; <LINK REF="STD-Brotons-2010" TYPE="STUDY">Brotons 2010</LINK>; <LINK REF="STD-Katsushima-1982" TYPE="STUDY">Katsushima 1982</LINK>; <LINK REF="STD-Katsushima-1984" TYPE="STUDY">Katsushima 1984</LINK>; <LINK REF="STD-Ma-2009a" TYPE="STUDY">Ma 2009a</LINK>; <LINK REF="STD-Naganuma-1984" TYPE="STUDY">Naganuma 1984</LINK>; <LINK REF="STD-Pinochet-2012" TYPE="STUDY">Pinochet 2012</LINK>; <LINK REF="STD-Salzman-1998" TYPE="STUDY">Salzman 1998</LINK>; <LINK REF="STD-Takahashi-1974" TYPE="STUDY">Takahashi 1974</LINK>; <LINK REF="STD-Watson-2000" TYPE="STUDY">Watson 2000</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-06-23 09:58:38 +1000" MODIFIED_BY="Liz Dooley">
<IMPLICATIONS_PRACTICE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>This review provides information relevant to immunisation policy makers. Routine childhood varicella vaccination has been provided through publicly funded immunisation programmes in few countries. Experience indicates that varicella zoster virus (VZV) circulation persists, despite moderately high vaccine coverage and therefore the risk of exposure of unimmunised individuals to those with varicella also persists. In countries that do not recommend the routine use of varicella vaccine, it may be recommended for susceptible adolescents and adults or certain high-risk groups. In countries without routine childhood immunisation, post-exposure prophylaxis (PEP) is relevant for those at high risk of severe varicella or at high risk of transmission. This study provides limited support for the use of varicella vaccine as PEP in settings where a known contact is present and secondary transmission rates are high. The findings of this review are particularly applicable to young children in the household or other close contact settings. However, safety data are not available.</P>
<P>Many countries recommend or suggest consideration of the use of varicella vaccine in PEP (<LINK REF="REF-ATAGI-2013" TYPE="REFERENCE">ATAGI 2013</LINK>; <LINK REF="REF-Marin-2007" TYPE="REFERENCE">Marin 2007</LINK>; <LINK REF="REF-NACI-2004" TYPE="REFERENCE">NACI 2004</LINK>). This review found some evidence to support that recommendation in children. This may be particularly relevant for the control of outbreaks in settings with low to moderate varicella vaccine coverage. Additional studies are required of the use of PEP in adolescents and adults who, by virtue of their age, experience higher rates of complications from varicella and have lower seroconversion rates following one dose of vaccine. It is possible that the efficacy of PEP may be reduced in people older than 13 years of age, who require two doses of the varicella vaccine schedule to generate a sufficient primary immune response.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-06-23 09:58:38 +1000" MODIFIED_BY="Liz Dooley">
<P>The focus of this review has been the use of live attenuated varicella vaccine for PEP in healthy participants. In immunocompetent people, there is qualified evidence for the effectiveness of varicella vaccine within three to five days of exposure. People who are significantly immunocompromised are generally not considered eligible to receive live viral vaccines but are known to experience the highest morbidity from varicella. The use of inactivated VZV vaccines for the prevention of varicella, herpes zoster or both has been the subject of studies in immunocompromised people (<LINK REF="STD-Hata-2002" TYPE="STUDY">Hata 2002</LINK>; <LINK REF="STD-Redman-1997" TYPE="STUDY">Redman 1997</LINK>) and should be the topic of further study and review. There is very limited evidence for the value (if any) of the alternative use of chemoprophylaxis with antiviral agents for PEP (<LINK REF="REF-Gershon-2013" TYPE="REFERENCE">Gershon 2013</LINK>). A head-to-head trial of varicella vaccine compared with chemoprophylaxis within five days of a varicella exposure may be justified.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>The review authors acknowledge Dr Barbara Law and Dr Louise Coole who drafted the original protocol for this review and began work on a review of the efficacy and safety of varicella zoster vaccines for use in a population-based context in healthy children and adults. The review authors also thank Ms Catherine King and Dr Greta Ridley for assistance in the preparation of this review. Acknowledgements also go to the following people for their valuable input and comments on the draft review: Marian Nicholson, Barbara Watson, Vic Spain and Robert Ware.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>Peter McIntyre is a member of the Australian Technical Advisory Group on Immunisation (ATAGI) in Australia, which provides advice on the clinical use of vaccines.<BR/>Kristine Macartney is the Deputy Director of Policy Support at the National Centre for Immunisation Research and Surveillance and also provides advice on policy related to immunisation in Australia.<BR/>Anita Hayward has received funding to conduct investigator-driven research from GSK and Sanofi Pasteur.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>Kristine Macartney (KM) was the primary author of this review. Anita Heywood (AH) updated the review and contributed to revisions. Peter McIntyre (PM) contributed revisions and gave additional input as co-author.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>The original published protocol for this review was broad-ranging and included the objectives of reviewing varicella vaccine efficacy and safety in the context of its use as a population-based preventative measure against varicella zoster virus infection. The review authors now feel that the original aims of the protocol, particularly regarding the use of vaccine in healthy children, may have been superceded by the considerable evidence on vaccine effectiveness that has come from the United States. The review authors decided to modify the review and focus on looking at vaccine use in post-exposure prophylaxis, as this is probably the most pertinent information currently available.<BR/>
</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-06-23 09:19:07 +1000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-06-19 01:28:09 +1000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-04-15 13:13:23 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Arbeter-1986a" NAME="Arbeter 1986a" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arbeter AM, Starr SE, Weibel RE, Plotkin SA</AU>
<TI>Varicella vaccine studies in healthy children and adults</TI>
<SO>Pediatrics</SO>
<YR>1986</YR>
<VL>78</VL>
<NO>Suppl</NO>
<PG>748-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Asano-1977a" MODIFIED="2008-04-15 13:13:23 +1000" MODIFIED_BY="[Empty name]" NAME="Asano 1977a" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;Asano Y, Nakayama H, Yazaki T, Kato R, Hirose S. &lt;br&gt;Protection against varicella in family contacts by immediate inoculation with&lt;br&gt;live varicella vaccine.Pediatrics 1977;59:3-7.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asano Y, Nakayama H, Yazaki T, Kato R, Hirose S</AU>
<TI>Protection against varicella in family contacts by immediate inoculation with live varicella vaccine</TI>
<SO>Pediatrics</SO>
<YR>1977</YR>
<VL>59</VL>
<PG>3-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mor-2004" NAME="Mor 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Mor M, Harel L, Kahan E, Amir J. Efficacy of postexposure immunization with live attenuated varicella vaccine in the household setting--a pilot study. Vaccine 2004; 23 :325-328&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mor M, Harel L, Kahan E, Amir J</AU>
<TI>Efficacy of postexposure immunization with live attenuated varicella vaccine in the household setting - a pilot study</TI>
<SO>Vaccine</SO>
<YR>2004</YR>
<VL>23</VL>
<PG>325-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-06-19 01:28:09 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Akazawa-2013" MODIFIED="2014-06-18 22:10:39 +1000" MODIFIED_BY="[Empty name]" NAME="Akazawa 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-06-18 22:10:39 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akazawa M, Yongue J, Ikeda S, Satoh T</AU>
<TI>Considering economic analyses in the revision of the preventive vaccination law: a new direction for health policy-making in Japan?</TI>
<SO>Value in Health</SO>
<YR>2013</YR>
<VL>16</VL>
<NO>7</NO>
<PG>A364</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alpay-2002" NAME="Alpay 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Alpay H, Yildiz N, Onar A, Temizer H, Ozcay S. Varicella vaccination in children with steroid-sensitive nephrotic syndrome. Pediatric Nephrology 2002; 17 :181-183&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alpay H, Yildiz N, Onar A, Temizer H, Ozcay S</AU>
<TI>Varicella vaccination in children with steroid-sensitive nephrotic syndrome</TI>
<SO>Pediatric Nephrology</SO>
<YR>2002</YR>
<VL>17</VL>
<PG>181-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ampofo-2002" NAME="Ampofo 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Ampofo K, Saiman L, LaRussa P, Steinberg S, Annunziato P, Gershon A. Persistence of immunity to live attenuated varicella vaccine in healthy adults. Clinical Infectious Diseases 2002; 34 :774-779&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ampofo K, Saiman L, LaRussa P, Steinberg S, Annunziato P, Gershon A</AU>
<TI>Persistence of immunity to live attenuated varicella vaccine in healthy adults</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2002</YR>
<VL>34</VL>
<PG>774-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andrei-2011" MODIFIED="2014-03-28 16:31:42 +1000" MODIFIED_BY="[Empty name]" NAME="Andrei 2011" YEAR="2011 Sep">
<REFERENCE MODIFIED="2014-03-28 16:31:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andrei G, Snoeck R</AU>
<TI>Emerging drugs for varicella-zoster virus infections</TI>
<SO>Expert Opinion of Emerging Drugs</SO>
<YR>2011</YR>
<VL>16</VL>
<NO>3</NO>
<PG>507-35</PG>
<IDENTIFIERS MODIFIED="2014-03-26 10:27:44 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arbeter-1982" NAME="Arbeter 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Arbeter AM, Starr SE, Weibel RE, Plotkin SA. Live attenuated varicella vaccine: immunization of healthy children with the OKA strain. Journal of Pediatrics 1982; 100 :886-893&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arbeter AM, Starr SE, Weibel RE, Plotkin SA</AU>
<TI>Live attenuated varicella vaccine: immunization of healthy children with the OKA strain</TI>
<SO>Journal of Pediatrics</SO>
<YR>1982</YR>
<VL>100</VL>
<PG>886-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arbeter-1983" NAME="Arbeter 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Arbeter AM, Starr SE, Weibel RE, Neff BJ, Plotkin SA. Live attenuated varicella vaccine: the KMcC strain in healthy children. Pediatrics 1983; 71(3):307-312.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arbeter AM, Starr SE, Weibel RE, Neff BJ, Plotkin SA</AU>
<TI>Live attenuated varicella vaccine: the KMcC strain in healthy children</TI>
<SO>Pediatrics</SO>
<YR>1983</YR>
<VL>71</VL>
<NO>3</NO>
<PG>307-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arbeter-1984" NAME="Arbeter 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Arbeter AM, Starr SE, Preblud SR, Ihara T, Paciorek PM, Miller DS, Zelson CM, Proctor EA, Plotkin SA. Varicella vaccine trials in healthy children. A summary of comparative and follow-up studies. American Journal of Diseases of Children 1984; 138 :434-438&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arbeter AM, Starr SE, Preblud SR, Ihara T, Paciorek PM, Miller DS et al</AU>
<TI>Varicella vaccine trials in healthy children. A summary of comparative and follow-up studies</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1984</YR>
<VL>138</VL>
<PG>434-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arbeter-1986" MODIFIED="2014-03-26 12:00:55 +1000" MODIFIED_BY="[Empty name]" NAME="Arbeter 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Arbeter AM, Starr SE, Plotkin SA. Varicella vaccine studies in healthy children and adults. Pediatrics 1986; 78 :748-756&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arbeter AM, Starr SE, Plotkin SA</AU>
<TI>Varicella vaccine studies in healthy children and adults</TI>
<SO>Pediatrics</SO>
<YR>1986</YR>
<VL>78</VL>
<PG>748-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arbeter-1990" NAME="Arbeter 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Arbeter AM, Granowetter L, Starr SE, Lange B, Wimmer R, Plotkin SA. Immunization of children with acute lymphoblastic leukemia with live attenuated varicella vaccine without complete suspension of chemotherapy. Pediatrics 1990; 85(3):338-344.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arbeter AM, Granowetter L, Starr SE, Lange B, Wimmer R, Plotkin SA</AU>
<TI>Immunization of children with acute lymphoblastic leukemia with live attenuated varicella vaccine without complete suspension of chemotherapy</TI>
<SO>Pediatrics</SO>
<YR>1990</YR>
<VL>85</VL>
<NO>3</NO>
<PG>338-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arent-2009" MODIFIED="2014-03-26 12:18:24 +1000" MODIFIED_BY="[Empty name]" NAME="Arent 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-03-26 12:18:24 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arent PM, Cunha L, Freitas PF</AU>
<TI>Vaccination status among medical students of Universidade do Sul de Santa Catarina before internship</TI>
<TO>Situação vacinal dos estudantes de medicina da Universidade do Sul de Santa Catarina no período prévio ao internato</TO>
<SO>Revista de Ciências Médicas</SO>
<YR>2009</YR>
<VL>18</VL>
<NO>1</NO>
<PG>13-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Asano-1975" NAME="Asano 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;Asano Y, Yazaki T, Miyata T, Nakayama H, Hirose S. Application of a live attenuated varicella vaccine to hospitalized children and its protective effect on spread of varicella infection. Biken Journal 1975; 18 :35-40&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asano Y, Yazaki T, Miyata T, Nakayama H, Hirose S</AU>
<TI>Application of a live attenuated varicella vaccine to hospitalized children and its protective effect on spread of varicella infection</TI>
<SO>Biken Journal</SO>
<YR>1975</YR>
<VL>18</VL>
<PG>35-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Asano-1977b" MODIFIED="2014-03-26 10:28:25 +1000" MODIFIED_BY="[Empty name]" NAME="Asano 1977b" YEAR="1977">
<REFERENCE MODIFIED="2014-03-26 10:28:25 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Asano Y, Takahashi M. Clinical and serologic testing of a live varicella vaccine and two-year follow-up for immunity of the vaccinated children. Pediatrics 1977; 60 :810-814&lt;/p&gt;" NOTES_MODIFIED="2014-03-26 10:28:25 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asano Y, Takahashi M</AU>
<TI>Clinical and serologic testing of a live varicella vaccine and two-year follow-up for immunity of the vaccinated children</TI>
<SO>Pediatrics</SO>
<YR>1977</YR>
<VL>60</VL>
<PG>810-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Asano-1977c" MODIFIED="2008-04-15 13:13:08 +1000" MODIFIED_BY="[Empty name]" NAME="Asano 1977c" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;Asano Y, Nakayama H, Yazaki T, Ito S, Isomura S. Protective efficacy of vaccination in children in four episodes of natural varicella and zoster in the ward. Pediatrics 1977; 59 :8-12&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asano Y, Nakayama H, Yazaki T, Ito S, Isomura S</AU>
<TI>Protective efficacy of vaccination in children in four episodes of natural varicella and zoster in the ward</TI>
<SO>Pediatrics</SO>
<YR>1977</YR>
<VL>59</VL>
<PG>8-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Asano-1982" MODIFIED="2014-03-26 10:28:30 +1000" MODIFIED_BY="[Empty name]" NAME="Asano 1982" YEAR="1982">
<REFERENCE MODIFIED="2014-03-26 10:28:30 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Asano Y, Hirose S, Iwayama S, Miyata T, Yazaki T, Takahashi M. Protective effect of immediate inoculation of a live varicella vaccine in household contacts in relation to the viral dose and interval between exposure and vaccination. Biken Journal 1982; 25 :43-45&lt;/p&gt;" NOTES_MODIFIED="2014-03-26 10:28:30 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asano Y, Hirose S, Iwayama S, Miyata T, Yazaki T, Takahashi M</AU>
<TI>Protective effect of immediate inoculation of a live varicella vaccine in household contacts in relation to the viral dose and interval between exposure and vaccination</TI>
<SO>Biken Journal</SO>
<YR>1982</YR>
<VL>25</VL>
<PG>43-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Asano-1983" MODIFIED="2014-06-18 22:13:30 +1000" MODIFIED_BY="[Empty name]" NAME="Asano 1983" YEAR="1983">
<REFERENCE MODIFIED="2014-06-18 22:13:30 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asano Y, Albrecht P, Vujcic LK, Quinnan GV Jr, Kawakami K, Takahashi M</AU>
<TI>Five-year follow-up study of recipients of live varicella vaccine using enhanced neutralization and fluorescent antibody membrane antigen assays</TI>
<SO>Pediatrics</SO>
<YR>1983</YR>
<VL>72</VL>
<NO>3</NO>
<PG>291-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Asano-1984" MODIFIED="2014-06-18 22:14:00 +1000" MODIFIED_BY="[Empty name]" NAME="Asano 1984" YEAR="1984">
<REFERENCE MODIFIED="2014-06-18 22:14:00 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Asano Y, Nagai T, Miyata T, Yazaki T, Ito S, Yamanishi K, Takahashi M. Persistence of protective immunity after inoculation with live varicella vaccine (strain Oka). Biken Journal 1984; 27 :123-128&lt;/p&gt;" NOTES_MODIFIED="2014-06-18 22:14:00 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asano Y, Nagai T, Miyata T, Yazaki T, Ito S, Yamanishi K et al</AU>
<TI>Persistence of protective immunity after inoculation with live varicella vaccine (strain Oka)</TI>
<SO>Biken Journal</SO>
<YR>1984</YR>
<VL>27</VL>
<PG>123-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Asano-1985" NAME="Asano 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Asano Y, Nagai T, Miyata T, Yazaki T, Ito S, Yamanishi K et al. Long-term protective immunity of recipients of the OKA strain of live varicella vaccine. Pediatrics 1985; 75(4):667-671.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asano Y, Nagai T, Miyata T, Yazaki T, Ito S, Yamanishi K et al</AU>
<TI>Long-term protective immunity of recipients of the OKA strain of live varicella vaccine</TI>
<SO>Pediatrics</SO>
<YR>1985</YR>
<VL>75</VL>
<NO>4</NO>
<PG>667-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Asano-1994" NAME="Asano 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Asano Y, Suga S, Yoshikawa T, Kobayashi I, Yazaki T, Shibata M, Tsuzuki K, Ito S. Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics 1994; 94 :524-526&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asano Y, Suga S, Yoshikawa T, Kobayashi I, Yazaki T, Shibata M et al</AU>
<TI>Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine</TI>
<SO>Pediatrics</SO>
<YR>1994</YR>
<VL>94</VL>
<PG>524-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Asano-2008" MODIFIED="2014-03-17 15:43:27 +1000" MODIFIED_BY="Liz Dooley" NAME="Asano 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-03-17 15:43:27 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asano Y</AU>
<TI>Clinicopathologic understanding and control of varicella-zoster virus infection</TI>
<SO>Vaccine</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>50</NO>
<PG>6487-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bai-2011" MODIFIED="2014-06-19 01:28:09 +1000" MODIFIED_BY="[Empty name]" NAME="Bai 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-06-19 01:28:09 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bai YH, Yang LQ, Guo LS, Tao H, Ai X, Li L et al</AU>
<TI>Safety and immunogenicity of gelatin-free freeze-dried live attenuated varicella vaccine</TI>
<SO>Chinese Journal of Biologicals</SO>
<YR>2011</YR>
<VL>24</VL>
<NO>11</NO>
<PG>1336-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baldacci-2008" MODIFIED="2014-03-26 12:35:20 +1000" MODIFIED_BY="[Empty name]" NAME="Baldacci 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-03-26 12:35:20 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baldacci ER, Fagundes SN, Koch VH</AU>
<TI>Evaluation of chickenpox susceptibility in children with chronic renal failure</TI>
<TO>Avaliação da suscetibilidade à varicela no paciente pediátrico portador de insuficiência renal crônica</TO>
<SO>Revista Paulista de Pediatria</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>1</NO>
<PG>20-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bancillon-1991" NAME="Bancillon 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Bancillon A, Leblanc T, Baruchel A, Schaison G, Leverger G, Mallarmey D, Teuliere L. Study of tolerance and effectiveness of a varicella vaccine in leukemic children. Nouvelle Revue Francaise d Hematologie 1991; 33 :555-556&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bancillon A, Leblanc T, Baruchel A, Schaison G, Leverger G, Mallarmey D et al</AU>
<TI>Study of tolerance and effectiveness of a varicella vaccine in leukemic children</TI>
<SO>Nouvelle Revue Francaise d'Hematologie</SO>
<YR>1991</YR>
<VL>33</VL>
<PG>555-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Banz-2009" MODIFIED="2014-03-17 14:43:38 +1000" MODIFIED_BY="[Empty name]" NAME="Banz 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-03-17 14:43:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Banz K, Iseli A, Aebi C, Brunner M, Schmutz AM, Heininger U</AU>
<TI>Economic evaluation of varicella vaccination in Swiss children and adolescents</TI>
<SO>Human Vaccines</SO>
<YR>2009</YR>
<VL>5</VL>
<NO>12</NO>
<PG>847-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barbosa-2009" MODIFIED="2014-03-24 12:14:37 +1000" MODIFIED_BY="[Empty name]" NAME="Barbosa 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-03-24 12:14:37 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barbosa CMP, Terreri MT, Len CA, Moraes-Pinto MI, Rosario P, Hilario MO, et al</AU>
<TI>Varicella vaccine in children and adolescents with systemic lupus erythematosus (SLE) immunogenicity and safety</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2009</YR>
<VL>60</VL>
<PG>1521</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barbosa-2012" MODIFIED="2014-03-28 16:32:13 +1000" MODIFIED_BY="[Empty name]" NAME="Barbosa 2012" YEAR="2012 Sep-Oct">
<REFERENCE MODIFIED="2014-03-28 16:32:13 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barbosa CMPL, Terreri MTRA, Rosario PO, de Moraes-Pinto MI, Silva CAA, Hilario MOE</AU>
<TI>Immune response and tolerability of varicella vaccine in children and adolescents with systemic lupus erythematosus previously exposed to varicella-zoster virus</TI>
<SO>Clinical and Experimental Rheumatology</SO>
<YR>2012</YR>
<VL>30</VL>
<NO>5</NO>
<PG>791-8</PG>
<IDENTIFIERS MODIFIED="2014-03-26 10:21:57 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bate-2011" MODIFIED="2014-06-18 22:15:24 +1000" MODIFIED_BY="[Empty name]" NAME="Bate 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-06-18 22:15:24 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bate J, Chisholm J, Heath PT, Breuer J, Skinner R, Manley S, et al</AU>
<TI>PEPtalk: postexposure prophylaxis against varicella in children with cancer</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2011</YR>
<VL>96</VL>
<NO>9</NO>
<PG>841-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bednarek-2004" NAME="Bednarek 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Bednarek M, Majda-Stanislawska E. Varicella vaccination safety in children with allergy. Pediatria Polska&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bednarek M, Majda-Stanislawska E</AU>
<TI>Varicella vaccination safety in children with allergy</TI>
<SO>Pediatria Polska</SO>
<YR>2004</YR>
<VL>79</VL>
<PG>27-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bekker-2006" NAME="Bekker 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bekker V, Westerlaken GHA, Scherpbier H, Alders S, Zaaijer H, Van BD et al</AU>
<TI>Varicella vaccination in HIV-1-infected children after immune reconstitution</TI>
<SO>AIDS</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>18</NO>
<PG>2321-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergen-1990" NAME="Bergen 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Bergen RE, Diaz PS, Arvin AM. The immunogenicity of the Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content. Journal of Infectious Diseases 1990; 162 :1049-1054&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergen RE, Diaz PS, Arvin AM</AU>
<TI>The immunogenicity of the Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1990</YR>
<VL>162</VL>
<PG>1049-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berger-1984" NAME="Berger 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Berger R, Luescher D, Just M. Enhancement of varicella-zoster-specific immune responses in the elderly by boosting with varicella vaccine. Journal of Infectious Diseases 1984; 149(4):647.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berger R, Luescher D, Just M</AU>
<TI>Enhancement of varicella-zoster-specific immune responses in the elderly by boosting with varicella vaccine</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1984</YR>
<VL>149</VL>
<NO>4</NO>
<PG>647</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berger-1985" NAME="Berger 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Berger R, Amstutz I, Just M, Just V, Luescher D. Booster vaccination of healthy adults with VZV antibody but without a VZV-specific cell-mediated immune response. Antiviral Research 1985; Suppl 1 :267-271&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berger R, Amstutz I, Just M, Just V, Luescher D</AU>
<TI>Booster vaccination of healthy adults with VZV antibody but without a VZV-specific cell-mediated immune response</TI>
<SO>Antiviral Research</SO>
<YR>1985</YR>
<VL>Suppl 1</VL>
<PG>267-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berger-1998" NAME="Berger 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Berger R, Trannoy E, Hollander G, Bailleux F, Rudin C, Creusvaux H. A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. Journal of Infectious Diseases 1998; 178 Suppl 1 :S99-103&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berger R, Trannoy E, Hollander G, Bailleux F, Rudin C, Creusvaux H</AU>
<TI>A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1998</YR>
<VL>178</VL>
<NO>Suppl 1</NO>
<PG>99-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berghella-2010" MODIFIED="2014-03-17 15:44:27 +1000" MODIFIED_BY="Liz Dooley" NAME="Berghella 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-03-17 15:44:27 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berghella V, Buchanan E, Pereira L, Baxter JK</AU>
<TI>Preconception care</TI>
<SO>Obstetrical &amp; Gynecological Survey</SO>
<YR>2010</YR>
<VL>65</VL>
<NO>2</NO>
<PG>119-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-07-05 18:19:23 +1000" MODIFIED_BY="Anita E Heywood"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bernstein-1993" NAME="Bernstein 1993" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Bernstein HH, Rothstein EP, Watson BM, Reisinger KS, Blatter MM, Wellman CO, Chartrand SA, Cho I, Ngai A, White CJ. Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka/Merck varicella vaccine. Pediatrics 1993; 92 :833-837&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bernstein HH, Rothstein EP, Watson BM, Reisinger KS, Blatter MM, Wellman CO et al</AU>
<TI>Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka/Merck varicella vaccine</TI>
<SO>Pediatrics</SO>
<YR>1993</YR>
<VL>92</VL>
<PG>833-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Black-2006" NAME="Black 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Black SB, Cimino CO, Hansen J, Lewis E, Ray P, Corsaro B et al</AU>
<TI>Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>4</NO>
<PG>306-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Black-2008" MODIFIED="2014-03-17 15:44:41 +1000" MODIFIED_BY="Liz Dooley" NAME="Black 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-03-17 15:44:41 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Black S, Ray P, Shinefield H, Saddier P, Nikas A</AU>
<TI>Lack of association between age at varicella vaccination and risk of breakthrough varicella, within the Northern California Kaiser Permanente Medical Care Program</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2008</YR>
<VL>197</VL>
<NO>Suppl 2</NO>
<PG>S139-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blatter-2012" MODIFIED="2014-06-18 22:17:08 +1000" MODIFIED_BY="[Empty name]" NAME="Blatter 2012" YEAR="2012 Aug">
<REFERENCE MODIFIED="2014-06-18 22:17:08 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blatter MM, Klein NP, Shepard JS, Leonardi M, Shapiro S, Schear M et al</AU>
<TI>Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis A and pneumococcal conjugate vaccines to children twelve to fourteen months of age</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2012</YR>
<VL>31</VL>
<NO>8</NO>
<PG>e133-40</PG>
<IDENTIFIERS MODIFIED="2014-03-26 10:23:56 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bogger_x002d_Goren-1982" NAME="Bogger-Goren 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Bogger-Goren S, Baba K, Hurley P, Yabuuchi H, Takahashi M, Ogra PL. Antibody response to varicella-zoster virus after natural or vaccine-induced infection. Journal of Infectious Diseases 1982; 146(2):260-265.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bogger-Goren S, Baba K, Hurley P, Yabuuchi H, Takahashi M, Ogra PL</AU>
<TI>Antibody response to varicella-zoster virus after natural or vaccine-induced infection</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1982</YR>
<VL>146</VL>
<NO>2</NO>
<PG>260-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brotons-2010" MODIFIED="2014-06-18 23:09:26 +1000" MODIFIED_BY="[Empty name]" NAME="Brotons 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-06-18 23:09:26 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brotons M, Campins M, Mendez L, Juste C, Rodrigo JA, Martinex X et al</AU>
<TI>Effectiveness of varicella vaccines as postexposure prophylaxis</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2010</YR>
<VL>29</VL>
<NO>1</NO>
<PG>10-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Broyer-1985" NAME="Broyer 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Broyer M, Boudailliez B. Varicella vaccine in children with chronic renal insufficiency. Postgraduate Medical Journal 1985; 61 Suppl 4 :103-106&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Broyer M, Boudailliez B</AU>
<TI>Varicella vaccine in children with chronic renal insufficiency</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>1985</YR>
<VL>61</VL>
<NO>Suppl 4</NO>
<PG>103-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brunell-1982" MODIFIED="2014-06-18 23:09:50 +1000" MODIFIED_BY="[Empty name]" NAME="Brunell 1982" YEAR="1982">
<REFERENCE MODIFIED="2014-06-18 23:09:50 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Brunell PA, Shehab Z, Geiser C, Waugh JE. Administration of live varicella vaccine to children wtih leukaemia. Lancet 1982; 2(8307):1069-1073.&lt;/p&gt;" NOTES_MODIFIED="2014-06-18 23:09:50 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brunell PA, Shehab Z, Geiser C, Waugh JE</AU>
<TI>Administration of live varicella vaccine to children with leukaemia</TI>
<SO>Lancet</SO>
<YR>1982</YR>
<VL>2</VL>
<NO>8307</NO>
<PG>1069-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brunell-1986" NAME="Brunell 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Brunell PA, Taylor-Wiedeman J, Geiser CF, Frierson L, Lydick E. Risk of herpes zoster in children with leukemia: varicella vaccine compared with history of chickenpox. Pediatrics 1986; 77(1):53-56.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brunell PA, Taylor-Wiedeman J, Geiser CF, Frierson L, Lydick E</AU>
<TI>Risk of herpes zoster in children with leukemia: varicella vaccine compared with history of chickenpox</TI>
<SO>Pediatrics</SO>
<YR>1986</YR>
<VL>77</VL>
<NO>1</NO>
<PG>53-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brunell-1988" NAME="Brunell 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Brunell PA, Novelli VM, Lipton SV, Pollock B. Combined vaccine against measles, mumps, rubella, and varicella. Pediatrics 1988; 81 :779-784&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brunell PA, Novelli VM, Lipton SV, Pollock B</AU>
<TI>Combined vaccine against measles, mumps, rubella, and varicella</TI>
<SO>Pediatrics</SO>
<YR>1988</YR>
<VL>81</VL>
<PG>779-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bryant-2012" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Bryant 2012" YEAR="2012 Aug">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bryant K, McVernon J, Marchant C, Nolan T, Marshall G, Richmond P et al</AU>
<TI>Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers: a pooled analysis of randomized trials</TI>
<SO>Human Vaccines and Immunotherapeutics</SO>
<YR>2012</YR>
<VL>8</VL>
<NO>8</NO>
<PG>1036-41</PG>
<IDENTIFIERS MODIFIED="2014-03-26 10:25:37 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bryant-2013" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Bryant 2013" YEAR="2013 Apr">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bryant KA, Gurtman A, Girgenti D, Reisinger K, Johnson A, Pride MW et al</AU>
<TI>Antibody responses to routine pediatric vaccines administered with 13-valent pneumococcal conjugate vaccine</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2013</YR>
<VL>32</VL>
<NO>4</NO>
<PG>383-8</PG>
<IDENTIFIERS MODIFIED="2014-03-26 10:27:06 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burgess-1999" NAME="Burgess 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Burgess MA, Cossart YE, Wilkins TD, Botham S, Fearns G, Chitour K. Varicella vaccination of health-care workers. Vaccine 1999; 17(7-8):765-769.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burgess MA, Cossart YE, Wilkins TD, Botham S, Fearns G, Chitour K</AU>
<TI>Varicella vaccination of health-care workers</TI>
<SO>Vaccine</SO>
<YR>1999</YR>
<VL>17</VL>
<NO>7-8</NO>
<PG>765-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ceyhan-2009" MODIFIED="2014-03-17 15:45:27 +1000" MODIFIED_BY="Liz Dooley" NAME="Ceyhan 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-03-17 15:45:27 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ceyhan M, Tezer H, Yildirim I</AU>
<TI>Secondary attack rate of hepatitis A, varicella and mumps in household settings and reliability of family history to detect seronegative children for necessity of vaccination</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>2009</YR>
<VL>41</VL>
<NO>6-7</NO>
<PG>501-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chao-2012" MODIFIED="2014-04-28 09:35:12 +1000" MODIFIED_BY="[Empty name]" NAME="Chao 2012" YEAR="2000-2008. Epidemiol Infect. 2012 Jun">
<REFERENCE MODIFIED="2014-03-28 16:33:54 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chao DY, Chien YZ, Yeh YP, Hsu PS, Lian IB</AU>
<TI>The incidence of varicella and herpes zoster in Taiwan during a period of increasing varicella vaccine coverage, 2000-2008</TI>
<SO>Epidemiology and Infection</SO>
<YR>2012</YR>
<VL>140</VL>
<NO>6</NO>
<PG>1131-40</PG>
<IDENTIFIERS MODIFIED="2014-03-26 10:28:59 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-03-24 12:19:16 +1000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chlibek-2014" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Chlibek 2014" YEAR="2014">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JAR, Richardus JH et al</AU>
<TI>Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study</TI>
<SO>Vaccine</SO>
<YR>2014</YR>
<VL>32</VL>
<NO>15</NO>
<PG>1745-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chui-2014" MODIFIED="2014-03-24 12:14:37 +1000" MODIFIED_BY="[Empty name]" NAME="Chui 2014" YEAR="2014">
<REFERENCE MODIFIED="2014-03-24 12:14:37 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chui KS, Wu HL, You JHS</AU>
<TI>Cost-effectiveness analysis of varicella vaccine as post-exposure prophylaxis in Hong Kong</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>2014</YR>
<VL>46</VL>
<NO>1</NO>
<PG>27-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clements-1995" NAME="Clements 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Clements DA, Armstrong CB, Ursano AM, Moggio MM, Walter EB, Wilfert CM. Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents. Pediatric Infectious Disease Journal 1995; 14 :874-879&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clements DA, Armstrong CB, Ursano AM, Moggio MM, Walter EB, Wilfert CM</AU>
<TI>Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1995</YR>
<VL>14</VL>
<PG>874-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Contopoulos_x002d_Ioannidis-2012" MODIFIED="2014-03-27 16:17:35 +1000" MODIFIED_BY="Liz Dooley" NAME="Contopoulos-Ioannidis 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-03-27 16:17:35 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Contopoulos-Ioannidis DG, Seto I, Hamm MP, Thomson D, Hartling L, Ioannidis JPA, et al</AU>
<TI>Empirical evaluation of age groups and age-subgroup analyses in pediatric randomized trials and pediatric meta-analyses</TI>
<SO>Pediatrics</SO>
<YR>2012</YR>
<VL>129</VL>
<NO>Suppl 3</NO>
<PG>161-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cristofani-1991" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Cristofani 1991" YEAR="1991">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cristofani LM, Weinberg A, Peixoto V, Boas LS, Marques HH, Maluf Júnior PT et al</AU>
<TI>Administration of live attenuated varicella vaccine to children with cancer before starting chemotherapy</TI>
<SO>Vaccine</SO>
<YR>1991</YR>
<VL>9</VL>
<NO>12</NO>
<PG>873-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Czajka-2009" MODIFIED="2014-03-17 15:46:18 +1000" MODIFIED_BY="Liz Dooley" NAME="Czajka 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-03-17 15:46:18 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czajka H, Schuster V, Zepp F, Esposito S, Douha M, Willems P</AU>
<TI>A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile</TI>
<SO>Vaccine</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>41</NO>
<PG>6504-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-D_x0027_Angio-2007" NAME="D'Angio 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>D'Angio CT, Boohene PA, Mowrer A, Audet S, Menegus MA, Schmid DS et al</AU>
<TI>Measles-mumps-rubella and varicella vaccine responses in extremely preterm infants</TI>
<SO>Pediatrics</SO>
<YR>2007</YR>
<VL>119</VL>
<NO>3</NO>
<PG>574-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davies-1994" NAME="Davies 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Davies J, Hallworth JA, McLeish P, Randall S, Martin BA, Buchan A et al. Characterization and immunogenicity of a candidate subunit vaccine against varicella-zoster virus. Medical Microbiology &amp;amp; Immunology 1994; 183(2):105-117.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davies J, Hallworth JA, McLeish P, Randall S, Martin BA, Buchan A et al</AU>
<TI>Characterization and immunogenicity of a candidate subunit vaccine against varicella-zoster virus</TI>
<SO>Medical Microbiology &amp; Immunology</SO>
<YR>1994</YR>
<VL>183</VL>
<NO>2</NO>
<PG>105-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dennehy-1991" NAME="Dennehy 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Dennehy PH, Reisinger KS, Blatter MM, Veloudis BA. Immunogenicity of subcutaneous versus intramuscular Oka/Merck varicella vaccination in healthy children. Pediatrics 1991; 88 :604-607&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dennehy PH, Reisinger KS, Blatter MM, Veloudis BA</AU>
<TI>Immunogenicity of subcutaneous versus intramuscular Oka/Merck varicella vaccination in healthy children</TI>
<SO>Pediatrics</SO>
<YR>1991</YR>
<VL>88</VL>
<PG>604-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dennehy-1994" NAME="Dennehy 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Dennehy PH, Saracen CL, Peter G. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection. Pediatrics 1994; 94 :514-516&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dennehy PH, Saracen CL, Peter G</AU>
<TI>Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection</TI>
<SO>Pediatrics</SO>
<YR>1994</YR>
<VL>94</VL>
<PG>514-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-So_x00e1_rez-2009" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="de Soárez 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Soárez PC, Novaes HMD, Sartori AMC</AU>
<TI>Impact of methodology on the results of economic evaluations of varicella vaccination programs: is it important for decision-making?</TI>
<TO>Impacto da metodologia nos resultados de avaliações econômicas de programas de vacinação da varicela: É importante para o processo de tomada de decisão?</TO>
<SO>Cadernos Saude Publica</SO>
<YR>2009</YR>
<VL>25</VL>
<NO>Suppl 3</NO>
<PG>401-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diaz-1991" NAME="Diaz 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Diaz PS, Au D, Smith S, Amylon M, Link M, Smith S et al. Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings. Pediatrics 1991; 87(2):166-170.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diaz PS, Au D, Smith S, Amylon M, Link M, Smith S et al</AU>
<TI>Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings</TI>
<SO>Pediatrics</SO>
<YR>1991</YR>
<VL>87</VL>
<NO>2</NO>
<PG>166-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diaz-2006" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Diaz 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diaz C, Dentico P, Gonzalez R, Mendez RG, Cinquetti S, Barben JL et al</AU>
<TI>Safety, tolerability, and immunogenicity of a two-dose regimen of high-titer varicella vaccine in subjects &gt; or = 13 years of age</TI>
<SO>Vaccine</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>47-8</NO>
<PG>6875-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dube-2012" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Dube 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dube E, Gilca V, Sauvageau C, Bettinger JA, Boucher FD, McNeil S et al</AU>
<TI>Clinicians' opinions on new vaccination programs implementation</TI>
<SO>Vaccine</SO>
<YR>2012</YR>
<VL>30</VL>
<NO>31</NO>
<PG>4632-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Duchateau-1985" NAME="Duchateau 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Duchateau J, Vrijens R, Nicaise J, D'Hondt E, Bogearts H, Andre FE. Stimulation of specific immune response to varicella antigens in the elderly with varicella vaccine. Postgraduate Medical Journal 1985; 61 Suppl 4 :147-150&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duchateau J, Vrijens R, Nicaise J, D'Hondt E, Bogearts H, Andre FE</AU>
<TI>Stimulation of specific immune response to varicella antigens in the elderly with varicella vaccine</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>1985</YR>
<VL>61</VL>
<NO>Suppl 4</NO>
<PG>147-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-El_x002d_Darouti-2012" MODIFIED="2014-04-28 09:53:59 +1000" MODIFIED_BY="Liz Dooley" NAME="El-Darouti 2012" YEAR="2012 Mar">
<REFERENCE MODIFIED="2014-04-28 09:53:59 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>El-Darouti MA, Hegazy MA, Abdel Hay RA, Abdel Halim RM, Dalia M</AU>
<TI>Live attenuated varicella vaccine: a new effective adjuvant weapon in the battlefield against severe resistant psoriasis, a pilot randomized controlled trial</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2012</YR>
<VL>66</VL>
<NO>3</NO>
<PG>511-3</PG>
<IDENTIFIERS MODIFIED="2014-03-26 10:04:39 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Englund-1989" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Englund 1989" YEAR="1989">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Englund JA, Suarez CS, Kelly J, Tate DY, Balfour HH, Jr. Placebo-controlled trial of varicella vaccine given with or after measles-mumps-rubella vaccine. Journal of Pediatrics 1989; 114 :37-44&lt;/p&gt;" NOTES_MODIFIED="2014-06-19 00:52:07 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Englund JA, Suarez CS, Kelly J, Tate DY, Balfour HH Jr</AU>
<TI>Placebo-controlled trial of varicella vaccine given with or after measles-mumps-rubella vaccine</TI>
<SO>Journal of Pediatrics</SO>
<YR>1989</YR>
<VL>114</VL>
<PG>37-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Enright-2006" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Enright 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Enright F, McMahon B, Washington A</AU>
<TI>Varicella outbreak in a residential home; a short report and literature review on postexposure prophylaxis</TI>
<SO>Irish Medical Journal</SO>
<YR>2006</YR>
<VL>99</VL>
<NO>5</NO>
<PG>133-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fadrowski-2004" NAME="Fadrowski 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Fadrowski JJ, Furth SL. Varicella zoster virus: vaccination and implications in children with renal failure. Expert Review of Vaccines 2004; 3 :291-298&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fadrowski JJ, Furth SL</AU>
<TI>Varicella zoster virus: vaccination and implications in children with renal failure</TI>
<SO>Expert Review of Vaccines</SO>
<YR>2004</YR>
<VL>3</VL>
<PG>291-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferrera-2009" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Ferrera 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferrera G, Gajdos V, Thomas S, Tran C, Fiquet A</AU>
<TI>Safety of a refrigerator-stable varicella vaccine (VARIVAX) in healthy 12- to 15-month-old children: a randomized, double-blind, cross-over study</TI>
<SO>Human Vaccines</SO>
<YR>2009</YR>
<VL>5</VL>
<NO>7</NO>
<PG>455-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferrera-2012" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Ferrera 2012" YEAR="2012 Mar">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferrera G, Cuccia M, Mereu G, Icardi G, Bona G, Esposito S et al</AU>
<TI>Booster vaccination of pre-school children with reduced-antigen-content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine co-administered with measles-mumps-rubella-varicella vaccine: a randomized, controlled trial in children primed according to a 2 + 1 schedule in infancy</TI>
<SO>Human Vaccines and Immunotherapies</SO>
<YR>2012</YR>
<VL>8</VL>
<NO>3</NO>
<PG>355-62</PG>
<IDENTIFIERS MODIFIED="2014-03-26 10:30:53 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fridman-2011" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Fridman 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fridman D, Monti A, Bonnet MC, Armoni J, Stamboulian D</AU>
<TI>Safety of a second dose of varicella vaccine administered at 4 to 6 years of age in healthy children in Argentina</TI>
<SO>Human Vaccines</SO>
<YR>2011</YR>
<VL>7</VL>
<NO>10</NO>
<PG>1066-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fu-2010" MODIFIED="2014-03-17 15:47:24 +1000" MODIFIED_BY="Liz Dooley" NAME="Fu 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-03-17 15:47:24 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fu C, Wang M, Liang J, Xu J, Wang C, Bialek S</AU>
<TI>The effectiveness of varicella vaccine in China</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2010</YR>
<VL>29</VL>
<NO>8</NO>
<PG>690-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Furth-2003a" NAME="Furth 2003a" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Furth SL, Hogg RJ, Tarver J, Moulton LH, Chan C, Fivush BA, Southwest Pediatric Nephrology Study Group. Varicella vaccination in children with chronic renal failure. A report of the Southwest Pediatric Nephrology Study Group. Pediatric Nephrology 2003; 18 :33-38&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Furth SL, Hogg RJ, Tarver J, Moulton LH, Chan C, Fivush BA et al</AU>
<TI>Varicella vaccination in children with chronic renal failure. A report of the Southwest Pediatric Nephrology Study Group</TI>
<SO>Pediatric Nephrology</SO>
<YR>2003</YR>
<VL>18</VL>
<PG>33-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Furth-2003b" NAME="Furth 2003b" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Furth SL, Arbus GS, Hogg R, Tarver J, Chan C, Fivush BA, Southwest Pediatric Nephrology Study Group. Varicella vaccination in children with nephrotic syndrome: a report of the Southwest Pediatric Nephrology Study Group. Journal of Pediatrics 2003; 142 :145-148&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Furth SL, Arbus GS, Hogg R, Tarver J, Chan C, Fivush BA et al</AU>
<TI>Varicella vaccination in children with nephrotic syndrome: a report of the Southwest Pediatric Nephrology Study Group</TI>
<SO>Journal of Pediatrics</SO>
<YR>2003</YR>
<VL>142</VL>
<PG>145-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gatchalian-2003" NAME="Gatchalian 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Gatchalian S, Leboulleux D, Desauziers E, Bermal N, Borja-Tabora C. Immunogenicity and safety of a varicella vaccine, Okavax, and a trivalent measles, mumps and rubella vaccine, MMR-II, administered concomitantly in healthy Filipino children aged 12-24 months. Southeast Asian Journal of Tropical Medicine &amp;amp; Public Health 2003; 34 :589-597&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gatchalian S, Leboulleux D, Desauziers E, Bermal N, Borja-Tabora C</AU>
<TI>Immunogenicity and safety of a varicella vaccine, Okavax, and a trivalent measles, mumps and rubella vaccine, MMR-II, administered concomitantly in healthy Filipino children aged 12-24 months</TI>
<SO>Southeast Asian Journal of Tropical Medicine &amp; Public Health</SO>
<YR>2003</YR>
<VL>34</VL>
<PG>589-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gatchalian-2004" NAME="Gatchalian 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Gatchalian S, Tabora C, Bermal N, Leboulleux D, Desauziers E. Immunogenicity and safety of a varicella vaccine (Okavax) and a trivalent measles, mumps, and rubella vaccine (Trimovax) administered concomitantly in healthy Filipino children 12-24 months old. American Journal of Tropical Medicine &amp;amp; Hygiene 2004; 70 :273-277&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gatchalian S, Tabora C, Bermal N, Leboulleux D, Desauziers E</AU>
<TI>Immunogenicity and safety of a varicella vaccine (Okavax) and a trivalent measles, mumps, and rubella vaccine (Trimovax) administered concomitantly in healthy Filipino children 12-24 months old</TI>
<SO>American Journal of Tropical Medicine &amp; Hygiene</SO>
<YR>2004</YR>
<VL>70</VL>
<PG>273-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gershon-1982" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Gershon 1982" YEAR="1982">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Gershon AA, Steinberg S, Borkowsky W. Clinical trial of live attenuated Varicella vaccine in high risk susceptibles--a preliminary report. Developments in Biological Standardization 1982; 52:391-397.&lt;/p&gt;" NOTES_MODIFIED="2014-06-19 00:52:07 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gershon AA, Steinberg S, Borkowsky W</AU>
<TI>Clinical trial of live attenuated varicella vaccine in high risk susceptibles--a preliminary report</TI>
<SO>Developments in Biological Standardization</SO>
<YR>1982</YR>
<VL>52</VL>
<PG>391-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gershon-1984" NAME="Gershon 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Gershon AA, Steinberg SP, Gelb L, Galasso G, Borkowsky W, LaRussa P et al. Live attenuated varicella vaccine. Efficacy for children with leukemia in remission. JAMA 1984; 252(3):355-362.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gershon AA, Steinberg SP, Gelb L, Galasso G, Borkowsky W, LaRussa P et al</AU>
<TI>Live attenuated varicella vaccine. Efficacy for children with leukemia in remission</TI>
<SO>JAMA</SO>
<YR>1984</YR>
<VL>252</VL>
<NO>3</NO>
<PG>355-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gershon-1985" NAME="Gershon 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Gershon AA, Steinberg S, Gelb L, Galasso G, Borkowsky W, LaRussa P et al. A multicentre trial of live attenuated varicella vaccine in children with leukaemia in remission. Postgraduate Medical Journal 1985; 61 Suppl 4:73-78.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gershon AA, Steinberg S, Gelb L, Galasso G, Borkowsky W, LaRussa P et al</AU>
<TI>A multicentre trial of live attenuated varicella vaccine in children with leukaemia in remission</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>1985</YR>
<VL>61</VL>
<NO>Suppl 4</NO>
<PG>73-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gershon-1986" NAME="Gershon 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Gershon AA, Steinberg SP, Gelb L. Live attenuated varicella vaccine use in immunocompromised children and adults. Pediatrics 1986; 78(4 Pt 2):757-762.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gershon AA, Steinberg SP, Gelb L</AU>
<TI>Live attenuated varicella vaccine use in immunocompromised children and adults</TI>
<SO>Pediatrics</SO>
<YR>1986</YR>
<VL>78</VL>
<NO>4 Pt 2</NO>
<PG>757-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gershon-1988" NAME="Gershon 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Gershon AA, Steinberg SP, LaRussa P, Ferrara A, Hammerschlag M, Gelb L. Immunization of healthy adults with live attenuated varicella vaccine.[erratum appears in J Infect Dis 1988 Nov;158(5):1149]. Journal of Infectious Diseases 1988; 158 :132-137&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gershon AA, Steinberg SP, LaRussa P, Ferrara A, Hammerschlag M, Gelb L</AU>
<TI>Immunization of healthy adults with live attenuated varicella vaccine [Erratum appears in J Infect Dis 1988 Nov;158(5):1149]</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1988</YR>
<VL>158</VL>
<PG>132-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gershon-1989" NAME="Gershon 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Gershon AA, Steinberg SP. Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine. New England Journal of Medicine 1989; 320 :892-897&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gershon AA, Steinberg SP</AU>
<TI>Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine</TI>
<SO>New England Journal of Medicine</SO>
<YR>1989</YR>
<VL>320</VL>
<PG>892-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gershon-1990" NAME="Gershon 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Gershon AA, Steinberg SP. Live attenuated varicella vaccine: protection in healthy adults compared with leukemic children. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. Journal of Infectious Diseases 1990; 161 :661-666&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gershon AA, Steinberg SP</AU>
<TI>Live attenuated varicella vaccine: protection in healthy adults compared with leukemic children. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1990</YR>
<VL>161</VL>
<PG>661-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Getaz-2010" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Getaz 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Getaz L, Siegrist C, Stoll B, Humair J, Scherrer Y, Franziskakis C et al</AU>
<TI>Chickenpox in a Swiss prison: susceptibility, post-exposure vaccination and control measures</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>2010</YR>
<VL>42</VL>
<PG>936-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giacchino-1995" NAME="Giacchino 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Giacchino R, Marcellini M, Timitilli A, Degli IL, Losurdo G, Palumbo M, Sartorelli M, Comparcola D, Mauro LM, Gusmano R. Varicella vaccine in children requiring renal or hepatic transplantation. Transplantation 1995; 60 :1055-1056&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giacchino R, Marcellini M, Timitilli A, Degli IL, Losurdo G, Palumbo M et al</AU>
<TI>Varicella vaccine in children requiring renal or hepatic transplantation</TI>
<SO>Transplantation</SO>
<YR>1995</YR>
<VL>60</VL>
<PG>1055-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gilderman-2008" MODIFIED="2014-06-18 23:19:34 +1000" MODIFIED_BY="[Empty name]" NAME="Gilderman 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-06-18 23:19:34 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gilderman LI, Lawless JF</AU>
<TI>A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax</TI>
<SO>Clinical and Vaccine Immunology</SO>
<YR>2008</YR>
<VL>15</VL>
<NO>2</NO>
<PG>314-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-05-17 10:28:47 +1000" MODIFIED_BY="Anita E Heywood"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gillet-2009a" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Gillet 2009a" YEAR="2009">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gillett Y, Steri GC, Behre U, Arsene JP, Lanse X, Helm K et al</AU>
<TI>Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine</TI>
<SO>Vaccine</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>3</NO>
<PG>446-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gillet-2009b" MODIFIED="2014-03-17 15:48:32 +1000" MODIFIED_BY="Liz Dooley" NAME="Gillet 2009b" YEAR="2009">
<REFERENCE MODIFIED="2014-03-17 15:48:32 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gillet Y, Habermehl P, Thomas S, Eymin C, Fiquet A</AU>
<TI>Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro) and a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial</TI>
<SO>BMC Medicine</SO>
<YR>2009</YR>
<VL>7</VL>
<PG>16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glanz-2010" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Glanz 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glanz JM, McClure DL, Magid DJ, Daley MF, France EK, Hambidge SJ</AU>
<TI>Parental refusal of varicella vaccination and the associated risk of varicella infection in children</TI>
<SO>Archives of Pediatrics and Adolescent Medicine</SO>
<YR>2010</YR>
<VL>164</VL>
<NO>1</NO>
<PG>66-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gnann-2008" MODIFIED="2014-03-17 15:48:56 +1000" MODIFIED_BY="Liz Dooley" NAME="Gnann 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-03-17 15:48:56 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gnann JW Jr</AU>
<TI>Vaccination to prevent herpes zoster in older adults</TI>
<SO>Journal of Pain</SO>
<YR>2008</YR>
<VL>9</VL>
<NO>1 Suppl 1</NO>
<PG>S31-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gonzaga-2008" MODIFIED="2014-03-27 16:19:17 +1000" MODIFIED_BY="Liz Dooley" NAME="Gonzaga 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-03-27 16:19:17 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gonzaga MA, Cruz AS, Ganem NS, Gaspar Filho MG, Simas TB</AU>
<TI>Contact with infectious diseases</TI>
<TO>Conduta nos contatos de doenças infecto-contagiosas</TO>
<SO>Jornal Brasileiro de Medicina</SO>
<YR>2008</YR>
<VL>94</VL>
<NO>6</NO>
<PG>11-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Groves-2010" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Groves 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Groves KC, Averbeck K, Quinlivan ML, Scott FT, Breuer J</AU>
<TI>A case of nosocomial VZV transmission</TI>
<SO>Journal of Clinical Virology</SO>
<YR>2010</YR>
<VL>48</VL>
<NO>3</NO>
<PG>226-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guerra-2006" NAME="Guerra 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guerra FA, Gress J, Werzberger A, Reisinger K, Walter E, Lakkis H et al</AU>
<TI>Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>10</NO>
<PG>912-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ha-1980" NAME="Ha 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Ha K, Baba K, Ikeda T, Nishida M, Yabuuchi H, Takahashi M. Application of live varicella vaccine to children with acute leukemia or other malignancies without suspension of anticancer therapy. Pediatrics 1980; 65(2):346-350.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ha K, Baba K, Ikeda T, Nishida M, Yabuuchi H, Takahashi M</AU>
<TI>Application of live varicella vaccine to children with acute leukemia or other malignancies without suspension of anticancer therapy</TI>
<SO>Pediatrics</SO>
<YR>1980</YR>
<VL>65</VL>
<NO>2</NO>
<PG>346-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Habermehl-1999" NAME="Habermehl 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Habermehl P, Lignitz A, Knuf M, Schmitt HJ, Slaoui M, Zepp F. Cellular immune response of a varicella vaccine following simultaneous DTaP and VZV vaccination. Vaccine 1999; 17(7-8):669-674.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Habermehl P, Lignitz A, Knuf M, Schmitt HJ, Slaoui M, Zepp F</AU>
<TI>Cellular immune response of a varicella vaccine following simultaneous DTaP and VZV vaccination</TI>
<SO>Vaccine</SO>
<YR>1999</YR>
<VL>17</VL>
<NO>7-8</NO>
<PG>669-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Halperin-2009" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Halperin 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Halperin SA, Ferrera G, Scheifele D, Predy G, Stella G, Cuccia M et al</AU>
<TI>Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age</TI>
<SO>Vaccine</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>20</NO>
<PG>2701-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hambleton-2008" MODIFIED="2014-03-26 12:21:07 +1000" MODIFIED_BY="[Empty name]" NAME="Hambleton 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-03-26 12:21:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hambleton S, Steinberg SP, Larussa PS, Shapiro ED, Gershon AA</AU>
<TI>Risk of herpes zoster in adults immunized with varicella vaccine</TI>
<SO>Journal of Infectious Disease</SO>
<YR>2008</YR>
<VL>197</VL>
<NO>Suppl 2</NO>
<PG>196-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hardy-1991" NAME="Hardy 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Hardy I, Gershon AA, Steinberg SP, LaRussa P. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. New England Journal of Medicine 1991; 325 :1545-1550&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hardy I, Gershon AA, Steinberg SP, LaRussa P</AU>
<TI>The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>1991</YR>
<VL>325</VL>
<PG>1545-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hartung-2013" MODIFIED="2014-03-24 12:14:37 +1000" MODIFIED_BY="[Empty name]" NAME="Hartung 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-03-24 12:14:37 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hartung HP, Bezuidenhoudt M, Sfikas N, Karan R, Von Rosenstiel P, Putzki N</AU>
<TI>Immunity to varicella zoster virus in clinical trials of fingolimod in patients with multiple sclerosis</TI>
<SO>Multiple Sclerosis</SO>
<YR>2013</YR>
<VL>19</VL>
<NO>11</NO>
<PG>494-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hata-2002" MODIFIED="2014-03-26 10:52:31 +1000" MODIFIED_BY="[Empty name]" NAME="Hata 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-03-26 10:52:31 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Hata A, Asanuma H, Rinki M, Sharp M, Wong RM, Blume K, Arvin AM. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. New England Journal of Medicine 2002; 347 :26-34&lt;/p&gt;" NOTES_MODIFIED="2014-03-26 10:52:31 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hata A, Asanuma H, Rinki M, Sharp M, Wong RM, Blume K</AU>
<TI>Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>347</VL>
<PG>26-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hayward-1992" NAME="Hayward 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Hayward A, Villanueba E, Cosyns M, Levin M. Varicella-zoster virus (VZV)-specific cytotoxicity after immunization of nonimmune adults with Oka strain attenuated VZV vaccine. Journal of Infectious Diseases 1992; 166 :260-264&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hayward A, Villanueba E, Cosyns M, Levin M</AU>
<TI>Varicella-zoster virus (VZV)-specific cytotoxicity after immunization of nonimmune adults with Oka strain attenuated VZV vaccine</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1992</YR>
<VL>166</VL>
<PG>260-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hayward-1994" NAME="Hayward 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Hayward AR, Buda K, Levin MJ. Immune response to secondary immunization with live or inactivated VZV vaccine in elderly adults. Viral Immunology 1994; 7 :31-36&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hayward AR, Buda K, Levin MJ</AU>
<TI>Immune response to secondary immunization with live or inactivated VZV vaccine in elderly adults</TI>
<SO>Viral Immunology</SO>
<YR>1994</YR>
<VL>7</VL>
<PG>31-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hayward-1996" NAME="Hayward 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Hayward AR, Buda K, Jones M, White CJ, Levin MJ. Varicella zoster virus-specific cytotoxicity following secondary immunization with live or killed vaccine. Viral Immunology 1996; 9(4):241-245.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hayward AR, Buda K, Jones M, White CJ, Levin MJ</AU>
<TI>Varicella zoster virus-specific cytotoxicity following secondary immunization with live or killed vaccine</TI>
<SO>Viral Immunology</SO>
<YR>1996</YR>
<VL>9</VL>
<NO>4</NO>
<PG>241-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heller-1985" NAME="Heller 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Heller L, Berglund G, Ahstrom L, Hellstrand K, Wahren B. Early results of a trial of the Oka-strain varicella vaccine in children with leukaemia or other malignancies in Sweden. Postgraduate Medical Journal 1985; 61 Suppl 4:79-83.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heller L, Berglund G, Ahstrom L, Hellstrand K, Wahren B</AU>
<TI>Early results of a trial of the Oka-strain varicella vaccine in children with leukaemia or other malignancies in Sweden</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>1985</YR>
<VL>61</VL>
<NO>Suppl 4</NO>
<PG>79-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hesley-2004" NAME="Hesley 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Hesley TM, Reisinger KS, Sullivan BJ, Jensen EH, Stasiorowski S, Meechan C, Chan CY, West DJ, THE HIB-HB VACCINE STUDY GROUP. Concomitant administration of a bivalent Haemophilus influenzae type b-hepatitis B vaccine, measles-mumps-rubella vaccine and varicella vaccine: safety, tolerability and immunogenicity. Pediatric Infectious Disease Journal 2004; 23 :240-245&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hesley TM, Reisinger KS, Sullivan BJ, Jensen EH, Stasiorowski S, Meechan C et al</AU>
<TI>Concomitant administration of a bivalent Haemophilus influenzae type b-hepatitis B vaccine, measles-mumps-rubella vaccine and varicella vaccine: safety, tolerability and immunogenicity</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2004</YR>
<VL>23</VL>
<PG>240-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holcomb-2008" MODIFIED="2014-03-17 15:56:04 +1000" MODIFIED_BY="Liz Dooley" NAME="Holcomb 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-03-17 15:56:04 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holcomb K, Weinberg JM</AU>
<TI>A novel vaccine (Zostavax) to prevent herpes zoster</TI>
<SO>Giornale Italiano di Dermatologia e Venereologia</SO>
<YR>2008</YR>
<VL>143</VL>
<NO>2</NO>
<PG>119-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horiuchi-1984" NAME="Horiuchi 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Horiuchi K. Chickenpox vaccination of healthy children: immunological and clinical responses and protective effect in 1978-1982. Biken Journal 1984; 27(2-3):37-38.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horiuchi K</AU>
<TI>Chickenpox vaccination of healthy children: immunological and clinical responses and protective effect in 1978-1982</TI>
<SO>Biken Journal</SO>
<YR>1984</YR>
<VL>27</VL>
<NO>2-3</NO>
<PG>37-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2013" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Huang 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang LM, Lee BW, Chan PC, Povey M, Henry O</AU>
<TI>Immunogenicity and safety of combined measles-mumps-rubella-varicella vaccine using new measles and rubella working seeds in healthy children in Taiwan and Singapore: a phase II, randomized, double-blind trial</TI>
<SO>Human Vaccines and Immunotherapeutics</SO>
<YR>2013</YR>
<VL>9</VL>
<NO>6</NO>
<PG>1308-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iovlev-1969" NAME="Iovlev 1969" YEAR="1969">
<REFERENCE NOTES="&lt;p&gt;Iovlev VI, Boichuk LM, Kuz'micheva AT, Ivanova MV, Smorodintsev AA. [Reactogenic and immunogenic properties of an attenuated strain of chicken pox virus]. [Russian]. Voprosy Neirokhirurgii 1969; 33(5):561-565.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iovlev VI, Boichuk LM, Kuz'micheva AT, Ivanova MV, Smorodintsev AA</AU>
<TI>Reactogenic and immunogenic properties of an attenuated strain of chicken pox virus</TI>
<SO>Voprosy Neirokhirurgii</SO>
<YR>1969</YR>
<VL>33</VL>
<NO>5</NO>
<PG>561-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iwaza-1977" NAME="Iwaza 1977" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;Izawa T, Ihara T, Hattori A, Iwasa T, Kamiya H, Sakurai M et al. Application of a live varicella vaccine in children with acute leukemia or other malignant diseases. Pediatrics 1977; 60(6):805-809.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Izawa T, Ihara T, Hattori A, Iwasa T, Kamiya H, Sakurai M et al</AU>
<TI>Application of a live varicella vaccine in children with acute leukemia or other malignant diseases</TI>
<SO>Pediatrics</SO>
<YR>1977</YR>
<VL>60</VL>
<NO>6</NO>
<PG>805-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-1988" NAME="Johnson 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Johnson CE, Shurin PA, Fattlar D, Rome LP, Kumar ML. Live attenuated varicella vaccine in healthy 12- to 24-month-old children. Pediatrics 1988; 81(4):512-518.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson CE, Shurin PA, Fattlar D, Rome LP, Kumar ML</AU>
<TI>Live attenuated varicella vaccine in healthy 12- to 24-month-old children</TI>
<SO>Pediatrics</SO>
<YR>1988</YR>
<VL>81</VL>
<NO>4</NO>
<PG>512-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-1989" NAME="Johnson 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Johnson C, Rome LP, Stancin T, Kumar ML. Humoral immunity and clinical reinfections following varicella vaccine in healthy children. Pediatrics 1989; 84(3):418-421.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson C, Rome LP, Stancin T, Kumar ML</AU>
<TI>Humoral immunity and clinical reinfections following varicella vaccine in healthy children</TI>
<SO>Pediatrics</SO>
<YR>1989</YR>
<VL>84</VL>
<NO>3</NO>
<PG>418-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-2009" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Jones 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones L, Malavige G, Jeffery K, Kemp E, Breuer J, Klenerman P et al</AU>
<TI>Tracking epitope-specific antiviral CD4+ T cell responses to a live attenuated vaccine reveals ongoing functional responses</TI>
<SO>Vaccine</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>52</NO>
<PG>7398-401</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Just-1985" NAME="Just 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Just M, Berger R, Luescher D. Live varicella vaccine in healthy individuals. Postgraduate Medical Journal 1985; 61 Suppl 4:129-132.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Just M, Berger R, Luescher D</AU>
<TI>Live varicella vaccine in healthy individuals</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>1985</YR>
<VL>61</VL>
<NO>Suppl 4</NO>
<PG>129-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Just-1986" NAME="Just 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Just M, Berger R, Just V. Evaluation of a combined measles-mumps-rubella-chickenpox vaccine. Developments in Biological Standardization 1986; 65:85-88.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Just M, Berger R, Just V</AU>
<TI>Evaluation of a combined measles-mumps-rubella-chickenpox vaccine</TI>
<SO>Developments in Biological Standardization</SO>
<YR>1986</YR>
<VL>65</VL>
<PG>85-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kanra-2000" NAME="Kanra 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Kanra G, Ceyhan M, Ozmert E. Safety and immunogenicity of live attenuated varicella vaccine in 9-month-old children. Pediatrics International 2000; 42(6):674-677.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kanra G, Ceyhan M, Ozmert E</AU>
<TI>Safety and immunogenicity of live attenuated varicella vaccine in 9-month-old children</TI>
<SO>Pediatrics International</SO>
<YR>2000</YR>
<VL>42</VL>
<NO>6</NO>
<PG>674-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Katsushima-1982" NAME="Katsushima 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Katsushima N, Yazaki N, Sakamoto M, Fujiyama J, Nakagawa M, Okuyama Y et al</AU>
<TI>Application of a live varicella vaccine to hospitalized children and its follow-up study</TI>
<SO>Biken Journal</SO>
<YR>1982</YR>
<VL>25</VL>
<NO>1</NO>
<PG>29-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Katsushima-1984" NAME="Katsushima 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Katsushima N, Yazaki N, Sakamoto M</AU>
<TI>Effect and follow-up study on varicella vaccine</TI>
<SO>Biken Journal</SO>
<YR>1984</YR>
<VL>27</VL>
<NO>2-3</NO>
<PG>51-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klein-2012a" MODIFIED="2014-03-26 12:28:41 +1000" MODIFIED_BY="[Empty name]" NAME="Klein 2012a" YEAR="2012 Jun 6">
<REFERENCE MODIFIED="2014-03-26 12:28:41 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klein NP, Shepard J, Bedell L, Odrljin T, Dull P</AU>
<TI>Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers</TI>
<SO>Vaccine</SO>
<YR>2012</YR>
<VL>30</VL>
<NO>26</NO>
<PG>3929-36</PG>
<IDENTIFIERS MODIFIED="2014-03-26 10:06:20 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klein-2012b" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Klein 2012b" YEAR="2012 Jan 11">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klein NP, Weston WM, Kuriyakose S, Kolhe D, Howe B, Friedland LR et al</AU>
<TI>An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children</TI>
<SO>Vaccine</SO>
<YR>2012</YR>
<VL>30</VL>
<NO>3</NO>
<PG>668-74</PG>
<IDENTIFIERS MODIFIED="2014-03-26 10:31:54 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knuf-2006" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Knuf 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Knuf M, Habermehl P, Zepp F, Mannhardt W, Kuttnig M, Muttonen P et al</AU>
<TI>Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>1</NO>
<PG>12-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knuf-2010" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Knuf 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Knuf M, Zepp F, Meyer CU, Habermehl P, Maurer L, Burow HM et al</AU>
<TI>Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles-mumps-rubella-varicella vaccine to children aged 11-21 months</TI>
<SO>European Journal of Pediatrics</SO>
<YR>2010</YR>
<VL>169</VL>
<NO>8</NO>
<PG>925-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knuf-2012" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Knuf 2012" YEAR="2012 Mar">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Knuf M, Zepp F, Helm K, Maurer H, Prieler A, Kieninger-Baum D et al</AU>
<TI>Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children</TI>
<SO>European Journal of Pediatrics</SO>
<YR>2012</YR>
<VL>171</VL>
<NO>3</NO>
<PG>463-70</PG>
<IDENTIFIERS MODIFIED="2014-03-26 10:32:08 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Konno-1984" NAME="Konno 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Konno T, Yamaguchi Y, Minegishi M, Goto Y, Tsuchiya S. A clinical trial of live attenuated varicella vaccine (Biken) in children with malignant diseases. Biken Journal 1984; 27(2-3):73-75.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Konno T, Yamaguchi Y, Minegishi M, Goto Y, Tsuchiya S</AU>
<TI>A clinical trial of live attenuated varicella vaccine (Biken) in children with malignant diseases</TI>
<SO>Biken Journal</SO>
<YR>1984</YR>
<VL>27</VL>
<NO>2-3</NO>
<PG>73-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kosuwon-2004" NAME="Kosuwon 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kosuwon P, Sutra S, Kosalaraksa P</AU>
<TI>Advantage of a two-dose versus one-dose varicella vaccine in healthy non-immune teenagers and young adults</TI>
<SO>Southeast Asian Journal of Tropical Medicine &amp; Public Health</SO>
<YR>2004</YR>
<VL>35</VL>
<NO>3</NO>
<PG>697-701</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krah-1997" NAME="Krah 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Krah DL, Cho I, Schofield T, Ellis RW. Comparison of gpELISA and neutralizing antibody responses to Oka/Merck live varicella vaccine (Varivax) in children and adults. Vaccine 1997; 15(1):61-64.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krah DL, Cho I, Schofield T, Ellis RW</AU>
<TI>Comparison of gpELISA and neutralizing antibody responses to Oka/Merck live varicella vaccine (Varivax) in children and adults</TI>
<SO>Vaccine</SO>
<YR>1997</YR>
<VL>15</VL>
<NO>1</NO>
<PG>61-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krause-1995" NAME="Krause 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Krause PR, Klinman DM. Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. Journal of Pediatrics 1995; 127 :518-525&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krause PR, Klinman DM</AU>
<TI>Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine</TI>
<SO>Journal of Pediatrics</SO>
<YR>1995</YR>
<VL>127</VL>
<PG>518-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kreth-1994" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Kreth 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Kreth HW, Prager J, Raue W, Sitzmann FC, Stehr K, Stuck B, Sanger R, Bock HL, Clemens R. Double-blind randomised study on the immunogenity and reactogenity of three different selections with two different virus titers each of a newly formulated attenuated Varicella vaccine (Oka-phylum) [trans]. Monatsschrift fur Kinderheilkunde 1994; 142 :S143&lt;/p&gt;" NOTES_MODIFIED="2014-06-19 00:52:07 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kreth HW, Prager J, Raue W, Sitzmann FC, Stehr K, Stuck B et al</AU>
<TI>Double-blind randomised study on the immunogenicity and reactogenicity of three different selections with two different virus titers each of a newly formulated attenuated varicella vaccine (Oka-phylum) [trans]</TI>
<SO>Monatsschrift fur Kinderheilkunde</SO>
<YR>1994</YR>
<VL>142</VL>
<NO>Suppl</NO>
<PG>143</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kreth-2006" NAME="Kreth 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kreth HW, Hoeger PH, The Members of the VZV-AD study group</AU>
<TI>Safety, reactogenicity, and immunogenicity of live attenuated varicella vaccine in children between 1 and 9 years of age with atopic dermatitis</TI>
<SO>European Journal of Pediatrics</SO>
<YR>2006</YR>
<VL>165</VL>
<NO>10</NO>
<PG>677-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kreth-2008" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Kreth 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kreth HW, Lee BW, Kosuwon P, Salazar J, Gloriani-Barzaga N, Bock HL et al</AU>
<TI>Sixteen years of global experience with the first refrigerator-stable varicella vaccine (Varilrix&#8482;)</TI>
<SO>Biodrugs</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>6</NO>
<PG>387-402</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kumagai-1980" NAME="Kumagai 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Kumagai T, Chiba Y, Fujiwara M, Hanazono H, Nakamura S, Chiba S et al. Humoral and cellular immune response to varicella-zoster virus in children inoculated with live attenuated varicella vaccine. Biken Journal 1980; 23(3):135-141.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kumagai T, Chiba Y, Fujiwara M, Hanazono H, Nakamura S, Chiba S et al</AU>
<TI>Humoral and cellular immune response to varicella-zoster virus in children inoculated with live attenuated varicella vaccine</TI>
<SO>Biken Journal</SO>
<YR>1980</YR>
<VL>23</VL>
<NO>3</NO>
<PG>135-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuter-1991" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Kuter 1991" YEAR="1991">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Kuter BJ, Weibel RE, Guess HA, et al. Oka/Merck varicella vaccine in healthy children: final report of 2 year efficacy study and 7 year follow up studies. Vaccine. 1991; 9: 643-647&lt;/p&gt;" NOTES_MODIFIED="2014-06-19 00:52:07 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuter BJ, Weibel RE, Guess HA, Matthews H, Morton DH, Neff BJ et al</AU>
<TI>Oka/Merck varicella vaccine in healthy children: final report of 2 year efficacy study and 7 year follow up studies</TI>
<SO>Vaccine</SO>
<YR>1991</YR>
<VL>9</VL>
<PG>643-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuter-1995" NAME="Kuter 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Kuter BJ, Ngai A, Patterson CM, Staehle BO, Cho I, Matthews H, Provost PJ, White CJ. Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Oka/Merck Varicella Vaccine Study Group. Vaccine 1995; 13 :967-972&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuter BJ, Ngai A, Patterson CM, Staehle BO, Cho I, Matthews H et al</AU>
<TI>Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Oka/Merck Varicella Vaccine Study Group</TI>
<SO>Vaccine</SO>
<YR>1995</YR>
<VL>13</VL>
<PG>967-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuter-2004" NAME="Kuter 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Kuter B, Matthews H, Shinefield H, Black S, Dennehy P, Watson B, Reisinger K, Kim LL, Lupinacci L, Hartzel J, Chan I, Study Group for Varivax. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatric Infectious Disease Journal 2004; 23 :132-137&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuter B, Matthews H, Shinefield H, Black S, Dennehy P, Watson B et al</AU>
<TI>Ten year follow-up of healthy children who received one or two injections of varicella vaccine</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2004</YR>
<VL>23</VL>
<PG>132-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuter-2006" NAME="Kuter 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuter BJ, Brown ML, Hartzel J, Williams WR, EvesiKaren A, Black S et al</AU>
<TI>Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad)</TI>
<SO>Human Vaccines</SO>
<YR>2006</YR>
<VL>2</VL>
<NO>5</NO>
<PG>205-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lau-2002" NAME="Lau 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Lau YL, Vessey SJ, Chan IS, Lee TL, Huang LM, Lee CY, Lin TY, Lee BW, Kwan K, Kasim SM, Chan CY, Kaplan KM, Distefano DJ, Harmon AL, Golie A, Hartzel J, Xu J, Li S, Matthews H, Sadoff JC, Shaw A. A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX in healthy children. Vaccine 2002; 20 :2942-2949&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lau YL, Vessey SJ, Chan IS, Lee TL, Huang LM, Lee CY et al</AU>
<TI>A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX in healthy children</TI>
<SO>Vaccine</SO>
<YR>2002</YR>
<VL>20</VL>
<PG>2942-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lawrence-1988" NAME="Lawrence 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Lawrence R, Gershon AA, Holzman R, Steinberg SP. The risk of zoster after varicella vaccination in children with leukemia. New England Journal of Medicine 1988; 318 :543-548&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lawrence R, Gershon AA, Holzman R, Steinberg SP</AU>
<TI>The risk of zoster after varicella vaccination in children with leukemia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1988</YR>
<VL>318</VL>
<PG>543-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leonardi-2011" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Leonardi 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leonardi M, Bromberg K, Baxter R, Gardner JL, Klopfer S, Nicholson O et al</AU>
<TI>Immunogenicity and safety of MMRV and PCV-7 administered concomitantly in healthy children</TI>
<SO>Pediatrics</SO>
<YR>2011</YR>
<VL>128</VL>
<NO>6</NO>
<PG>e1387-94</PG>
<IDENTIFIERS MODIFIED="2014-03-26 10:08:46 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leroux_x002d_Roels-2012" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Leroux-Roels 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leroux-Roels I, Leroux-Roels G, Clement G, Vandepapeliere P, Vassilev V, Ledent E et al</AU>
<TI>A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults</TI>
<SO>Journal of Infectious Disease</SO>
<YR>2012</YR>
<VL>206</VL>
<NO>8</NO>
<PG>1280-90</PG>
<IDENTIFIERS MODIFIED="2014-03-26 10:09:09 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leung-2004" NAME="Leung 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Leung TF, Li CK, Hung EC, Chan PK, Mo CW, Wong RP, Chik KW. Immunogenicity of a two-dose regime of varicella vaccine in children with cancers. European Journal of Haematology 2004; 72 :353-357&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leung TF, Li CK, Hung EC, Chan PK, Mo CW, Wong RP et al</AU>
<TI>Immunogenicity of a two-dose regime of varicella vaccine in children with cancers</TI>
<SO>European Journal of Haematology</SO>
<YR>2004</YR>
<VL>72</VL>
<PG>353-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levin-1992" NAME="Levin 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Levin MJ, Murray M, Rotbart HA, Zerbe GO, White CJ, Hayward AR. Immune response of elderly individuals to a live attenuated varicella vaccine. Journal of Infectious Diseases 1992; 166 :253-259&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levin MJ, Murray M, Rotbart HA, Zerbe GO, White CJ, Hayward AR</AU>
<TI>Immune response of elderly individuals to a live attenuated varicella vaccine</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1992</YR>
<VL>166</VL>
<PG>253-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levin-2000" NAME="Levin 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Levin MJ, Ellison MC, Zerbe GO, Barber D, Chan C, Stinson D et al. Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine 2000; 18(25):2915-2920.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levin MJ, Ellison MC, Zerbe GO, Barber D, Chan C, Stinson D et al</AU>
<TI>Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older</TI>
<SO>Vaccine</SO>
<YR>2000</YR>
<VL>18</VL>
<NO>25</NO>
<PG>2915-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levin-2001" NAME="Levin 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Levin MJ, Gershon AA, Weinberg A, Blanchard S, Nowak B, Palumbo P, Chan CY, AIDS Clinical Trials Group. Immunization of HIV-infected children with varicella vaccine. Journal of Pediatrics 2001; 139 :305-310&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levin MJ, Gershon AA, Weinberg A, Blanchard S, Nowak B, Palumbo P et al</AU>
<TI>Immunization of HIV-infected children with varicella vaccine</TI>
<SO>Journal of Pediatrics</SO>
<YR>2001</YR>
<VL>139</VL>
<PG>305-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levin-2003" NAME="Levin 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY, Chan IS, Li DJ, Wang W, Keller PM, Shaw A, Silber JL, Schlienger K, Chalikonda I, Vessey SJ, Caulfield MJ. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-hose VZV vaccine. Journal of Infectious Diseases 2003; 188 :1336-1344&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY et al</AU>
<TI>Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-hose VZV vaccine</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2003</YR>
<VL>188</VL>
<PG>1336-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levin-2008a" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Levin 2008a" YEAR="2008">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR et al</AU>
<TI>Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2008</YR>
<VL>197</VL>
<NO>6</NO>
<PG>825-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levin-2008b" MODIFIED="2014-03-17 16:10:52 +1000" MODIFIED_BY="Liz Dooley" NAME="Levin 2008b" YEAR="2008">
<REFERENCE MODIFIED="2014-03-17 16:10:52 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levin MJ</AU>
<TI>Varicella vaccination of immunocompromised children</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2008</YR>
<VL>197</VL>
<NO>Suppl 2</NO>
<PG>200-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2012" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Li 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li YC, Gao ZG, Tao H, Zhang Y, Zhang ZL, Han YG et al</AU>
<TI>Safety of freeze-dried live attenuated varicella vaccine</TI>
<SO>Chinese Journal of Biologicals</SO>
<YR>2012</YR>
<VL>25</VL>
<NO>12</NO>
<PG>1667-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lieberman-2006" NAME="Lieberman 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lieberman JM, Williams WR, Miller JM, Black S, Shinefield H, Henderson F et al</AU>
<TI>The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>7</NO>
<PG>615-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lim-1998" NAME="Lim 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Lim YJ, Chew FT, Tan AY, Lee BW. Risk factors for breakthrough varicella in healthy children. Archives of Disease in Childhood 1998; 79 :478-480&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lim YJ, Chew FT, Tan AY, Lee BW</AU>
<TI>Risk factors for breakthrough varicella in healthy children</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1998</YR>
<VL>79</VL>
<PG>478-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-1981" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Lin 1981" YEAR="1981">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Lin TY, Wang YM, Lin ST. Application of a live varicella vaccine in children with acute leukemia or nephrotic syndrome. Taiwan i Hsueh Hui Tsa Chih - Journal of the Formosan Medical Association 1981; 80 :683-690&lt;/p&gt;" NOTES_MODIFIED="2014-06-19 00:52:07 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin TY, Wang YM, Lin ST</AU>
<TI>Application of a live varicella vaccine in children with acute leukemia or nephrotic syndrome</TI>
<SO>Taiwan i Hsueh Hui Tsa Chih [Journal of the Formosan Medical Association]</SO>
<YR>1981</YR>
<VL>80</VL>
<PG>683-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2009" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Liu 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu J, Wang M, Gan L, Liao W, Chen J</AU>
<TI>Seroepidemiology of varicella-zoster virus infection measured by the fluorescent antibody to membrane antigen test</TI>
<SO>Chung-Hua Liu Hsing Ping Hsueh Tsa Chih [Chinese Journal of Epidemiology]</SO>
<YR>2009</YR>
<VL>30</VL>
<NO>4</NO>
<PG>371-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lopez-2011" MODIFIED="2014-03-26 10:32:44 +1000" MODIFIED_BY="[Empty name]" NAME="Lopez 2011" YEAR="2000-2006: the 1-dose varicella vaccination era. Pediatrics. 2011 Feb">
<REFERENCE MODIFIED="2014-03-26 10:32:44 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lopez AS, Zhang J, Brown C, Bialek S</AU>
<TI>Varicella-related hospitalizations in the United States, 2000-2006: the 1-dose varicella vaccination era</TI>
<SO>Pediatrics</SO>
<YR>2011</YR>
<VL>127</VL>
<NO>2</NO>
<PG>238-45</PG>
<IDENTIFIERS MODIFIED="2014-03-26 10:10:36 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lou-1996" NAME="Lou 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Lou J, Tan AM, Tan CK. Experience of varicella vaccination in acute lymphoplastic leukaemia. Singapore Medical Journal 1996; 37(6):607-610.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lou J, Tan AM, Tan CK</AU>
<TI>Experience of varicella vaccination in acute lymphoplastic leukaemia</TI>
<SO>Singapore Medical Journal</SO>
<YR>1996</YR>
<VL>37</VL>
<NO>6</NO>
<PG>607-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loulergue-2013" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Loulergue 2013" YEAR="2009: The Studyvax Survey. Vaccine. 2013">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loulergue P, Fonteneau L, Armengaud JB, Momcilovic S, Levy-Bruhl D, Launay O et al</AU>
<TI>Vaccine coverage of healthcare students in hospitals of the Paris region in 2009: The Studyvax Survey</TI>
<SO>Vaccine</SO>
<YR>2013</YR>
<VL>31</VL>
<NO>26</NO>
<PG>2835-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-1998" NAME="Lu 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Lu MY, Huang LM, Lee CY, Lee PI, Chiu HH, Tsai HY. Evaluation of a live attenuated varicella vaccine in 15- to 18-month-old healthy children. Chung-Hua Min Kuo Hsiao Erh Ko i Hsueh Hui Tsa Chih 1998; 39 :38-42&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lu MY, Huang LM, Lee CY, Lee PI, Chiu HH, Tsai HY</AU>
<TI>Evaluation of a live attenuated varicella vaccine in 15- to 18-month-old healthy children</TI>
<SO>Chung-Hua Min Kuo Hsiao Erh Ko i Hsueh Hui Tsa Chih</SO>
<YR>1998</YR>
<VL>39</VL>
<PG>38-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ma-2009a" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Ma 2009a" YEAR="2009">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ma R, Sun MP, Sun M, Hou WJ, Jiang GY, Peng XH et al</AU>
<TI>Effectiveness on post-exposure vaccination of varicella and its influencing factors in elementary schools in Beijing</TI>
<SO>Zhonghua Liu Xing Bing Xue Za Zhi</SO>
<YR>2009</YR>
<VL>30</VL>
<NO>6</NO>
<PG>559-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ma-2009b" MODIFIED="2014-03-17 16:11:28 +1000" MODIFIED_BY="Liz Dooley" NAME="Ma 2009b" YEAR="2009">
<REFERENCE MODIFIED="2014-03-17 16:11:28 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ma F, Luo L, Zhang L</AU>
<TI>Study on epidemiological effect of the freeze-dried attenuated live varicella vaccine</TI>
<SO>Zhongguo Jihua Mianyi</SO>
<YR>2009</YR>
<VL>15</VL>
<NO>3</NO>
<PG>193-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Macaladad-2007" NAME="Macaladad 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Macaladad N, Marcano T, Guzman M, Moya J, Jurado F, Thompson M et al</AU>
<TI>Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults</TI>
<SO>Vaccine</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>11</NO>
<PG>2139-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Macartney-2012" MODIFIED="2014-03-24 12:14:37 +1000" MODIFIED_BY="[Empty name]" NAME="Macartney 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-03-24 12:14:37 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Macartney K, McLntyre P</AU>
<TI>Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults</TI>
<SO>Sao Paulo Medical Journal</SO>
<YR>2012</YR>
<VL>130</VL>
<NO>2</NO>
<PG>133</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marin-2008" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Marin 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marin M, Meissner HC, Seward JF</AU>
<TI>Varicella prevention in the United States: a review of successes and challenges</TI>
<SO>Pediatrics</SO>
<YR>2008</YR>
<VL>122</VL>
<NO>3</NO>
<PG>e744-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marquez_x002d_Pelaez-2009" MODIFIED="2014-03-17 16:11:48 +1000" MODIFIED_BY="Liz Dooley" NAME="Marquez-Pelaez 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-03-17 16:11:48 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marquez-Pelaez S, Ruiz-Aragon J</AU>
<TI>A systematic review of the economic studies on vaccine against herpes zoster and postherpetic neuralgia in adults</TI>
<SO>Vacunas</SO>
<YR>2009</YR>
<VL>10</VL>
<NO>4</NO>
<PG>118-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marshall-2009" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Marshall 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marshall H, Ryan P, Roberton D, Beilby J</AU>
<TI>Varicella immunisation practice: implications for provision of a recommended, non-funded vaccine</TI>
<SO>Journal of Paediatrics and Child Health</SO>
<YR>2009</YR>
<VL>45</VL>
<NO>5</NO>
<PG>297-303</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McAdam-2013" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="McAdam 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McAdam L, Eberhardson M, Grainger W, Papp K, Hall S, Sterling T et al</AU>
<TI>Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with autoimmune disease</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2013</YR>
<VL>65</VL>
<NO>12</NO>
<PG>3327</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meurice-1996" NAME="Meurice 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Meurice F, De Bouver JL, Vandevoorde D, Woods S, Bogaerts H. Immunogenicity and safety of a live attenuated varicella vaccine (Oka/SB Bio) in healthy children. Journal of Infectious Diseases 1996; 174 Suppl 3 :S324-S329&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meurice F, De Bouver JL, Vandevoorde D, Woods S, Bogaerts H</AU>
<TI>Immunogenicity and safety of a live attenuated varicella vaccine (Oka/SB Bio) in healthy children</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1996</YR>
<VL>174</VL>
<NO>Suppl 3</NO>
<PG>324-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mick-2010" MODIFIED="2014-03-17 16:12:09 +1000" MODIFIED_BY="Liz Dooley" NAME="Mick 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-03-17 16:12:09 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mick G</AU>
<TI>Vaccination: a new option to reduce the burden of herpes zoster</TI>
<SO>Expert Review of Vaccines</SO>
<YR>2010</YR>
<VL>9</VL>
<NO>Suppl 3</NO>
<PG>31-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mills-2010" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Mills 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mills R, Tyring SK, Levin MJ, Parrino J, Li X, Coll KE et al</AU>
<TI>Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster</TI>
<SO>Vaccine</SO>
<YR>2010</YR>
<VL>28</VL>
<NO>25</NO>
<PG>4204-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morales-2000" NAME="Morales 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Morales-Castillo ME, Alvarez-Munoz MT, Solorzano-Santos F, Gonzalez-Robledo R, Jasso-Gutierrez L, Munoz-Hernandez O. Live varicella vaccine in both immunocompromised and healthy children. Archives of Medical Research 2000; 31 :85-87&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morales-Castillo ME, Alvarez-Munoz MT, Solorzano-Santos F, Gonzalez-Robledo R, Jasso-Gutierrez L, Munoz-Hernandez O</AU>
<TI>Live varicella vaccine in both immunocompromised and healthy children</TI>
<SO>Archives of Medical Research</SO>
<YR>2000</YR>
<VL>31</VL>
<PG>85-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mustafa-2009" MODIFIED="2014-03-17 16:12:42 +1000" MODIFIED_BY="Liz Dooley" NAME="Mustafa 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-03-17 16:12:42 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mustafa MB, Arduino PG, Porter SR</AU>
<TI>Varicella zoster virus: review of its management</TI>
<SO>Journal of Oral Pathology and Medicine</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>9</NO>
<PG>673-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nader-1995" NAME="Nader 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Nader S, Bergen R, Sharp M, Arvin AM. Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. Journal of Infectious Diseases 1995; 171 :13-17&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nader S, Bergen R, Sharp M, Arvin AM</AU>
<TI>Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1995</YR>
<VL>171</VL>
<PG>13-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naganuma-1984" NAME="Naganuma 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Naganuma Y, Osawa S, Takahashi R. Clinical application of a live varicella vaccine (Oka strain) in a hospital. Biken Journal 1984; 27 :59-61&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naganuma Y, Osawa S, Takahashi R</AU>
<TI>Clinical application of a live varicella vaccine (Oka strain) in a hospital</TI>
<SO>Biken Journal</SO>
<YR>1984</YR>
<VL>27</VL>
<PG>59-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ndumbe-1985" NAME="Ndumbe 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Ndumbe PM, Cradock-Watson JE, Macqueen S, Dunn H, Holzel H, Andre F et al. Immunisation of nurses with a live varicella vaccine. Lancet 1985; 1(8438):1144-1147.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ndumbe PM, Cradock-Watson JE, Macqueen S, Dunn H, Holzel H, Andre F et al</AU>
<TI>Immunisation of nurses with a live varicella vaccine</TI>
<SO>Lancet</SO>
<YR>1985</YR>
<VL>1</VL>
<NO>8438</NO>
<PG>1144-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neff-1981" NAME="Neff 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Neff BJ, Weibel RE, Villarejos VM, Buynak EB, McLean AA, Morton DH et al. Clinical and laboratory studies of KMcC strain live attenuated varicella virus. Proceedings of the Society for Experimental Biology &amp;amp; Medicine 1981; 166(3):339-347.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neff BJ, Weibel RE, Villarejos VM, Buynak EB, McLean AA, Morton DH et al</AU>
<TI>Clinical and laboratory studies of KMcC strain live attenuated varicella virus</TI>
<SO>Proceedings of the Society for Experimental Biology &amp; Medicine</SO>
<YR>1981</YR>
<VL>166</VL>
<NO>3</NO>
<PG>339-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ngai-1996" NAME="Ngai 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Ngai AL, Staehle BO, Kuter BJ, Cyanovich NM, Cho I, Matthews H, Keller P, Arvin AM, Watson B, White CJ. Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children. Pediatric Infectious Disease Journal 1996; 15 :49-54&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ngai AL, Staehle BO, Kuter BJ, Cyanovich NM, Cho I, Matthews H et al</AU>
<TI>Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1996</YR>
<VL>15</VL>
<PG>49-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nithichaiyo-2001" NAME="Nithichaiyo 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Nithichaiyo C, Chongsrisawat V, Hutagalung Y, Bock HL, Poovorawa Y. Immunogenicity and adverse effects of live attenuated varicella vaccine (Oka-strain) in children with chronic liver disease. Asian Pacific Journal of Allergy &amp;amp; Immunology 2001; 19(2):101-105.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nithichaiyo C, Chongsrisawat V, Hutagalung Y, Bock HL, Poovorawa Y</AU>
<TI>Immunogenicity and adverse effects of live attenuated varicella vaccine (Oka-strain) in children with chronic liver disease</TI>
<SO>Asian Pacific Journal of Allergy &amp; Immunology</SO>
<YR>2001</YR>
<VL>19</VL>
<NO>2</NO>
<PG>101-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nolan-2002" NAME="Nolan 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Nolan T, McIntyre P, Roberton D, Descamps D. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine. Vaccine 2002; 21 :281-289&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nolan T, McIntyre P, Roberton D, Descamps D</AU>
<TI>Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine</TI>
<SO>Vaccine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>281-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nolan-2008" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Nolan 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nolan T, Bernstein DI, Block SL, Hilty M, Keyserling HL, Marchant C et al</AU>
<TI>Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age</TI>
<SO>Pediatrics</SO>
<YR>121</YR>
<VL>3</VL>
<PG>508-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Novadzki-2010" MODIFIED="2014-03-27 16:22:21 +1000" MODIFIED_BY="Liz Dooley" NAME="Novadzki 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-03-27 16:22:21 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Novadzki IM, Rosario Filho N</AU>
<TI>Anaphylaxis associated with the vaccine against measles, mumps and rubella</TI>
<TO>Anafilaxia associada à vacina contra sarampo, caxumba e rubéola</TO>
<SO>Revisita de Saúde Pública</SO>
<YR>2009</YR>
<VL>44</VL>
<NO>2</NO>
<PG>372-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oxman-2005" NAME="Oxman 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD et al</AU>
<TI>A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>352</VL>
<NO>22</NO>
<PG>2271-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oxman-2008" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Oxman 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oxman MN, Levin MJ and the Shingles Prevention Study Group</AU>
<TI>Vaccination against herpes zoster and postherpetic neuralgia</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2008</YR>
<VL>197</VL>
<NO>Suppl 2</NO>
<PG>228-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oxman-2009" MODIFIED="2014-03-17 16:13:52 +1000" MODIFIED_BY="Liz Dooley" NAME="Oxman 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-03-17 16:13:52 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oxman MN</AU>
<TI>Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence</TI>
<SO>Journal of the American Osteopathic Association</SO>
<YR>2009</YR>
<VL>109</VL>
<NO>6 Suppl 2</NO>
<PG>13-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oxman-2010" MODIFIED="2014-03-17 16:14:01 +1000" MODIFIED_BY="Liz Dooley" NAME="Oxman 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-03-17 16:14:01 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oxman MN</AU>
<TI>Zoster vaccine: current status and future prospects</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2010</YR>
<VL>51</VL>
<NO>2</NO>
<PG>197-213</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ozaki-1978" NAME="Ozaki 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Ozaki T, Nagayoshi S, Morishima T, Isomura S, Suzuki S, Asano Y et al. Use of a live varicella vaccine for acute leukemic children shortly after exposure in a children's ward. Biken Journal 1978; 21(2):69-72.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ozaki T, Nagayoshi S, Morishima T, Isomura S, Suzuki S, Asano Y et al</AU>
<TI>Use of a live varicella vaccine for acute leukemic children shortly after exposure in a children's ward</TI>
<SO>Biken Journal</SO>
<YR>1978</YR>
<VL>21</VL>
<NO>2</NO>
<PG>69-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ozaki-1984" NAME="Ozaki 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Ozaki T, Matsui T, Ichikawa T, Asano Y, Yamanishi K, Takahashi M. Clinical trial of the Oka strain of live attenuated varicella vaccine on healthy children. Biken Journal 1984; 27 :39-42&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ozaki T, Matsui T, Ichikawa T, Asano Y, Yamanishi K, Takahashi M</AU>
<TI>Clinical trial of the Oka strain of live attenuated varicella vaccine on healthy children</TI>
<SO>Biken Journal</SO>
<YR>1984</YR>
<VL>27</VL>
<PG>39-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parment-2003" NAME="Parment 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Parment PA, Svahn A, Ruden U, Brakenhielm G, Storsaeter J, Akesson L et al. Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age. Scandinavian Journal of Infectious Diseases 2003; 35(10):736-742.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parment PA, Svahn A, Ruden U, Brakenhielm G, Storsaeter J, Akesson L et al</AU>
<TI>Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>2003</YR>
<VL>35</VL>
<NO>10</NO>
<PG>736-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pileggi-2010" MODIFIED="2014-03-28 16:36:09 +1000" MODIFIED_BY="[Empty name]" NAME="Pileggi 2010" YEAR="2010 Jul">
<REFERENCE MODIFIED="2014-03-28 16:36:09 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pileggi GS, de Souza CBS, Ferriani VPL</AU>
<TI>Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids</TI>
<SO>Arthritis Care and Research</SO>
<YR>2010</YR>
<VL>62</VL>
<NO>7</NO>
<PG>1034-9</PG>
<IDENTIFIERS MODIFIED="2014-03-26 10:12:47 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pinochet-2012" MODIFIED="2014-04-13 12:39:14 +1000" MODIFIED_BY="Liz Dooley" NAME="Pinochet 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-04-13 12:39:14 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pinochet C, Cerda J, Hirsch T, Mieres J, Inostroza C, Abarca K</AU>
<TI>Effectiveness of varicella vaccine as post exposure prophylaxis in Chilean children</TI>
<TO>Efectividad de la vacuna antivaricela como proflaxis post exposición en niños chilenos</TO>
<SO>Revista Chilena de Infectología</SO>
<YR>2012</YR>
<VL>29</VL>
<NO>6</NO>
<PG>635-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prelog-2010" MODIFIED="2014-03-17 16:14:11 +1000" MODIFIED_BY="Liz Dooley" NAME="Prelog 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-03-17 16:14:11 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prelog M, Zimmerhackl LB</AU>
<TI>Varicella vaccination in pediatric kidney and liver transplantation</TI>
<SO>Pediatric Transplantation</SO>
<YR>2010</YR>
<VL>14</VL>
<NO>1</NO>
<PG>41-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prymula-2014" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Prymula 2014" YEAR="2014">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prymula R, Bergsaker MR, Esposito S, Gothefors L, Man S, Snegova N et al</AU>
<TI>Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial</TI>
<SO>Lancet</SO>
<YR>2014</YR>
<VL>12</VL>
<PG>61461-5</PG>
<IDENTIFIERS MODIFIED="2014-04-13 12:40:21 +1000" MODIFIED_BY="Liz Dooley">
<IDENTIFIER MODIFIED="2014-04-13 12:40:21 +1000" MODIFIED_BY="Liz Dooley" TYPE="DOI" VALUE="10.1016/S0140-6736"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quian-2010" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Quian 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quian RJ, Protasio PA, Dall'Orso VP, Mas GM, Romero OC, Ferreira JN et al</AU>
<TI>Varicella outbreak in a village in Uruguay</TI>
<TO>Estudio de un brote de varicela en un pueblo del Uruguay</TO>
<SO>Revisita Chilena de Infectologia</SO>
<YR>2010</YR>
<VL>27</VL>
<NO>1</NO>
<PG>47-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quien-1977" NAME="Quien 1977" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;Quien RM, Kaiser BA, Deforest A, Polinsky MS, Fisher M, Baluarte HJ. Response to the varicella vaccine in children with nephrotic syndrome. Journal of Pediatrics 1997; 131 :688-690&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quien RM, Kaiser BA, Deforest A, Polinsky MS, Fisher M, Baluarte HJ</AU>
<TI>Response to the varicella vaccine in children with nephrotic syndrome</TI>
<SO>Journal of Pediatrics</SO>
<YR>1997</YR>
<VL>131</VL>
<PG>688-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ramkissoon-1995" NAME="Ramkissoon 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Ramkissoon A, Coovadia HM, Jugnundan P, Haffejee IE, Meurice F, Vandevoorde D. Immunogenicity and safety of a live attenuated varicella vaccine in healthy Indian children aged 9-24 months. South African Medical Journal 1995; 85 :1295-1298&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ramkissoon A, Coovadia HM, Jugnundan P, Haffejee IE, Meurice F, Vandevoorde D</AU>
<TI>Immunogenicity and safety of a live attenuated varicella vaccine in healthy Indian children aged 9-24 months</TI>
<SO>South African Medical Journal</SO>
<YR>1995</YR>
<VL>85</VL>
<PG>1295-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Redman-1997" NAME="Redman 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Redman RL, Nader S, Zerboni L, Liu C, Wong RM, Brown BW, Arvin AM. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. Journal of Infectious Diseases 1997; 176 :578-585&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Redman RL, Nader S, Zerboni L, Liu C, Wong RM, Brown BW et al</AU>
<TI>Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1997</YR>
<VL>176</VL>
<PG>578-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reisinger-2006" NAME="Reisinger 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reisinger KS, Brown ML, Xu J, Sullivan BJ, Marshall GS, Nauert B et al</AU>
<TI>A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax [Erratum appears in Pediatrics. 2006 Jun;117(6):2338]</TI>
<SO>Pediatrics</SO>
<YR>2006</YR>
<VL>117</VL>
<NO>2</NO>
<PG>265-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reuman-1997" NAME="Reuman 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Reuman PD, Sawyer MH, Kuter BJ, Matthews H. Safety and immunogenicity of concurrent administration of measles-mumps-rubella-varicella vaccine and PedvaxHIB vaccines in healthy children twelve to eighteen months old. The MMRV Study Group. Pediatric Infectious Disease Journal 1997; 16 :662-667&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reuman PD, Sawyer MH, Kuter BJ, Matthews H</AU>
<TI>Safety and immunogenicity of concurrent administration of measles-mumps-rubella-varicella vaccine and PedvaxHIB vaccines in healthy children twelve to eighteen months old. The MMRV Study Group</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1997</YR>
<VL>16</VL>
<PG>662-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riera-2012" MODIFIED="2014-03-28 16:37:15 +1000" MODIFIED_BY="[Empty name]" NAME="Riera 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-03-28 16:37:15 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riera R, Sato HK</AU>
<TI>Vaccines against varicella in children and adults for post-exposure prophylaxis</TI>
<TO>Vacinas contra a varicela em crianças e adultos para profilaxia pós-exposição</TO>
<SO>Revista Diagnóstico e Tratamento</SO>
<YR>2012</YR>
<VL>17</VL>
<NO>2</NO>
<PG>88-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rinderknecht-2011" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Rinderknecht 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rinderknecht S, Michaels MG, Blatter M, Gaglani M, Andrews W, Abughali N et al</AU>
<TI>Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with measles-mumps-rubella and varicella vaccines in children less than 2 years of age</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2011</YR>
<VL>30</VL>
<NO>10</NO>
<PG>e179-85</PG>
<IDENTIFIERS MODIFIED="2014-03-26 10:14:12 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rios-2009" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Rios 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rios FFA, Mallozi MC, Solé D</AU>
<TI>Sepsis by S. aureus in a patient with atopic dermatitis and herpeticum eczema: a case report</TI>
<TO>Sepse por S. aureus em paciente com dermatite atópica e eczema herpético: relato de caso</TO>
<SO>Revista Brasileira de Alergia e Imunopatologia</SO>
<YR>2009</YR>
<VL>32</VL>
<NO>1</NO>
<PG>35-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ross-1997" NAME="Ross 1997" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Ross RT, Nicolle LE, Cheang M. The varicella zoster virus: a pilot trial of a potential therapeutic agent in multiple sclerosis. Journal of Clinical Epidemiology 1997; 50 :63-68&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ross RT, Nicolle LE, Cheang M</AU>
<TI>The varicella zoster virus: a pilot trial of a potential therapeutic agent in multiple sclerosis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1997</YR>
<VL>50</VL>
<PG>63-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rothstein-1997" NAME="Rothstein 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Rothstein EP, Bernstein HH, Ngai AL, Cho I, White CJ. Dose titration study of live attenuated varicella vaccine in healthy children. Pennridge Pediatric Associates. Journal of Infectious Diseases 1997; 175 :444-447&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rothstein EP, Bernstein HH, Ngai AL, Cho I, White CJ</AU>
<TI>Dose titration study of live attenuated varicella vaccine in healthy children. Pennridge Pediatric Associates</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1997</YR>
<VL>175</VL>
<PG>444-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rozenbaum-2008" MODIFIED="2014-03-17 16:15:28 +1000" MODIFIED_BY="Liz Dooley" NAME="Rozenbaum 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-03-17 16:15:28 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rozenbaum MH, Van Hoek AJ, Vegter S, Postma MJ</AU>
<TI>Cost-effectiveness of varicella vaccination programs: an update of the literature</TI>
<SO>Expert Review of Vaccines</SO>
<YR>2008</YR>
<VL>7</VL>
<NO>6</NO>
<PG>753-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruger-2012" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Ruger 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruger G, Gabutti G, Rumke H, Rombo L, Bernaola E, Diez-Domingo J et al</AU>
<TI>Safety of a 2-dose regimen of a combined measles, mumps, rubella and varicella live vaccine manufactured with recombinant human albumin</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2012</YR>
<VL>31</VL>
<NO>11</NO>
<PG>1166-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rumke-2011" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Rumke 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rumke HC, Loch HP, Hoppenbrouwers K, Vandermeulen C, Malfroot A, Helm K et al</AU>
<TI>Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses</TI>
<SO>Vaccine</SO>
<YR>2011</YR>
<VL>29</VL>
<NO>22</NO>
<PG>3842-9</PG>
<IDENTIFIERS MODIFIED="2014-03-26 10:15:48 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sadaoka-2008" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Sadaoka 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sadaoka K, Okamoto S, Gomi Y, Tanimoto T, Ishikawa T, Yoshikawa T et al</AU>
<TI>Measurement of varicella-zoster virus (VZV)-specific cell-mediated immunity: comparison between VZV skin test and interferon-(gamma) enzyme-linked immunospot assay</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2008</YR>
<VL>198</VL>
<NO>9</NO>
<PG>1327-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saiman-2001" NAME="Saiman 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Saiman L, LaRussa P, Steinberg SP, Zhou J, Baron K, Whittier S, Della-Latta P, Gershon AA. Persistence of immunity to varicella-zoster virus after vaccination of healthcare workers. Infection Control &amp;amp; Hospital Epidemiology 2001; 22 :279-283&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saiman L, LaRussa P, Steinberg SP, Zhou J, Baron K, Whittier S et al</AU>
<TI>Persistence of immunity to varicella-zoster virus after vaccination of healthcare workers</TI>
<SO>Infection Control &amp; Hospital Epidemiology</SO>
<YR>2001</YR>
<VL>22</VL>
<PG>279-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salleras-2009" MODIFIED="2014-06-18 23:42:33 +1000" MODIFIED_BY="[Empty name]" NAME="Salleras 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-06-18 23:42:33 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salleras L</AU>
<TI>Chapter 7. Chickenpox vaccine for adolescents and adults</TI>
<TO>Capítulo 7. Vacunación antivaricela para adolescentes y adultos</TO>
<SO>Medicina Preventiva</SO>
<YR>2009</YR>
<VL>15</VL>
<NO>4</NO>
<PG>5-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salleras-Sanmarti-2008" MODIFIED="2014-03-17 12:26:48 +1000" MODIFIED_BY="[Empty name]" NAME="Salleras Sanmarti 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-03-17 12:26:48 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salleras Sanmarti L, Redonnet MS, Prat A, Garrido P, Dominguez A</AU>
<TI>Vaccines against varicella-zoster virus</TI>
<SO>Enfermedades Infecciosas y Microbiologia Clinica</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>Suppl 1</NO>
<PG>29-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salzman-1998" NAME="Salzman 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Salzman MB, Garcia C. Postexposure varicella vaccination in siblings of children with active varicella. Pediatric Infectious Disease Journal 1998; 17 :256-257&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salzman MB, Garcia C</AU>
<TI>Postexposure varicella vaccination in siblings of children with active varicella</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1998</YR>
<VL>17</VL>
<PG>256-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanford-2010" MODIFIED="2014-03-17 16:16:14 +1000" MODIFIED_BY="Liz Dooley" NAME="Sanford 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-03-17 16:16:14 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanford M, Keating GM</AU>
<TI>Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults</TI>
<SO>Drugs and Aging</SO>
<YR>2010</YR>
<VL>27</VL>
<NO>2</NO>
<PG>159-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmid-2010" MODIFIED="2014-03-17 16:16:21 +1000" MODIFIED_BY="Liz Dooley" NAME="Schmid 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-03-17 16:16:21 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmid DS, Jumaan AO</AU>
<TI>Impact of varicella vaccine on varicella-zoster virus dynamics</TI>
<SO>Clinical Microbiology Reviews</SO>
<YR>2010</YR>
<VL>23</VL>
<NO>1</NO>
<PG>202-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schuster-2008" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Schuster 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K et al</AU>
<TI>Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>8</NO>
<PG>724-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seward-2008" MODIFIED="2014-03-17 16:16:48 +1000" MODIFIED_BY="Liz Dooley" NAME="Seward 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-03-17 16:16:48 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seward JF, Marin M, Vázquez M</AU>
<TI>Varicella vaccine effectiveness in the US vaccination program: a review</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2008</YR>
<VL>197</VL>
<NO>Suppl 2</NO>
<PG>82-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shapiro-2011" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Shapiro 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shapiro ED, Vazquez M, Esposito D, Holabird N, Steinberg SP, Dziura J et al</AU>
<TI>Effectiveness of 2 doses of varicella vaccine in children</TI>
<SO>Journal of Infectious Disease</SO>
<YR>2011</YR>
<VL>203</VL>
<NO>3</NO>
<PG>312-5</PG>
<IDENTIFIERS MODIFIED="2014-03-26 10:17:05 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharp-1992" NAME="Sharp 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Sharp M, Terada K, Wilson A, Nader S, Kinchington PE, Ruyechan WT, Hay J, Arvin AM. Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine. Journal of Infectious Diseases 1992; 165 :852-858&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharp M, Terada K, Wilson A, Nader S, Kinchington PE, Ruyechan WT et al</AU>
<TI>Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1992</YR>
<VL>165</VL>
<PG>852-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shinefield-1998" NAME="Shinefield 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Shinefield HR, Black SB, Staehle BO, Adelman T, Ensor K, Ngai A et al. Safety, tolerability and immunogenicity of concomitant injections in separate locations of M-M-R II, VARIVAX and TETRAMUNE in healthy children vs. concomitant injections of M-M-R II and TETRAMUNE followed six weeks later by VARIVAX. Pediatric Infectious Disease Journal 1998; 17(11):980-985.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shinefield HR, Black SB, Staehle BO, Adelman T, Ensor K, Ngai A et al</AU>
<TI>Safety, tolerability and immunogenicity of concomitant injections in separate locations of M-M-R II, VARIVAX and TETRAMUNE in healthy children vs. concomitant injections of M-M-R II and TETRAMUNE followed six weeks later by VARIVAX</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>11</NO>
<PG>980-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shinefield-2002" NAME="Shinefield 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Shinefield HR, Black SB, Staehle BO, Matthews H, Adelman T, Ensor K, Li S, Chan I, Heyse J, Waters M, Chan CY, Vessey SJ, Kaplan KM, Kuter BJ, Kaiser Permanente Medical Team for Varivax. Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children. Pediatric Infectious Disease Journal 2002; 21 :555-561&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shinefield HR, Black SB, Staehle BO, Matthews H, Adelman T, Ensor K et al</AU>
<TI>Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>555-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shinefield-2005a" NAME="Shinefield 2005a" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shinefield H, Black S, Digilio L, Reisinger K, Blatter M, Gress JO et al</AU>
<TI>Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>8</NO>
<PG>665-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shinefield-2005b" NAME="Shinefield 2005b" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shinefield H, Black S, Williams WR, Marchant C, Reisinger K, Stewart T et al</AU>
<TI>Dose-response study of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children [Erratum appears in Pediatr Infect Dis J. 2005 Nov;24(11):983]</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>8</NO>
<PG>670-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shinefield-2006" NAME="Shinefield 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shinefield H, Black S, Thear M, Coury D, Reisinger K, Rothstein E et al</AU>
<TI>Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>4</NO>
<PG>287-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shinefield-2008" MODIFIED="2014-03-17 16:16:59 +1000" MODIFIED_BY="Liz Dooley" NAME="Shinefield 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-03-17 16:16:59 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shinefield HR, Black S, Kuter BJ</AU>
<TI>Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2008</YR>
<VL>197</VL>
<NO>Suppl 2</NO>
<PG>152-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simberkoff-2010" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Simberkoff 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simberkoff MS, Arbeit RD, Johnson GR, Oxman MN, Boardman KD, Williams HM et al</AU>
<TI>Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2010</YR>
<VL>152</VL>
<NO>9</NO>
<PG>545-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-2003" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Smith 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Smith JG, Levin M, Vessey R, Chan IS, Hayward AR, Liu X, Kaufhold RM, Clair J, Chalikonda I, Chan C, Bernard M, Wang WW, Keller P, Caulfield MJ. Measurement of cell-mediated immunity with a Varicella-Zoster Virus-specific interferon-gamma ELISPOT assay: responses in an elderly population receiving a booster immunization. Journal of Medical Virology 2003; 70 Suppl 1 :S38-S41&lt;/p&gt;" NOTES_MODIFIED="2014-06-19 00:52:07 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith JG, Levin M, Vessey R, Chan IS, Hayward AR, Liu X et al</AU>
<TI>Measurement of cell-mediated immunity with a varicella-zoster virus-specific interferon-gamma ELISPOT assay: responses in an elderly population receiving a booster immunization</TI>
<SO>Journal of Medical Virology</SO>
<YR>2003</YR>
<VL>70</VL>
<NO>Suppl 1</NO>
<PG>38-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sperber-1992" NAME="Sperber 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Sperber SJ, Smith BV, Hayden FG. Serologic response and reactogenicity to booster immunization of healthy seropositive adults with live or inactivated varicella vaccine. Antiviral Research 1992; 17 :213-222&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sperber SJ, Smith BV, Hayden FG</AU>
<TI>Serologic response and reactogenicity to booster immunization of healthy seropositive adults with live or inactivated varicella vaccine</TI>
<SO>Antiviral Research</SO>
<YR>1992</YR>
<VL>17</VL>
<PG>213-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stadtmauer-2013" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Stadtmauer 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stadtmauer EA, Sullivan K, Marty F, Dadwal SS, Papanicoleau GA, Shea TC et al</AU>
<TI>One-year safety and immunogenicity of two formulations of an adjuvanted varicella-zoster virus (VZV) subunit candidate vaccine in adult autologous hematopoietic cell transplant (HCT) recipients</TI>
<SO>Biology of Blood and Marrow Transplantation</SO>
<YR>2013</YR>
<VL>19</VL>
<NO>2</NO>
<PG>S168-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Streng-2010" MODIFIED="2014-03-26 10:18:24 +1000" MODIFIED_BY="[Empty name]" NAME="Streng 2010" YEAR="2004. Vaccine. 2010">
<REFERENCE MODIFIED="2014-03-26 10:18:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Streng A, Seeger K, Grote V, Liese JG</AU>
<TI>Varicella vaccination coverage in Bavaria (Germany) after general vaccine recommendation in 2004</TI>
<SO>Vaccine</SO>
<YR>2010</YR>
<VL>28</VL>
<NO>35</NO>
<PG>5738-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stuck-2002" NAME="Stuck 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Stuck B, Stehr K, Bock HL. Concomitant administration of varicella vaccine with combined measles, mumps, and rubella vaccine in healthy children aged 12 to 24 months of age. Asian Pacific Journal of Allergy &amp;amp; Immunology 2002; 20 :113-120&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stuck B, Stehr K, Bock HL</AU>
<TI>Concomitant administration of varicella vaccine with combined measles, mumps, and rubella vaccine in healthy children aged 12 to 24 months of age</TI>
<SO>Asian Pacific Journal of Allergy &amp; Immunology</SO>
<YR>2002</YR>
<VL>20</VL>
<PG>113-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sutradhar-2009" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Sutradhar 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sutradhar SC, Wang WB, Schlienger K, Stek JE, Xu J, Chan ISF et al</AU>
<TI>Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or older</TI>
<SO>Clinical and Vaccine Immunology</SO>
<YR>2009</YR>
<VL>16</VL>
<NO>5</NO>
<PG>646-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takahashi-1974" NAME="Takahashi 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974; 2(7892):1288-1290.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T</AU>
<TI>Live vaccine used to prevent the spread of varicella in children in hospital</TI>
<SO>Lancet</SO>
<YR>1974</YR>
<VL>2</VL>
<NO>7892</NO>
<PG>1288-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takahashi-1985" NAME="Takahashi 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Takahashi M, Kamiya H, Baba K, Asano Y, Ozaki T, Horiuchi K. Clinical experience with Oka live varicella vaccine in Japan. Postgraduate Medical Journal 1985; 61 Suppl 4:61-67.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takahashi M, Kamiya H, Baba K, Asano Y, Ozaki T, Horiuchi K</AU>
<TI>Clinical experience with Oka live varicella vaccine in Japan</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>1985</YR>
<VL>61</VL>
<NO>Suppl 4</NO>
<PG>61-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takahashi-2001" NAME="Takahashi 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Takahashi M. 25 years' experience with the Biken Oka strain varicella vaccine: a clinical overview. Paediatric Drugs 2001; 3 :285-292&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takahashi M</AU>
<TI>25 years' experience with the Biken Oka strain varicella vaccine: a clinical overview</TI>
<SO>Paediatric Drugs</SO>
<YR>2001</YR>
<VL>3</VL>
<PG>285-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takahashi-2003" NAME="Takahashi 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Takahashi M, Okada S, Miyagawa H, Amo K, Yoshikawa K, Asada H, Kamiya H, Torigoe S, Asano Y, Ozaki T, Terada K, Muraki R, Higa K, Iwasaki H, Akiyama M, Takamizawa A, Shiraki K, Yanagi K, Yamanishi K. Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay. Vaccine 2003; 21 :3845-3853&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takahashi M, Okada S, Miyagawa H, Amo K, Yoshikawa K, Asada H et al</AU>
<TI>Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay</TI>
<SO>Vaccine</SO>
<YR>2003</YR>
<VL>21</VL>
<PG>3845-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takahashi-2008" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Takahashi 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takahashi M, Asano Y, Kamiya H, Baba K, Ozaki T, Otsuka T et al</AU>
<TI>Development of varicella vaccine</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2008</YR>
<VL>197</VL>
<NO>Suppl 2</NO>
<PG>41-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takayama-1992" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Takayama 1992" YEAR="1992">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Takayama N, Kidokoro M, Suzuki K, Morita M. [Immunization of healthy children with measles-mumps-rubella trivalent vaccine simultaneously given with varicella vaccine]. [Japanese]. Kansenshogaku Zasshi - Journal of the Japanese Association for Infectious Diseases 1992; 66(6):776-780.&lt;/p&gt;" NOTES_MODIFIED="2014-06-19 00:52:07 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takayama N, Kidokoro M, Suzuki K, Morita M</AU>
<TI>Immunization of healthy children with measles-mumps-rubella trivalent vaccine simultaneously given with varicella vaccine</TI>
<SO>Kansenshogaku Zasshi [Journal of the Japanese Association for Infectious Diseases]</SO>
<YR>1992</YR>
<VL>66</VL>
<NO>6</NO>
<PG>776-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tan-1996" MODIFIED="2013-06-28 16:00:01 +1000" MODIFIED_BY="[Empty name]" NAME="Tan 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-06-28 16:00:01 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Tan AY, Connett CJ, Connett GJ, Quek SC, Yap HK, Meurice F, Lee BW. Use of a reformulated Oka strain varicella vaccine (SmithKline Beecham Biologicals/Oka) in healthy children. European Journal of Pediatrics 1996; 155 :706-711&lt;/p&gt;" NOTES_MODIFIED="2013-06-28 16:00:01 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tan AY, Connett CJ, Connett GJ, Quek SC, Yap HK, Meurice F et al</AU>
<TI>Use of a reformulated Oka strain varicella vaccine (SmithKline Beecham Biologicals/Oka) in healthy children</TI>
<SO>European Journal of Pediatrics</SO>
<YR>1996</YR>
<VL>155</VL>
<PG>706-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tang-2012" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Tang 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tang Y, Su JL, Xia YH, Feng SZ, Huang YD, Lin WB et al</AU>
<TI>Safety and immunogenicity of domestic gelatin-free freeze-dried live attenuated varicella vaccine</TI>
<SO>Chinese Journal of Biologicals</SO>
<YR>2012</YR>
<VL>25</VL>
<NO>11</NO>
<PG>1516-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Terada-2002" NAME="Terada 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Terada K, Niizuma T, Ogita S, Kataoka N. Responses of varicella zoster virus (VZV)-specific immunity in seropositive adults after inhalation of inactivated or live attenuated varicella vaccine. Vaccine 2002; 20(31-32):3638-3643.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Terada K, Niizuma T, Ogita S, Kataoka N</AU>
<TI>Responses of varicella zoster virus (VZV)-specific immunity in seropositive adults after inhalation of inactivated or live attenuated varicella vaccine</TI>
<SO>Vaccine</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>31-2</NO>
<PG>3638-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tillieux-2008" MODIFIED="2014-06-19 00:35:42 +1000" MODIFIED_BY="[Empty name]" NAME="Tillieux 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-06-19 00:35:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tillieux SL, Halsey WS, Thomas ES, Voycik JJ, Sathe GM, Vassilev V</AU>
<TI>Complete DNA sequences of two Oka strain varicella-zoster virus genomes</TI>
<SO>Journal of Virology</SO>
<YR>2008</YR>
<VL>82</VL>
<NO>22</NO>
<PG>11023-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trannoy-2000" NAME="Trannoy 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Trannoy E, Berger R, Hollander G, Bailleux F, Heimendinger P, Vuillier D, Creusvaux H. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine 2000; 18 :1700-1706&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trannoy E, Berger R, Hollander G, Bailleux F, Heimendinger P, Vuillier D et al</AU>
<TI>Vaccination of immunocompetent elderly subjects with a live attenuate Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial</TI>
<SO>Vaccine</SO>
<YR>2000</YR>
<VL>18</VL>
<PG>1700-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ueda-1977" NAME="Ueda 1977" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;Ueda K, Yamada I, Goto M, Nanri T, Fukuda H, Katsuta M et al. Use of a live varicella vaccine to prevent the spread of varicella in handicapped or immunosuppressed children including MCLS (muco-cutaneous lymphnode syndrome) patients in hospitals. Biken Journal 1977; 20(3-4):117-123.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ueda K, Yamada I, Goto M, Nanri T, Fukuda H, Katsuta M et al</AU>
<TI>Use of a live varicella vaccine to prevent the spread of varicella in handicapped or immunosuppressed children including MCLS (muco-cutaneous lymphnode syndrome) patients in hospitals</TI>
<SO>Biken Journal</SO>
<YR>1977</YR>
<VL>20</VL>
<NO>3-4</NO>
<PG>117-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Varis-1996" NAME="Varis 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Varis T, Vesikari T. Efficacy of high-titer live attenuated varicella vaccine in healthy young children. Journal of Infectious Diseases 1996; 174 Suppl 3 :S330-S334&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Varis T, Vesikari T</AU>
<TI>Efficacy of high-titer live attenuated varicella vaccine in healthy young children</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1996</YR>
<VL>174</VL>
<NO>Suppl 3</NO>
<PG>330-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vazquez-2004" NAME="Vazquez 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Vazquez M, LaRussa PS, Gershon AA, Niccolai LM, Muehlenbein CE, Steinberg SP et al. Effectiveness over time of varicella vaccine. JAMA 2004; 291(7):851-855.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vazquez M, LaRussa PS, Gershon AA, Niccolai LM, Muehlenbein CE, Steinberg SP et al</AU>
<TI>Effectiveness over time of varicella vaccine</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>291</VL>
<NO>7</NO>
<PG>851-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vesikari-1991" NAME="Vesikari 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Vesikari T, Ohrling A, Baer M, Delem A, Bogaerts H, Andre FE. Evaluation of live attenuated varicella vaccine (Oka-RIT strain) and combined varicella and MMR vaccination in 13-17-month-old children. Acta Paediatrica Scandinavica 1991; 80 :1051-1057&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vesikari T, Ohrling A, Baer M, Delem A, Bogaerts H, Andre FE</AU>
<TI>Evaluation of live attenuated varicella vaccine (Oka-RIT strain) and combined varicella and MMR vaccination in 13-17-month-old children</TI>
<SO>Acta Paediatrica Scandinavica</SO>
<YR>1991</YR>
<VL>80</VL>
<PG>1051-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vesikari-2007" NAME="Vesikari 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vesikari T, Baer M, Willems P</AU>
<TI>Immunogenicity and safety of a second dose of measles-mumps-rubella- varicella vaccine in healthy children aged 5 to 6 years</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>2</NO>
<PG>153-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vesikari-2010" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Vesikari 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vesikari T, Karvonen A, Lindblad N, Korhonen T, Lommel P, Willems P et al</AU>
<TI>Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2010</YR>
<VL>29</VL>
<NO>6</NO>
<PG>e47-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vesikari-2012" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Vesikari 2012" YEAR="2012 Apr 26">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vesikari T, Becker T, Gajdos V, Fiquet A, Thomas S, Richard P et al</AU>
<TI>Immunogenicity and safety of a two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (ProQuad(®)) in infants from 9 months of age</TI>
<SO>Vaccine</SO>
<YR>2012</YR>
<VL>30</VL>
<NO>20</NO>
<PG>3082-9</PG>
<IDENTIFIERS MODIFIED="2014-03-26 10:19:22 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vessey-2001" NAME="Vessey 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Vessey SJ, Chan CY, Kuter BJ, Kaplan KM, Waters M, Kutzler DP, Carfagno PA, Sadoff JC, Heyse JF, Matthews H, Li S, Chan IS. Childhood vaccination against varicella: persistence of antibody, duration of protection, and vaccine efficacy. Journal of Pediatrics 2001; 139 :297-304&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vessey SJ, Chan CY, Kuter BJ, Kaplan KM, Waters M, Kutzler DP et al</AU>
<TI>Childhood vaccination against varicella: persistence of antibody, duration of protection, and vaccine efficacy</TI>
<SO>Journal of Pediatrics</SO>
<YR>2001</YR>
<VL>139</VL>
<PG>297-304</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2013" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Wang 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang Z, Yang H, Li K, Zhang A, Feng Z, Seward JF et al</AU>
<TI>Single-dose varicella vaccine effectiveness in school settings in China</TI>
<SO>Vaccine</SO>
<YR>2013</YR>
<VL>31</VL>
<NO>37</NO>
<PG>3834-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Watson-1993a" NAME="Watson 1993a" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Watson B, Piercy S, Soppas D, Browngoehl K, Warner M, Isganitis K, White CJ, Kuter B, Chua J, Starr S. The effect of decreasing amounts of live virus, while antigen content remains constant, on immunogenicity of Oka/Merck varicella vaccine. Journal of Infectious Diseases 1993; 168 :1356-1360&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Watson B, Piercy S, Soppas D, Browngoehl K, Warner M, Isganitis K et al</AU>
<TI>The effect of decreasing amounts of live virus, while antigen content remains constant, on immunogenicity of Oka/Merck varicella vaccine</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1993</YR>
<VL>168</VL>
<PG>1356-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Watson-1993b" NAME="Watson 1993b" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Watson BM, Piercy SA, Plotkin SA, Starr SE. Modified chickenpox in children immunized with the Oka/Merck varicella vaccine. Pediatrics 1993; 91 :17-22&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Watson BM, Piercy SA, Plotkin SA, Starr SE</AU>
<TI>Modified chickenpox in children immunized with the Oka/Merck varicella vaccine</TI>
<SO>Pediatrics</SO>
<YR>1993</YR>
<VL>91</VL>
<PG>17-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Watson-1994" NAME="Watson 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Watson B, Gupta R, Randall T, Starr S. Persistence of cell-mediated and humoral immune responses in healthy children immunized with live attenuated varicella vaccine. Journal of Infectious Diseases 1994; 169(1):197-199.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Watson B, Gupta R, Randall T, Starr S</AU>
<TI>Persistence of cell-mediated and humoral immune responses in healthy children immunized with live attenuated varicella vaccine</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1994</YR>
<VL>169</VL>
<NO>1</NO>
<PG>197-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Watson-1995" NAME="Watson 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Watson B, Boardman C, Laufer D, Piercy S, Tustin N, Olaleye D, Cnaan A, Starr SE. Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine. Clinical Infectious Diseases 1995; 20 :316-319&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Watson B, Boardman C, Laufer D, Piercy S, Tustin N, Olaleye D et al</AU>
<TI>Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1995</YR>
<VL>20</VL>
<PG>316-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Watson-1996" NAME="Watson 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Watson BM, Laufer DS, Kuter BJ, Staehle B, White CJ, Starr SE. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children.[erratum appears in J Infect Dis 1996 Jun;173(6):1529]. Journal of Infectious Diseases 1996; 173(3):731-734.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Watson BM, Laufer DS, Kuter BJ, Staehle B, White CJ, Starr SE</AU>
<TI>Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children [Erratum appears in J Infect Dis 1996 Jun;173(6):1529]</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1996</YR>
<VL>173</VL>
<NO>3</NO>
<PG>731-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Watson-2000" NAME="Watson 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Watson B, Seward J, Yang A, Witte P, Lutz J, Chan C, Orlin S, Levenson R. Postexposure effectiveness of varicella vaccine. Pediatrics 2000; 105 :84-88&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Watson B, Seward J, Yang A, Witte P, Lutz J, Chan C et al</AU>
<TI>Postexposure effectiveness of varicella vaccine</TI>
<SO>Pediatrics</SO>
<YR>2000</YR>
<VL>105</VL>
<PG>84-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Watson-2008" MODIFIED="2014-03-17 16:18:50 +1000" MODIFIED_BY="Liz Dooley" NAME="Watson 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-03-17 16:18:50 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Watson B</AU>
<TI>Humoral and cell-mediated immune responses in children and adults after 1 and 2 doses of varicella vaccine</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2008</YR>
<VL>197</VL>
<NO>Suppl 2</NO>
<PG>143-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Webb-2000" NAME="Webb 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Webb NJ, Fitzpatrick MM, Hughes DA, Brocklebank TJ, Judd BA, Lewis MA, Postlethwaite RJ, Smith PA, Corbitt G. Immunisation against varicella in end stage and pre-end stage renal failure. Trans-Pennine Paediatric Nephrology Study Group. Archives of Disease in Childhood 2000; 82 :141-143&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Webb NJ, Fitzpatrick MM, Hughes DA, Brocklebank TJ, Judd BA, Lewis MA et al</AU>
<TI>Immunisation against varicella in end stage and pre-end stage renal failure. Trans-Pennine Paediatric Nephrology Study Group</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2000</YR>
<VL>82</VL>
<PG>141-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weibel-1984" NAME="Weibel 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Weibel RE, Neff BJ, Kuter BJ, Guess HA, Rothenberger CA, Fitzgerald AJ, Connor KA, McLean AA, Hilleman MR, Buynak EB. Live attenuated varicella virus vaccine. Efficacy trial in healthy children. New England Journal of Medicine 1984; 310 :1409-1415&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weibel RE, Neff BJ, Kuter BJ, Guess HA, Rothenberger CA, Fitzgerald AJ et al</AU>
<TI>Live attenuated varicella virus vaccine. Efficacy trial in healthy children</TI>
<SO>New England Journal of Medicine</SO>
<YR>1984</YR>
<VL>310</VL>
<PG>1409-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weibel-1985" NAME="Weibel 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Weibel RE, Kuter BJ, Neff BJ, Rothenberger CA, Fitzgerald AJ, Connor KA, Morton D, McLean AA, Scolnick EM. Live Oka/Merck varicella vaccine in healthy children. Further clinical and laboratory assessment. JAMA 1985; 254 :2435-2439&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weibel RE, Kuter BJ, Neff BJ, Rothenberger CA, Fitzgerald AJ, Connor KA et al</AU>
<TI>Live Oka/Merck varicella vaccine in healthy children. Further clinical and laboratory assessment</TI>
<SO>JAMA</SO>
<YR>1985</YR>
<VL>254</VL>
<PG>2435-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weinberg-2009" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Weinberg 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weinberg A, Zhang JH, Oxman MN, Johnson GR, Hayward AR, Caulfield MJ et al</AU>
<TI>Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2009</YR>
<VL>200</VL>
<NO>7</NO>
<PG>1068-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weinberg-2010" MODIFIED="2014-03-26 10:20:34 +1000" MODIFIED_BY="[Empty name]" NAME="Weinberg 2010" YEAR="2010 Apr">
<REFERENCE MODIFIED="2014-03-26 10:20:22 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weinberg A, Levin MJ, Macgregor RR</AU>
<TI>Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults</TI>
<SO>Human Vaccines</SO>
<YR>2010</YR>
<VL>6</VL>
<NO>4</NO>
<PG>318-21</PG>
<IDENTIFIERS MODIFIED="2014-03-26 10:20:22 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-White-1991" NAME="White 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;White CJ, Kuter BJ, Hildebrand CS, Isganitis KL, Matthews H, Miller WJ, Provost PJ, Ellis RW, Gerety RJ, Calandra GB. Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989. Pediatrics 1991; 87 :604-610&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>White CJ, Kuter BJ, Hildebrand CS, Isganitis KL, Matthews H, Miller WJ et al</AU>
<TI>Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989</TI>
<SO>Pediatrics</SO>
<YR>1991</YR>
<VL>87</VL>
<PG>604-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-White-1992" NAME="White 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;White CJ, Kuter BJ, Ngai A, Hildebrand CS, Isganitis KL, Patterson CM, Capra A, Miller WJ, Krah DL, Provost PJ. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatric Infectious Disease Journal 1992; 11 :19-23&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>White CJ, Kuter BJ, Ngai A, Hildebrand CS, Isganitis KL, Patterson CM et al</AU>
<TI>Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1992</YR>
<VL>11</VL>
<PG>19-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-White-1997" NAME="White 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;White CJ. Varicella-zoster virus vaccine. Clinical Infectious Diseases 1997; 24 :753-761&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>White CJ</AU>
<TI>Varicella-zoster virus vaccine</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1997</YR>
<VL>24</VL>
<PG>753-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wise-2000" NAME="Wise 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Wise RP, Salive ME, Braun MM, Mootrey GT, Seward JF, Rider LG, Krause PR. Postlicensure safety surveillance for varicella vaccine.[erratum appears in JAMA 2000 Dec 27;284(24):3129]. JAMA 2000; 284 :1271-1279&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wise RP, Salive ME, Braun MM, Mootrey GT, Seward JF, Rider LG et al</AU>
<TI>Postlicensure safety surveillance for varicella vaccine [Erratum appears in JAMA 2000 Dec 27;284(24):3129]</TI>
<SO>JAMA</SO>
<YR>2000</YR>
<VL>284</VL>
<PG>1271-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2010" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Wu 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu YM, Li G, Zhao WL</AU>
<TI>Immunogenicity and safety of measles-mumps-rubella-varicella vaccine: a systematic review</TI>
<SO>Chinese Journal of Evidence-Based Medicine</SO>
<YR>2010</YR>
<VL>10</VL>
<NO>7</NO>
<PG>862-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamaguti-2008" MODIFIED="2014-03-26 12:24:53 +1000" MODIFIED_BY="[Empty name]" NAME="Yamaguti 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-03-26 12:24:53 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamaguti HY, dos Santos ACJ, de Lima GZ</AU>
<TI>Knowledge about varicella by first year healthcare students in State University of Londrina and verification of the presence of varicella scars in the students</TI>
<TO>Conhecimentos sobre varicela de alunos ingressantes em cursos da área de saúde na Universidade Estadual de Londrina e verificação da presença de cicatrizes da doença</TO>
<SO>Semina: Ciências Biológicas e da Saúde, Londrina</SO>
<YR>2008</YR>
<VL>29</VL>
<NO>1</NO>
<PG>3-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yerkovich-2007" NAME="Yerkovich 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yerkovich ST, Rowe J, Richmond P, Suriyaarachchi D, Heaton T, Hollams E et al</AU>
<TI>Assessment of the potency and potential immunomodulatory effects of the measles mumps rubella and varicella vaccine in infants</TI>
<SO>Vaccine</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>10</NO>
<PG>1764-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yetman-2013" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Yetman 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yetman RJ, Shepard JS, Duke A, Stek JE, Petrecz M, Klopfer SO et al</AU>
<TI>Concomitant administration of hepatitis A vaccine with measles/mumps/rubella/varicella and pneumococcal vaccines in healthy 12- to 23-month-old children</TI>
<SO>Human Vaccines and Immunotherapeutics</SO>
<YR>2013</YR>
<VL>9</VL>
<NO>8</NO>
<PG>1691-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yeung-1992" NAME="Yeung 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Yeung CY, Liang DC. Varicella vaccine in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Pediatric Hematology &amp;amp; Oncology 1992; 9 :29-34&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yeung CY, Liang DC</AU>
<TI>Varicella vaccine in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma</TI>
<SO>Pediatric Hematology &amp; Oncology</SO>
<YR>1992</YR>
<VL>9</VL>
<PG>29-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zerboni-1998" NAME="Zerboni 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Zerboni L, Nader S, Aoki K, Arvin AM. Analysis of the persistence of humoral and cellular immunity in children and adults immunized with varicella vaccine. Journal of Infectious Diseases 1998; 177 :1701-1704&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zerboni L, Nader S, Aoki K, Arvin AM</AU>
<TI>Analysis of the persistence of humoral and cellular immunity in children and adults immunized with varicella vaccine</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1998</YR>
<VL>177</VL>
<PG>1701-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-06-28 16:10:48 +1000" MODIFIED_BY="Anita E Heywood"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-06-23 09:19:07 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-06-23 09:19:07 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-ATAGI-2013" MODIFIED="2014-03-17 14:32:38 +1000" MODIFIED_BY="[Empty name]" NAME="ATAGI 2013" TYPE="BOOK">
<AU>Australian Technical Advisory Group on Immunisation (ATAGI)</AU>
<SO>The Australian Immunisation Handbook</SO>
<YR>2013</YR>
<EN>10th</EN>
<PB>Australian Government</PB>
<IDENTIFIERS MODIFIED="2014-03-17 12:30:42 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-03-17 12:30:42 +1000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Black-1999" NAME="Black 1999" TYPE="JOURNAL_ARTICLE">
<AU>Black S, Shinefield H, Ray P, Lewis E, Hansen J, Schwalbe J et al</AU>
<TI>Postmarketing evaluation of the safety and effectiveness of varicella vaccine</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>12</NO>
<PG>1041-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Breuer-2001" NAME="Breuer 2001" TYPE="JOURNAL_ARTICLE">
<AU>Breuer J</AU>
<TI>Vaccination to prevent varicella and shingles</TI>
<SO>Journal of Clinical Pathology</SO>
<YR>2001</YR>
<VL>54</VL>
<NO>10</NO>
<PG>743-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Enders-1994" NAME="Enders 1994" TYPE="JOURNAL_ARTICLE">
<AU>Enders G, Miller E, Cradock-Watson J, Bolley I, Ridehalgh M</AU>
<TI>Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases</TI>
<SO>Lancet</SO>
<YR>1994</YR>
<VL>343</VL>
<NO>8912</NO>
<PG>1548-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ferson-2001" NAME="Ferson 2001" TYPE="JOURNAL_ARTICLE">
<AU>Ferson MJ</AU>
<TI>Varicella vaccine in post-exposure prophylaxis</TI>
<SO>Communicable Diseases Intelligence</SO>
<YR>2001</YR>
<VL>25</VL>
<PG>13-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gershon-2013" MODIFIED="2014-06-23 09:19:07 +1000" MODIFIED_BY="[Empty name]" NAME="Gershon 2013" TYPE="BOOK_SECTION">
<AU>Gershon AA,Takahashi M, Seward J</AU>
<TI>Varicella vaccine</TI>
<SO>Vaccines</SO>
<YR>2013</YR>
<PG>837-869</PG>
<EN>6th</EN>
<ED>Plotkin SA, Orenstein WA, Offit PA</ED>
<PB>Saunders</PB>
<CY>London, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gnann-2002" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Gnann 2002" TYPE="JOURNAL_ARTICLE">
<AU>Gnann JW Jr, Whitley RJ</AU>
<TI>Clinical practice. Herpes zoster</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>347</VL>
<NO>5</NO>
<PG>340-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guess-1986" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Guess 1986" TYPE="JOURNAL_ARTICLE">
<AU>Guess HA, Broughton DD, Melton LJ III, Kurland LT</AU>
<TI>Population-based studies of varicella complications</TI>
<SO>Pediatrics</SO>
<YR>1986</YR>
<VL>78</VL>
<NO>4 Pt 2</NO>
<PG>723-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hambleton-2005" NAME="Hambleton 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hambleton S, Gershon AA</AU>
<TI>Preventing varicella-zoster disease</TI>
<SO>Clinical Microbiology Reviews</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>1</NO>
<PG>70-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2011</YR>
<ED>Higgins JPT, Green S</ED>
<PB>Wiley-Blackwell</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2010-12-21 14:02:29 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Kesson-1996" NAME="Kesson 1996" TYPE="JOURNAL_ARTICLE">
<AU>Kesson AM, Grimwood K, Burgess MA, Ferson MJ, Gilbert GL, Hogg G et al</AU>
<TI>Acyclovir for the prevention and treatment of varicella zoster in children, adolescents and pregnancy</TI>
<SO>Journal of Paediatrics and Child Health</SO>
<YR>1996</YR>
<VL>32</VL>
<NO>3</NO>
<PG>211-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2011" TYPE="BOOK_SECTION">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2011</YR>
<ED>Higgins JPT, Green S</ED>
<PB>Wiley-Blackwell</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Macartney-2005" NAME="Macartney 2005" TYPE="JOURNAL_ARTICLE">
<AU>Macartney KK, Beutels P, McIntyre P, Burgess MA</AU>
<TI>Varicella vaccination in Australia</TI>
<SO>Journal of Paediatrics and Child Health</SO>
<YR>2005</YR>
<VL>41</VL>
<NO>11</NO>
<PG>544-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marin-2007" NAME="Marin 2007" TYPE="JOURNAL_ARTICLE">
<AU>Marin M, Guris D, Chaves SS, Schmid S, Seward JF, Advisory Committee on Immunization Practices CfDCaPC</AU>
<TI>Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP)</TI>
<SO>Morbidity and Mortality Weekly Report</SO>
<YR>2007</YR>
<VL>56</VL>
<NO>RR-4</NO>
<PG>1-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MMWR-1996" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="MMWR 1996" TYPE="JOURNAL_ARTICLE">
<AU>MMWR</AU>
<TI>Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP)</TI>
<SO>Morbidity and Mortality Weekly Report</SO>
<YR>1996</YR>
<VL>45</VL>
<NO>RR-11</NO>
<PG>1-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NACI-2004" NAME="NACI 2004" TYPE="JOURNAL_ARTICLE">
<AU>National Advisory Committee on Immunization (NACI)</AU>
<TI>National Advisory Committee on Immunization (NACI) update on varicella</TI>
<SO>Canada Communicable Disease Report</SO>
<YR>2004</YR>
<VL>30</VL>
<PG>1-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ogilvie-1998" NAME="Ogilvie 1998" TYPE="JOURNAL_ARTICLE">
<AU>Ogilvie MM</AU>
<TI>Antiviral prophylaxis and treatment in chickenpox. A review prepared for the UK Advisory Group on Chickenpox on behalf of the British Society for the Study of Infection</TI>
<SO>Journal of Infection</SO>
<YR>1998</YR>
<VL>36</VL>
<NO>Suppl 1</NO>
<PG>31-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pastuszac-1994" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Pastuszac 1994" TYPE="JOURNAL_ARTICLE">
<AU>Pastuszac AL, Levy M, Schick B, Zuber C, Feldkamp M, Gladstone J et al</AU>
<TI>Outcome after maternal varicella infection in the first 20 weeks of pregnancy</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<NO>13</NO>
<PG>901-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Preblud-1984" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Preblud 1984" TYPE="JOURNAL_ARTICLE">
<AU>Preblud SR, Orenstein WA, Bart KJ</AU>
<TI>Varicella: clinical manifestations, epidemiology and health impact in children</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1984</YR>
<VL>3</VL>
<NO>6</NO>
<PG>505-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Quian-2008" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Quian 2008" TYPE="JOURNAL_ARTICLE">
<AU>Quian J, Ruttimann R, Romero C, Dall&#8217;Orso P, Cerisola A, Breuer T et al</AU>
<TI>Impact of universal varicella vaccination on 1-year olds in Uruguay: 1997&#8211;2005</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2008</YR>
<VL>93</VL>
<PG>845-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2014-03-18 09:50:05 +1000" MODIFIED_BY="Liz Dooley" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.2</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sadzot_x002d_Delvaux-2008" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NAME="Sadzot-Delvaux 2008" TYPE="JOURNAL_ARTICLE">
<AU>Sadzot-Delvaux C, Rentier B, Wutzler P, Asano Y, Suga S, Yoshikawa T et al</AU>
<TI>Varicella vaccination in Japan, South Korea, and Europe</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2008</YR>
<VL>197</VL>
<NO>Suppl 2</NO>
<PG>185-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sharrar-2000" NAME="Sharrar 2000" TYPE="JOURNAL_ARTICLE">
<AU>Sharrar RG, LaRussa P, Galea SA, Steinberg SP, Sweet AR, Keatley RM et al</AU>
<TI>The postmarketing safety profile of varicella vaccine</TI>
<SO>Vaccine</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>7-8</NO>
<PG>916-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1952" MODIFIED="2014-03-17 14:33:11 +1000" MODIFIED_BY="[Empty name]" NAME="Simpson 1952" TYPE="JOURNAL_ARTICLE">
<AU>Simpson REH</AU>
<TI>Infectiousness of communicable diseases in the household (measles, chickenpox, and mumps)</TI>
<SO>Lancet</SO>
<YR>1952</YR>
<VL>ii</VL>
<PG>549-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Skull-2001" MODIFIED="2014-03-17 14:33:17 +1000" MODIFIED_BY="[Empty name]" NAME="Skull 2001" TYPE="JOURNAL_ARTICLE">
<AU>Skull SA, Wang EE</AU>
<TI>Varicella vaccination - a critical review of the evidence</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2001</YR>
<VL>85</VL>
<NO>2</NO>
<PG>83-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Takahashi-1996" MODIFIED="2014-03-17 14:33:22 +1000" MODIFIED_BY="[Empty name]" NAME="Takahashi 1996" TYPE="JOURNAL_ARTICLE">
<AU>Takahashi M</AU>
<TI>The varicella vaccine. Vaccine development</TI>
<SO>Infectious Disease Clinics of North America</SO>
<YR>1996</YR>
<VL>10</VL>
<NO>3</NO>
<PG>469-88</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-06-19 01:21:12 +1000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-06-19 01:21:12 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arbeter-1986a">
<CHAR_METHODS MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blinded, placebo-controlled, randomised trial of post-exposure prophylaxis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>Healthy exposed siblings<BR/>Aged 18 months to 16 years<BR/>n = 13 vaccine<BR/>n = 13 placebo<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oka/Merck vaccine lot 867<BR/>4350 pfu frozen versus placebo (not stated)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-04-02 11:27:13 +1000" MODIFIED_BY="[Empty name]">
<P>Clinical varicella<BR/>Varicella severity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-03-17 16:32:25 +1000" MODIFIED_BY="Liz Dooley">
<P>Length of follow-up not stated</P>
<P>Serologic testing not discussed or reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Asano-1977a">
<CHAR_METHODS MODIFIED="2008-04-01 15:52:51 +1000" MODIFIED_BY="[Empty name]">
<P> Controlled trial of post-exposure prophylaxis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-04-15 13:10:07 +1000" MODIFIED_BY="[Empty name]">
<P>Healthy exposed siblings, aged 1 month to 11 years, with a negative history of varicella<BR/>n = 24 vaccine<BR/>n = 19 unvaccinated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oka/BIKEN vaccine versus no vaccine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>Clinical varicella<BR/>Post-vaccination serology (in index cases and vaccine recipients only)<BR/>Follow-up period ranged from 4 to 8 weeks<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-04-15 13:10:43 +1000" MODIFIED_BY="[Empty name]">
<P>No discussion of randomisation <BR/>All participants had serology performed at enrolment and those found to be seropositive for varicella IgG were excluded from analysis of results</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mor-2004">
<CHAR_METHODS MODIFIED="2014-03-17 16:31:08 +1000" MODIFIED_BY="Liz Dooley">
<P>Double-blinded, placebo-controlled trial of post-exposure prophylaxis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>Healthy exposed siblings, aged 1 to 13 years, with a negative history of varicella<BR/>n = 22 vaccine (mean age 40 months)<BR/>n = 20 placebo (mean age 53 months)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-01 15:52:51 +1000" MODIFIED_BY="[Empty name]">
<P>Varilix, GSK, (Oka/RIT) 2000 pfu versus placebo (vaccine diluent)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>Clinical varicella. Varicella severity<BR/>Follow-up period was 28 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-04-02 11:26:52 +1000" MODIFIED_BY="[Empty name]">
<P>Serologic testing not discussed or reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>pfu: plaque-forming units<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-06-18 22:06:54 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:15 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Akazawa-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:15 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT/VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Alpay-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:02:16 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ampofo-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:02:16 +1000" MODIFIED_BY="[Empty name]">
<P>No non-treatment group; duration of immunity</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:56:15 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Andrei-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:56:15 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT/review non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arbeter-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:17 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT/no non-treatment group<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Arbeter-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group <BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:56:34 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arbeter-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:56:34 +1000" MODIFIED_BY="[Empty name]">
<P>Summary of 10 comparative clinical trials, no original data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Arbeter-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group (MMRV vaccine) <BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Arbeter-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arent-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:17 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Asano-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:17 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT/no non-treatment group<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:02:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Asano-1977b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:02:23 +1000" MODIFIED_BY="[Empty name]">
<P>No non-treatment group; cohort study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:02:29 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Asano-1977c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:02:29 +1000" MODIFIED_BY="[Empty name]">
<P>No non-treatment group; cohort study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:02:31 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Asano-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:02:31 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT/no non-treatment group; PEP of family contacts</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Asano-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:57:06 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Asano-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:57:06 +1000" MODIFIED_BY="[Empty name]">
<P>No non-treatment group; prospective cohort follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:57:07 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Asano-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:57:07 +1000" MODIFIED_BY="[Empty name]">
<P>No non-treatment group; prospective cohort follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:18 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Asano-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:18 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:18 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Asano-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:18 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:02:37 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bai-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:02:37 +1000" MODIFIED_BY="[Empty name]">
<P>RCT; VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:19 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baldacci-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:19 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:19 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bancillon-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:19 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:19 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Banz-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:19 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:02:39 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barbosa-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:02:39 +1000" MODIFIED_BY="[Empty name]">
<P>RCT; VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:02:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barbosa-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:02:41 +1000" MODIFIED_BY="[Empty name]">
<P>RCT; VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:05:24 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bate-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:05:24 +1000" MODIFIED_BY="[Empty name]">
<P>PEP; non-RCT; no non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:05:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bednarek-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:05:27 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT; no non-treatment group<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:20 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bekker-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:20 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bergen-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:20 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berger-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:20 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:20 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berger-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:20 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:02:56 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berger-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:02:56 +1000" MODIFIED_BY="[Empty name]">
<P>Non-PEP RCT; immunologic outcomes in elderly participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berghella-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:21 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bernstein-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:21 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:54:51 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Black-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:54:51 +1000" MODIFIED_BY="[Empty name]">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Black-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:21 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:03:03 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blatter-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:03:03 +1000" MODIFIED_BY="[Empty name]">
<P>RCT; VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bogger_x002d_Goren-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:22 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:03:19 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brotons-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:03:19 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT; no non-treatment group; PEP of household contacts</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:05:28 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Broyer-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:05:28 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT; no non-treatment group<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:05:29 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brunell-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:05:29 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT; no non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:05:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brunell-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:05:30 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT; no non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brunell-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:03:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bryant-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:03:21 +1000" MODIFIED_BY="[Empty name]">
<P>RCT; VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:03:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bryant-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:03:23 +1000" MODIFIED_BY="[Empty name]">
<P>RCT; VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Burgess-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ceyhan-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:23 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chao-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:23 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT/VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:03:24 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chlibek-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:03:24 +1000" MODIFIED_BY="[Empty name]">
<P>RCT; VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:56:16 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chui-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:56:16 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT/VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:05:31 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clements-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:05:31 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT; no non-treatment group<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:03:25 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Contopoulos_x002d_Ioannidis-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:03:25 +1000" MODIFIED_BY="[Empty name]">
<P>RCT; VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:05:47 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cristofani-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:05:47 +1000" MODIFIED_BY="[Empty name]">
<P>Non-PEP; RCT; vaccine versus placebo in immunocompromised children</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:24 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Czajka-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:24 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:05:50 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-D_x0027_Angio-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:05:50 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT; no non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:25 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Davies-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:25 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:26 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-de-So_x00e1_rez-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:26 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dennehy-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dennehy-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:05:52 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Diaz-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:05:52 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT; no non-treatment group<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Diaz-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:56:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dube-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:56:17 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT/review non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Duchateau-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:03:26 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-El_x002d_Darouti-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:03:26 +1000" MODIFIED_BY="[Empty name]">
<P>RCT; VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:55:03 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Englund-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:55:03 +1000" MODIFIED_BY="[Empty name]">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Enright-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:27 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:05:53 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fadrowski-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:05:53 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT; review<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:55:04 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ferrera-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:55:04 +1000" MODIFIED_BY="[Empty name]">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:03:26 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ferrera-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:03:26 +1000" MODIFIED_BY="[Empty name]">
<P>RCT; VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fridman-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:27 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT/VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:28 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fu-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:28 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:05:54 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Furth-2003a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:05:54 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT; no non-treatment group<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:05:55 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Furth-2003b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:05:55 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT; no non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gatchalian-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gatchalian-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gershon-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:05:56 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gershon-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:05:56 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT; no non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gershon-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:30 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:03:29 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gershon-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:03:29 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT; cohort study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gershon-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gershon-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:31 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gershon-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:31 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:03:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Getaz-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:03:41 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT; no non-treatment group; PEP of susceptible prison contacts</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:32 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Giacchino-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:32 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:55:07 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gilderman-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:55:07 +1000" MODIFIED_BY="[Empty name]">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-17 16:29:25 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Gillet-2009a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-17 16:29:25 +1000" MODIFIED_BY="Liz Dooley">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-17 16:29:29 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Gillet-2009b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-17 16:29:29 +1000" MODIFIED_BY="Liz Dooley">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:38 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Glanz-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:38 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:38 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gnann-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:38 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:39 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gonzaga-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:39 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:39 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Groves-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:39 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:55:10 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guerra-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:55:10 +1000" MODIFIED_BY="[Empty name]">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:39 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ha-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:39 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Habermehl-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-17 16:28:49 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Halperin-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-17 16:28:49 +1000" MODIFIED_BY="Liz Dooley">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:39 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hambleton-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:39 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:55:11 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hardy-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:55:11 +1000" MODIFIED_BY="[Empty name]">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:03:47 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hartung-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:03:47 +1000" MODIFIED_BY="[Empty name]">
<P>RCT; VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:55:13 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hata-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:55:13 +1000" MODIFIED_BY="[Empty name]">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:40 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hayward-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:40 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:40 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hayward-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:40 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:40 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hayward-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:40 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:40 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Heller-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:40 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:55:14 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hesley-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:55:14 +1000" MODIFIED_BY="[Empty name]">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Holcomb-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:41 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Horiuchi-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:41 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:03:49 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:03:49 +1000" MODIFIED_BY="[Empty name]">
<P>RCT; VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Iovlev-1969">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:41 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Iwaza-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:41 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:42 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:42 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jones-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:42 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Just-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:42 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:03:52 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Just-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:03:52 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT; no non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:04:00 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kanra-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:04:00 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT; no non-treatment group<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:43 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Katsushima-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:43 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Katsushima-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:44 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:04:03 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Klein-2012a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:04:03 +1000" MODIFIED_BY="[Empty name]">
<P>RCT; VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:04:05 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Klein-2012b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:04:05 +1000" MODIFIED_BY="[Empty name]">
<P>RCT; VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:55:18 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Knuf-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:55:18 +1000" MODIFIED_BY="[Empty name]">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-17 16:28:30 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Knuf-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-17 16:28:30 +1000" MODIFIED_BY="Liz Dooley">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Knuf-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:44 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT/VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:04:08 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Konno-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:04:08 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT; no non-treatment group<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kosuwon-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Krah-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:44 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Krause-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:44 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kreth-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:45 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kreth-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:45 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:45 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kreth-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:45 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:45 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kumagai-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:45 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:55:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuter-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:55:21 +1000" MODIFIED_BY="[Empty name]">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kuter-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kuter-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kuter-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lau-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:45 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lawrence-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:45 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:04:10 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leonardi-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:04:10 +1000" MODIFIED_BY="[Empty name]">
<P>RCT; VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:04:11 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leroux_x002d_Roels-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:04:11 +1000" MODIFIED_BY="[Empty name]">
<P>RCT; VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:04:19 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leung-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:04:19 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT; no non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:04:28 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Levin-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:04:28 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT; no non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Levin-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:04:33 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Levin-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:04:33 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT/no placebo; immunisation of HIV-infected children</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Levin-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-17 16:28:03 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Levin-2008a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-17 16:28:03 +1000" MODIFIED_BY="Liz Dooley">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:47 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Levin-2008b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:47 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:47 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:47 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT/VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lieberman-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lim-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:47 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lin-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:47 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:47 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:47 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:48 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lopez-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:48 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT/VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lou-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:48 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Loulergue-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:48 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT/VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lu-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:04:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ma-2009a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:04:42 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT; no non-treatment group; PEP of primary school contacts</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:48 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ma-2009b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:48 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:55:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Macaladad-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:55:27 +1000" MODIFIED_BY="[Empty name]">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:05:57 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Macartney-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:05:57 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT; PEP review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:49 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marin-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:49 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:49 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marquez_x002d_Pelaez-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:49 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:49 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marshall-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:49 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:04:55 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McAdam-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:04:55 +1000" MODIFIED_BY="[Empty name]">
<P>RCT; VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:55:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meurice-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:55:30 +1000" MODIFIED_BY="[Empty name]">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:50 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mick-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:50 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-17 16:27:26 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Mills-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-17 16:27:26 +1000" MODIFIED_BY="Liz Dooley">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Morales-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:50 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mustafa-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:50 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nader-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:00:11 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Naganuma-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:00:11 +1000" MODIFIED_BY="[Empty name]">
<P>Use as PEP but non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:50 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ndumbe-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:50 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:50 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Neff-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:50 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ngai-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:51 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nithichaiyo-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:51 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nolan-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-17 16:27:12 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Nolan-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-17 16:27:12 +1000" MODIFIED_BY="Liz Dooley">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:51 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Novadzki-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:51 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:55:32 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oxman-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:55:32 +1000" MODIFIED_BY="[Empty name]">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-17 12:19:53 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oxman-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-17 12:19:53 +1000" MODIFIED_BY="[Empty name]">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:51 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oxman-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:51 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:51 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oxman-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:51 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:52 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ozaki-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:52 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:52 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ozaki-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:52 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:52 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Parment-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:52 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:53 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pileggi-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:53 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT/VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-24 10:57:37 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pinochet-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-24 10:57:37 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:53 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prelog-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:53 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:04:56 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prymula-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:04:56 +1000" MODIFIED_BY="[Empty name]">
<P>RCT; VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:53 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Quian-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:53 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:53 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Quien-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:53 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ramkissoon-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:55:36 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Redman-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:55:36 +1000" MODIFIED_BY="[Empty name]">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:55:37 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reisinger-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:55:37 +1000" MODIFIED_BY="[Empty name]">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Reuman-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:05:58 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Riera-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:05:58 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT; PEP review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:04:56 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rinderknecht-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:04:56 +1000" MODIFIED_BY="[Empty name]">
<P>RCT; VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:54 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rios-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:54 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:54 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ross-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:54 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rothstein-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:54 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rozenbaum-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:54 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:55 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ruger-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:55 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT/VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:04:57 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rumke-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:04:57 +1000" MODIFIED_BY="[Empty name]">
<P>RCT; VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:55 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sadaoka-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:55 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Saiman-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:55 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Salleras-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:55 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:55 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Salleras-Sanmarti-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:55 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:05:59 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Salzman-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:05:59 +1000" MODIFIED_BY="[Empty name]">
<P>PEP; non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:56 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sanford-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:56 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:56 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmid-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:56 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-17 16:26:35 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Schuster-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-17 16:26:35 +1000" MODIFIED_BY="Liz Dooley">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:56 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Seward-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:56 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:56 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shapiro-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:56 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT/VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:57 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sharp-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:57 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shinefield-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shinefield-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group <BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shinefield-2005a">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shinefield-2005b">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shinefield-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:57 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shinefield-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:57 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-17 16:26:21 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Simberkoff-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-17 16:26:21 +1000" MODIFIED_BY="Liz Dooley">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:57 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smith-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:57 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sperber-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:04:58 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stadtmauer-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:04:58 +1000" MODIFIED_BY="[Empty name]">
<P>RCT; VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:57 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Streng-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:57 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT/VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stuck-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:58 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sutradhar-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:58 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:05:03 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Takahashi-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:05:03 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT; no non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:58 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Takahashi-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:58 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:59 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Takahashi-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:59 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:59 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Takahashi-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:59 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:53:59 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Takahashi-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:53:59 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:54:00 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Takayama-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:54:00 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tan-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:05:05 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tang-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:05:05 +1000" MODIFIED_BY="[Empty name]">
<P>RCT; VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:54:00 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Terada-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:54:00 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:54:00 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tillieux-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:54:00 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:55:46 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trannoy-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:55:46 +1000" MODIFIED_BY="[Empty name]">
<P>Non-PEP RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:55:47 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ueda-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:55:47 +1000" MODIFIED_BY="[Empty name]">
<P>Non-PEP clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:55:48 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Varis-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:55:48 +1000" MODIFIED_BY="[Empty name]">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:54:01 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vazquez-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:54:01 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vesikari-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:55:48 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vesikari-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:55:48 +1000" MODIFIED_BY="[Empty name]">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-17 16:26:04 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Vesikari-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-17 16:26:04 +1000" MODIFIED_BY="Liz Dooley">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:05:06 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vesikari-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:05:06 +1000" MODIFIED_BY="[Empty name]">
<P>RCT; VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vessey-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:54:01 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:54:01 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT/VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:54:02 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Watson-1993a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:54:02 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Watson-1993b">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:54:03 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Watson-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:54:03 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Watson-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Watson-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:06:00 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Watson-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:06:00 +1000" MODIFIED_BY="[Empty name]">
<P>PEP; but non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:54:03 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Watson-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:54:03 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:54:04 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Webb-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:54:04 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:55:52 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weibel-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:55:52 +1000" MODIFIED_BY="[Empty name]">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Weibel-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>No non-treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:54:04 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weinberg-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:54:04 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:05:07 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weinberg-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:05:07 +1000" MODIFIED_BY="[Empty name]">
<P>RCT; VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:06:01 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-White-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:06:01 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT; review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:54:05 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-White-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:54:05 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:06:04 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-White-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:06:04 +1000" MODIFIED_BY="[Empty name]">
<P>No placebo; MMRV, MMR and varicella and concomitant vaccines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:54:06 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wise-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:54:06 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:56:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wu-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:56:17 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT/review non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:54:06 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yamaguti-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:54:06 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:55:55 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yerkovich-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:55:55 +1000" MODIFIED_BY="[Empty name]">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 22:05:10 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yetman-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 22:05:10 +1000" MODIFIED_BY="[Empty name]">
<P>RCT; VV non-PEP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:55:57 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yeung-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:55:57 +1000" MODIFIED_BY="[Empty name]">
<P>Non-PEP RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 21:54:06 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zerboni-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 21:54:06 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>MMR: measles, mumps and rubella vaccine<BR/>MMRV: measles, mumps, rubella and varicella vaccine<BR/>PEP: post-exposure prophylaxis<BR/>RCT: randomised controlled trial<BR/>VV: varicella vaccine</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-06-28 16:10:48 +1000" MODIFIED_BY="Anita E Heywood" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Reason for exclusion" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-03-17 14:28:20 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 11:59:03 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Arbeter-1986a">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 11:59:24 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Asano-1977a">
<DESCRIPTION>
<P>Non-random allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 14:28:20 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mor-2004">
<DESCRIPTION>
<P>Quote: "children were assigned the next available study number on the basis of a randomised number table with a block size of eight."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Arbeter-1986a">
<DESCRIPTION>
<P>Unclear. Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 11:59:27 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asano-1977a">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 16:30:48 +1000" MODIFIED_BY="Liz Dooley" RESULT="YES" STUDY_ID="STD-Mor-2004">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Arbeter-1986a">
<DESCRIPTION>
<P>Insufficient information to permit judgement. "Double blinding" stated but no additional details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Asano-1977a">
<DESCRIPTION>
<P>Unblinded study but we judged that the outcome and the outcome measurement are not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-03-17 11:59:56 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mor-2004">
<DESCRIPTION>
<P>Quote: "The placebo vial and diluent container were identical to the varicella vaccine vial and the same injection procedure was followed." "Statistical analysis was done blindly, with the statistician being unaware of which code referred to the placebo or the vaccine."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-03-17 16:32:07 +1000" MODIFIED_BY="Liz Dooley" RESULT="YES" STUDY_ID="STD-Arbeter-1986a">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-03-17 11:54:32 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asano-1977a">
<DESCRIPTION>
<P>Insufficient reporting of attrition/exclusions to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mor-2004">
<DESCRIPTION>
<P>No missing outcome data. However, no laboratory confirmation was performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-03-17 16:32:08 +1000" MODIFIED_BY="Liz Dooley" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 16:32:08 +1000" MODIFIED_BY="Liz Dooley" RESULT="YES" STUDY_ID="STD-Arbeter-1986a">
<DESCRIPTION>
<P>All relevant outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 16:31:25 +1000" MODIFIED_BY="Liz Dooley" RESULT="YES" STUDY_ID="STD-Asano-1977a">
<DESCRIPTION>
<P>The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 12:00:05 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mor-2004">
<DESCRIPTION>
<P>The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-03-17 16:31:02 +1000" MODIFIED_BY="Liz Dooley" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 11:59:14 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Arbeter-1986a">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 11:59:36 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asano-1977a">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 16:31:02 +1000" MODIFIED_BY="Liz Dooley" RESULT="YES" STUDY_ID="STD-Mor-2004">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2014-06-18 22:09:27 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2014-06-18 22:09:27 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2014-06-18 22:07:37 +1000" MODIFIED_BY="[Empty name]">Cases of varicella in three clinical trials of the use of varicella vaccine as post-exposure prophylaxis (compared with placebo or no vaccine) when given within five days of varicella exposure</TITLE>
<TABLE COLS="10" ROWS="6">
<TR>
<TD ALIGN="LEFT" VALIGN="BOTTOM">
<P/>
</TD>
<TH ALIGN="LEFT" COLSPAN="4" VALIGN="BOTTOM">
<P>Vaccine recipients</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="4" VALIGN="BOTTOM">
<P>Placebo (or no vaccine) recipients</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Statistical significance (moderate-severe disease versus no disease)*</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No disease</P>
<P>(%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mild disease</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Moderate to severe disease</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Total number</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No disease</P>
<P>(%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mild disease</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Moderate to severe disease</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Total number</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Arbeter</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9</P>
<P>(69.2%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 (30.8%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
<P>(7.7%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12 (92.3%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>P value &lt; 0.000003</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Asano</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21 (100%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
<P>(0%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21 (100%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not done</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Mor</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13</P>
<P>(59.1%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8 (36.4%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (4.5%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>22</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11</P>
<P>(55.0%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (5.0%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8 (40.0%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Risk ratio (RR) 8 (95% confidence interval (CI) 1.2 to 51.5)</P>
<P>P = 0.003</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Total</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>43</P>
<P>(76.8%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12</P>
<P>(21.4%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
<P>(1.8%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>56</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12</P>
<P>(22.2%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
<P>(1.9%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>41</P>
<P>(75.9%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>54</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*Statistical test as stated in source publication.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-03-25 15:01:23 +1000" MODIFIED_BY="[Empty name]"/>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-06-19 01:26:42 +1000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-06-18 16:18:46 +1000" MODIFIED_BY="[Empty name]">Previous searches</TITLE>
<APPENDIX_BODY MODIFIED="2014-06-19 00:52:07 +1000" MODIFIED_BY="[Empty name]">
<P>The search strategy was updated to the current search strategy when the review was updated in June 2010. We searched <I>The Cochrane Library</I>, Cochrane Central Register of Controlled Trials (CENTRAL Issue 2, 2010); MEDLINE (February 2008 to June week 2, 2010); and EMBASE.com (March 2008 to June 2010). The clinical trials register www.clinicaltrials.gov was also reviewed (to June 2010) for unpublished studies. Details of the original search are in Appendix 1.</P>
<P>Previously we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I>, 2008, Issue 1); MEDLINE (1966 to February 2008); and EMBASE (January 1990 to March 2008). The following search terms were used in MEDLINE and CENTRAL and adapted for EMBASE.<BR/>
<B>
<BR/>MEDLINE (OVID) </B>
<BR/>1     exp CHICKENPOX/<BR/>2     (chickenpox or chicken pox).mp. [mp=title, original title, abstract, name of substance word, subject heading word]<BR/>3     exp Varicellovirus/<BR/>4     varicella.mp.<BR/>5     or/1-4<BR/>6     exp VACCINES/<BR/>7     (vaccin$ or inoculat$).mp. [mp=title, original title, abstract, name of substance word, subject heading word]<BR/>8     or/6-7<BR/>9     5 and 8<BR/>10     exp CHICKENPOX VACCINE/<BR/>11     or/9-10<BR/>12     randomized controlled trial.pt.<BR/>13     controlled clinical trial.pt.<BR/>14     randomized.ab.<BR/>15     placebo.ab.<BR/>16     drug therapy.fs.<BR/>17     randomly.ab.<BR/>18     trial.ab.<BR/>19     groups.ab.<BR/>20     12 or 13 or 14 or 15 or 16 or 17 or 18 or 19<BR/>21     humans.sh.<BR/>22     20 and 21<BR/>23     11 and 22</P>
<P>
<B>EMBASE (Webspirs)</B>
</P>
<P>#25 ((((explode 'chickenpox-' / all subheadings in DEM,DER,DRM,DRR) or ((chickenpox in ti) or (chickenpox in ab)) or ((chicken pox in ti) or (chicken pox in ab)) or (explode 'Varicella-zoster-virus' / all subheadings in DEM,DER,DRM,DRR) or ((varicella in ti) or (varicella in ab))) and ((explode 'vaccine-' / all subheadings in DEM,DER,DRM,DRR) or ((vaccine* in ti) or (vaccine* in ab)))) or (explode 'chickenpox-vaccine' / all subheadings in DEM,DER,DRM,DRR)) and (((explode 'randomized-controlled-trial' / all subheadings) or (explode 'controlled-study' / all subheadings) or (explode 'single-blind-procedure' / all subheadings) or (explode 'double-blind-procedure' / all subheadings) or (explode 'crossover-procedure' / all subheadings) or (explode 'phase-3-clinical-trial' / all subheadings) or ((randomi?ed controlled trial in ti) or (randomi?ed controlled trial in ab)) or (((random* or placebo* or double-blind*)in ti) or ((random* or placebo* or double-blind*)in ab)) or ((controlled clinical trial* in ti) or (controlled clinical trial* in ab))) not ((nonhuman in der) not ((human in der)and (nonhuman in der))))<BR/>#24 ((explode 'randomized-controlled-trial' / all subheadings) or (explode 'controlled-study' / all subheadings) or (explode 'single-blind-procedure' / all subheadings) or (explode 'double-blind-procedure' / all subheadings) or (explode 'crossover-procedure' / all subheadings) or (explode 'phase-3-clinical-trial' / all subheadings) or ((randomi?ed controlled trial in ti) or (randomi?ed controlled trial in ab)) or (((random* or placebo* or double-blind*)in ti) or ((random* or placebo* or double-blind*)in ab)) or ((controlled clinical trial* in ti) or (controlled clinical trial* in ab))) not ((nonhuman in der) not ((human in der)and (nonhuman in der)))<BR/>#23 (nonhuman in der) not ((human in der)and (nonhuman in der))<BR/>#22 (explode 'randomized-controlled-trial' / all subheadings) or (explode 'controlled-study' / all subheadings) or (explode 'single-blind-procedure' / all subheadings) or (explode 'double-blind-procedure' / all subheadings) or (explode 'crossover-procedure' / all subheadings) or (explode 'phase-3-clinical-trial' / all subheadings) or ((randomi?ed controlled trial in ti) or (randomi?ed controlled trial in ab)) or (((random* or placebo* or double-blind*)in ti) or ((random* or placebo* or double-blind*)in ab)) or ((controlled clinical trial* in ti) or (controlled clinical trial* in ab))<BR/>#21 (controlled clinical trial* in ti) or (controlled clinical trial* in ab)<BR/>#20 ((random* or placebo* or double-blind*)in ti) or ((random* or placebo* or double-blind*)in ab)<BR/>#19 (randomi?ed controlled trial in ti) or (randomi?ed controlled trial in ab)<BR/>#18 explode 'phase-3-clinical-trial' / all subheadings<BR/>#17 explode 'crossover-procedure' / all subheadings<BR/>#16 explode 'double-blind-procedure' / all subheadings<BR/>#15 explode 'single-blind-procedure' / all subheadings<BR/>#14 explode 'controlled-study' / all subheadings<BR/>#13 explode 'randomized-controlled-trial' / all subheadings<BR/>#12 (((explode 'chickenpox-' / all subheadings in DEM,DER,DRM,DRR) or ((chickenpox in ti) or (chickenpox in ab)) or ((chicken pox in ti) or (chicken pox in ab)) or (explode 'Varicella-zoster-virus' / all subheadings in DEM,DER,DRM,DRR) or ((varicella in ti) or (varicella in ab))) and ((explode 'vaccine-' / all subheadings in DEM,DER,DRM,DRR) or ((vaccine* in ti) or (vaccine* in ab)))) or (explode 'chickenpox-vaccine' / all subheadings in DEM,DER,DRM,DRR)<BR/>#11 explode 'chickenpox-vaccine' / all subheadings in DEM,DER,DRM,DRR<BR/>#10 ((explode 'chickenpox-' / all subheadings in DEM,DER,DRM,DRR) or ((chickenpox in ti) or (chickenpox in ab)) or ((chicken pox in ti) or (chicken pox in ab)) or (explode 'Varicella-zoster-virus' / all subheadings in DEM,DER,DRM,DRR) or ((varicella in ti) or (varicella in ab))) and ((explode 'vaccine-' / all subheadings in DEM,DER,DRM,DRR) or ((vaccine* in ti) or (vaccine* in ab)))<BR/>#9 (explode 'vaccine-' / all subheadings in DEM,DER,DRM,DRR) or ((vaccine* in ti) or (vaccine* in ab))<BR/>#8 (vaccine* in ti) or (vaccine* in ab)<BR/>#7 explode 'vaccine-' / all subheadings in DEM,DER,DRM,DRR<BR/>#6 (explode 'chickenpox-' / all subheadings in DEM,DER,DRM,DRR) or ((chickenpox in ti) or (chickenpox in ab)) or ((chicken pox in ti) or (chicken pox in ab)) or (explode 'Varicella-zoster-virus' / all subheadings in DEM,DER,DRM,DRR) or ((varicella in ti) or (varicella in ab))<BR/>#5 (varicella in ti) or (varicella in ab)<BR/>#4 explode 'Varicella-zoster-virus' / all subheadings in DEM,DER,DRM,DRR<BR/>#3 (chicken pox in ti) or (chicken pox in ab)<BR/>#2 (chickenpox in ti) or (chickenpox in ab)<BR/>#1 explode 'chickenpox-' / all subheadings in DEM,DER,DRM,DRR</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-03-21 13:53:43 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-06-18 16:32:28 +1000" MODIFIED_BY="[Empty name]">Embase.com</TITLE>
<APPENDIX_BODY MODIFIED="2014-03-21 13:53:43 +1000" MODIFIED_BY="[Empty name]">
<P>#20. #16 AND #19 <BR/>#19. #17 OR #18 <BR/>#18. random*:ab,ti OR placebo*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR 'cross over':ab,ti OR 'cross-over':ab,ti OR volunteer*:ab,ti OR allocat*:ab,ti OR assign*:ab,ti OR ((singl* OR doubl*) NEAR/2 (blind* OR mask*)):ab,ti <BR/>#17. 'randomized controlled trial'/exp OR 'single blind procedure'/exp OR 'double blind procedure'/exp OR 'crossover procedure'/exp <BR/>#16. #14 OR #15 <BR/>#15. 'chickenpox vaccine'/exp 0<BR/>#14. #8 AND #13 <BR/>#13. #9 OR #10 OR #11 OR #12 <BR/>#12. vaccin*:ab,ti OR immuni*:ab,ti OR inocul*:ab,ti <BR/>#11. 'immunization'/de <BR/>#10. 'vaccination'/de <BR/>#9. 'vaccine'/exp <BR/>#8. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 1<BR/>#7. vzv:ab,ti <BR/>#6. varicell*:ab,ti <BR/>#5. 'varicellovirus'/de <BR/>#4. 'human herpesvirus 3':ab,ti OR 'human herpes virus 3':ab,ti <BR/>#3. 'varicella zoster virus'/de <BR/>#2. chickenpox:ab,ti OR 'chicken pox':ab,ti <BR/>#1. 'chickenpox'/de </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-06-19 01:26:42 +1000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2014-03-21 13:54:04 +1000" MODIFIED_BY="[Empty name]">LILACS (BIREME) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-06-19 01:26:42 +1000" MODIFIED_BY="[Empty name]">
<P>(((mh:chickenpox OR "chicken pox" OR chickenpox OR varicela OR varicella OR catapora OR mh:"Herpesvirus 3,Human" OR "Herpesvirus Humano 3" OR "Vírus da Varicela" OR "Vírus do Herpes Zoster" OR "Herpesvirus varicellae" OR "Herpesvirus Humano Tipo 3" OR "Vírus VZ" OR "Vírus da Varicela-Zoster" OR mh:varicellovirus OR varicel* OR vzv) AND (mh:vaccines OR vacunas OR vacinas OR mh:d20.215.894* OR vacina OR mh:vaccination OR vacunación OR vacinação OR mh:e02.095.465.425.400.530.890* OR mh:e05.478.550.600.890* OR mh:n02.421.726.758.310.890* OR mh:n06.850.780.200.425.900* OR mh:n06.850.780.680.310.890* OR mh:sp4.001.012.178* OR mh:sp8.946.819.838.803* OR mh:immunization OR inmunización OR imunização OR vaccin* OR immuni* OR inocul*)) OR (mh:"Chickenpox Vaccine" OR "Vacuna contra la Varicela" OR "Vacina contra Varicela" OR "Varicella Vaccine" OR "Vacuna contra la Varicella" OR "Vacuna Chickenpox" OR "Vacina contra Varicela" OR " Vacina Antivaricela")) AND (instance:"regional") AND (db:("LILACS") AND type_of_study:("clinical_trials"))</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>